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The main themes of this study were l) the development of a new
T.R.C.H.I.I. (F.D.P.) in which human red cells replace sheep
erythrocytes, II) the development of a new standarised assay for
urinary heterophile haemagglutinins, and III) the application of the
first and second technologies in glomei-ulonephritis and transplant¬
ation.
In the first series of studies it was discovered that glutaralde-
hyde was the best fixative for human erythrocytes compared to
formaldehyde and pyruvicaldehyde, as these two fixatives tended to
produce autoagglutination. The optimal conditions for fixation,
tanning and coating were studied and defined in some detail. The
fixed cells could be stored satisfactorily for at least 2 years
without a reduction in the antibody titre. The sensitivity of the
cells was more than a million and the test was sensitive, reliable
and could detect as little as 0.5^g/ml of fibrinogen equivalent.
In the second technological study - techniques were developed
which provided stable and reproducible reagents for the assay of
urinary heterophile haemagglutinins. A new finding in this study
was the existance of high and low reacting sheep erythrocytes and the
difference in reactivity between sheep cells to haemagglutinins in
normal human sera and patients' urine. The practical significane of
V
these results are discussed in detail. As a result of these methodol¬
ogical studies - a suitable glutaraldehyde fixed sheen cell prepar¬
ation was obtained and the optimal conditions for the reaction ascer¬
tain for subsequent clinical application.
In the third technological study - the direct latex agglutin¬
ation test (Thrombo-Wellcotest) for F.D.P. was studied. The
sensitivity of this test was 4^g/ml to fibrinogen and D fragment and
0.5/tg/ml to E fragment. There was a satisfactory correlation
between this method and the T.R.C.H.I.I. In vitro studies, it was
clearly demonstrated that the sensitivity to all digested products
was good and in terms of E fragment more sensitive then T.R.C.H.I.I.
using whole antifibrinogen sera. The test provides a simple rapid
"one-off" bed side semiquanti;ation of serum F.D,P. It is new
as it is sensitive to both fragment D and E, which does not apply
to the existing latex technique known as the Fi-test. For urine the
test was inadequate as the urine needs prior concentration and
increases nonspecific agglutination reactions.
Fii ally, the T.R.C.H.I.I. and the heterophile haemagglutination
test were used to study urinary excretion of F.D.P. and heterophile
haemagglutinins in glomerulonephritis and transplantation. These
studies confirmed the concept that the origin of urinary F.D.P. in
proliferative glomerulonephritis and renal transplantation is likely
to be immune. Urinary sheep cells haemagglutinin were not detected
in the 3.00 normal subjects studied nor did the F.D.P. content exceed
0.25^g/ml. There was a positive correlation obtained between the
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heterophile (sheep) haemagglutinin and F.D.P. content in the urine
from proliferative glomerulonephritis and following renal transplant¬
ation. Serial studies performed on individuals revealed a general
tendency for periods of high heterophile haemagglutinin excretion
to coincide with similar excess of F.D.P. excretion. No correlation
was demonstrated between heterophile haemagglutinin titre and total
protein content in the urine studied.
A correlation was recorded between the urinary heterophile
(sheep) haemagglutinin, C3, IgG, IgM concentrations in the homotrans-
plant urines, and between IgG and C3 in the proliferative and IgG
in minimal lesion. In the transplant patient a rejection episode
was associated with an elevation in all parameters assayed.
In a group of highly selected patients with proliferative
glomerulonephritis, these parameters gave parallel information,
namely the excretion of heterophile (sheep) haemagglutinin, IgG and
C3. However, a patient who showed evidence of an excellent F.D.P.
response to indomethacin, there was continued excretion of hetero¬
phile (sheep) haemagglutinin, IgM and C3» This patient's renal
function continued to deteriorate as did the patient whose combined
measurements showed no change during indomethacin administration.
The patient whose renal function improved on indomethacin treatment
showed a dramatic fall in the excretion of F.D.P., heterophile
(sheep) haemagglutinins, IgM and C3.
In comparative studies, it was observed that rabbit erythrocytes
gave an overall higher titre and detected agglutinins in a higher
proportion in urines from transplant and proliferative glomerulonephritis
VII
compared to sheep and rat cells, but in minimal lesion the sheep
cells detected a greater number of positive urines than other cells.
Absorption studies suggest that it is not a Paul-Bunnel type of
antibody and that antibody is IgG and IgM type. The reactivity to
rat cells excluded Forssman antibody.
In preliminary studies - it was observed that the techniques
can be readily modified to automation using Technicon Single
Channel Autoanalyser. The results are discussed in full detail.
It is proposed that the introduction of urinary heterophile
haemagglutinin excretion may represent an important new tool in the
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INTRODUCTION
There is now an increasing amount of experimental and clinical
evidence which points to a link between immunological and coagulation
mechanisms (Salmon et al, 1971; Luscher and Pfueller, 1971)• Thus
various diseases with an immunological pathogenesis are accompanied
by the deposition of fibrin in organs, and the presence of antigen-
antibody comxjlexes may be of particular importance in the initiation
of coagulation, probably through platelet and endothelial cell
damage (Mustard, 1971)•
The general approach to the work contained in this thesis
is one in which efforts have been made to correlate immunological
activity with evidence of fibrin deposition in certain forms of
renal disease. The markers used have been heterophile antibodies




The events which lead to the formation of fibrin from
fibrinogen consitutes the coagulation mechanism. It is a complex
and dynamic process believed to be dependent on the activation of
a series of enzyme systems, whose sequence has been tentatively
documented from in vitro studies.
In 1771) Hewson first demonstrated that the coagulation part
of the blood appeared to reside in the plasma, rather than the red
cells. In 1856 Virchow postulated the existence of fibrinogen and
this key
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protein was isolated three years later by Denis (l859)« However, it
was suggested by Schmidt (1872) that at least one other factor was
required which he named thrombin, and thrombin was shown by Gamgee
(1879) to be a protein of the globulin variety. In what is now
recognised as a series of classical experiments, Morawitz (1905)
observed that tissue extracts appeared to accelerate the clotting
time of plasma and that serum contained a coagulant of plasma which
was not demonstrable in plasma. He concluded that blood remained
fluid in blood vessels unless and until it came into contact with
tissue extracts. In the presence of such extracts a precursor
substance, called prothrombin, was converted to the enzyme thrombin
which transformed fibrinogen to fibrin.
Although the basic principles of this theory have stood the test
of time subsequent investigations and technical developments have
shown it to be somewhat over-simplified. However, its basic content
led Quick (1935) to develop the one-stage prothrombin time test from
which he argued that the clotting time was primarily dependant upon
the percursor (prothrombin) concentration. Patients were soon
discovered with prolonged one-stage prothrombin times who were
believed, for other reasons, not to be deficient in prothrombin.
Moreover, Quick (1935) clearly demonstrated a normal prothrombin
time in haemophiliac patients who had serious clinical haemostatic
problems. Thus, although this original work provided the foundation
for what is now known as the extrinsic coagulation pathway, these
latter findings initiated studies during the period 1937 to 1954 which
culminated in the realisation of an alternative pathway, now known as
the intrinsic coagulation system. Since this time much effort has
been spent in attempts to define the sequence of events in which the
various coagulation factors interact in both the extrinsic and
intrinsic systems. Current evidence would suggest that the most
important feature is the production of activated coagulation factor
X which in turn plays a key role in the conversion of prothrombin to
thrombin.
It has also become apparent that both systems consist essentially
of a series of chain reactions in which inert stable coagulation
factors are converted to active forms, which in turn act as pro¬
enzymes for other factors. Such a scheme, as presented in Fig. 1,
was first proposed by MacFarlane in 1964 and is now referred to as the
'cascade theory' or the 'waterfall theory'. Thrombin is believed
to have auto-catalytic properties at earlier sites in the cascade and
this feature together with the sequential nature of the inter-
reactions results in a biological amplification mechanism which results
in the progressive acceleration of the reaction as it proceeds
(MacFarlane, 1964). The reaction is essentially explosive in nature
and is probably partly controlled by complex inhibitor systems.
CONTACT ACTIVATION
Coagulation factor XII (Hageman factor) is present in the plasma
in trace amounts and has a molecular weight between a hundred to two
hundred thousand. Biochemical studies would suggest that it is a
glycoprotein. Although the activation of Hageman factor may be
achieved by a variety of substances in vitro, the in vivo stimulus
has not yet been fully elucidated, although collagen probably plays a






I (fibrinogen) I a (fibrin)
Fig. 1 Current concept of the Blood Coagulation System.
The sequence of events in which various coagulation
factors interact in both the extrinsic and intrinsic
systems. P indicates phospholipid and Ca++ calcium.
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XII is thought to be absorbed onto the activating surface where it
complexes with factor XI which converts factor XII to its activated
form (Ratnoff et al, 196l). The activation of factor XII leads to the
activation of coagulation factor XI (plasma thromboplastin antecedent).
Activated factor XI in turn is believed to be responsible for
activating factorIX (Christmas factor) (Ratnoff and Davie, 1962)•
Niewiarowski and Prou-wartelle, (1959) and Iatridis and
Ferguson (196l) demonstrated increasing fibrinolytic activity of the
euglobulin fraction from normal plasma when incubated with glass or
in the presence of kaolin. Plasma from Hageman factor deficient
patients did not show such a response in the presence of glass or
kaolin. Eisen (1964) has also demonstrated that polybrene, which
inhibits Hageman factor, also inhibits the fibrinolytic activity.
Thus, there appears to be a link between fibrinolysis and the
activation of Hageman factor. However, conflicting reports of the
fibrinolytic activity of patients with factor XII deficiency would
suggest that fibrinolytic activity is not triggered off solely
through contact activation. Other studies have suggested that
activated factor XII also plays a key role in the generation of
kinins and the activation of the complement system. (Ratnoff and
Miles, 1964: Pondman, 1969)•
In the intrinsic coagulation system activated factor IX is
complexed with factor VIII, calcium ions and phospholipid derived
from platelets which converts factor X to its activated form.
TISSUE ACTIVATION
An alternative pathway for the activation of factor X is known
as the extrinsic coagulation system. It is probable that in normal
physiological circumstances this system may serve as a rapid means of
making available small amounts of thrombin which facilitate the
activation of the slower intrinsic system. In certain pathological
situations, particularly those related to intravascular coagulation
in x>regnancy, the extrinsic system may well be the primary mechanism
underlying the conversion of fibrinogen to fibrin. The initiating
event in the extrinsic coagulation mechanism is the activation of
factor VII by material known as tissue thromboplastin, derived from a
variety of cells. Tissue thromboplastin is a protein-phospolipid
complex connected with an endoplasmic reticulum, which can split in to
two components (Deutsch et al, 1964). Although the details of this
system have yet to be fully worked out current evidence would suggest
that tissue thromboplastin binds calcium ions and factor VII to form
a complex which has enzymatic properties directed towards factor X.
Factor VII is thought to be a glyco-protein which has a high affinity
for binding divalent cations. It is probable that besides being of
great importance in the extrinsic system factor VII, along with tissue
thromboplastin, may activate factor IX in much the same way as this
factor is activated in the intrinsic system. It is believed that by
this route patients with Hageman factor deficiency sustain satisfactory
haemostasis.
EVENTS SUBSEQUENT TO THE ACTIVATION OF FACTOR X
The conversion of prothromin to thrombin requires the presence of
activated factor X, factor V, bivalent cations and phospholipid.
Activated factor X lies at the heart of the coagulation cascade
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mechanism and can therefore be derived from both the extrinsic and
intrinsic systems. Activated factor X is an enzyme with a molecular
weight of approximately 24,000 and possesses esterolytic as well as
coagulant properties. Pro-thrombin is very slowly converted to
thrombin by activated factor X, but, in the presence of calcium ions,
factor V and phospholipid derived from platelets, the reaction is
greatly accelerated. Factor V is probably a high molecular weight
substance whose stability is largely dependant upon the presence of
calcium ions. Neither factor V nor phospholipids either alone or
together can activate prothrombin, however, it has been suggested
that prothrombin is absorbed onto the phospholipid and factor V by
which process its structural configuration is changed rendering
it susceptible to the enzymatic action of adsorbed activated factor X,
this adsorfction process appears to be calcium dependant.
FIBRIN FORMATION
Fibrinogen is composed of three chains of peptides known as the
alpha, beta and gamma chains which are linked at the end terminal by
a strong disulphide knot. Thrombin acts by splitting fibrino-peptides
(A and B) from the alpha and beta chains at the N-terminal ends.
Thrombin has an exceedingly narrow specificity of action and hydrolyses
arginyl-glycine bonds linking the fibrino-peptides to the rest of the
fibrinogen molecule (Blonback and Blomback, 1969)-
There is some evidence to show that the fibrino-peptides may
have specific physiological roles, for they act as homeostatic
inhibitors in the clotting mechanism (Silver and Murray, 1966). The
fibrino-peptides may also be of some importance in the haemodynamic
control of the micro-circulation as they have been shown to potentiate
the action of bradykinin and histamine (Colman et al, 1967) and
affect changes in blood flow of the heart, lung and uterus when
injected in exceedingly minute amounts (Bayley et al, 1967).
After the release of fibrino-peptides A and B the resultant
fibrin monomer aggregates with other monomers to form a three
dimensional network of fibrin polymers. This structure is
unstable, soluble in urea and monochloracetic acid, but is stabilised
by the action of coagulation factor XIII (fibrin stabilising factor).
The end result of this interaction, in which thrombin plays a key role
in the activation of factor XIII, is the production of an insoluble
polymer with normal haemostatic function. These sequence of events
are shown diagramatically in Figure 2.
FIBRIN MONOMER COMPLEXES
The normal polymerisation of fibrinogen may be interupted by the
complexing of fibrin monomers with fibrinogen and other fibrinogen
derivatives, notably fibrinogen or fibrin degradation products. The
existance of such complexes was first suspected by Morrison (1946).
This substance was called cryofibrinogen. Recent studies, have shown
that cryofibrinogen is not simply a complex of altered fibrinogen, and
Lipinski et al (1964) have demonstrated that fibrinogen degradation
products, derived from the action of plasmin, complex with fibrin
monomers. The most important physiological feature of these complexes
is that they can interfere with normal fibrin formation and result in
defective fibrin polymerisation. They may also interact with platelets
and produce platelet aggregation (Wegrzynowiczet al, 1971). At the
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Fig. 2 A scheme of the sequence of events in the conversion
of fibrinogen to fibrin.
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notably platelet factor IV, which may precipitate these complexes
(Niewiarowski et al, 1968).
IMMUNOLOGICAL ASPECTS OF COAGULATION
The isolated activation of the contact factors, as brought about
for instance by injections of ellagic acid, does not lead to intra¬
vascular coagulation, most likely because phospholipids are the
limiting factor for complete activation of the intrinsic system
(Botti and Ratnoff, 1964). Essential phospholipids are provided by
injured cells. The platelet is of particular interest because it is
capable of making available its phospholipid under a wide variety of
stimuli which leave other cells intact. However, platelets displaying
PF3-activity do not induce extensive intravascular coagulation
provided the contact system is not simultaneously activated.
Cell damage by immunological mechanisms giving rise to intravas¬
cular coagulation has been extensively documented (Luscher, and
Pfueller, 1971)- At least two mechanisms have been suggested: the
interaction of cell antigens with specific antibodies and the cell
damaging effects of immune-complexes. Both these reactions appear to
involve complement activation (Gocke, 1965) and platelet involvement
appears to be an important source of phospholipid. Damaged endothelial
cells are also regarded as an essential component in some forms of
these diseases. It is also possible that fibrin formation may be
associated with the delayed hypersensitivity type of immunological
response one which is not thought to be concerned with antibody
involvement. Such a tentative conclusion comes from the finding of
high immune fibrin/fibrinogen degradation product content during
renal homograft rejection (Clarkson et al, 1970).
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CHAPTER 2.
THE FIBRINOLYTIC ENZYME SYSTEM
The primary role of the fibrinolytic enzyme system is believed to
be concerned with the removal of unwanted fibrin in the body. Despite
the original observations made by Morgagni in 17&1 that blood from
individuals dying suddenly, remained fluid, knowledge in this field
is relatively sparse. The discovery of streptokinase, a substance
derived from actively growing streptococci which facilitates the lysis
of fibrin (Tilleft and Garner, 1933)1 stimulated much research,
particularly by Milstone (l94l) and Christensen and MacLeod (1945).
Despite this excellent start, progress has been erratic and many would
consider that our understanding of the fibrinolytic enzyme system
remains relatively rudimentary. This arises partly because of the
paucity of satisfactory methods, but also because much of the
scientific effort in this area has been devoted to the highly attrac¬
tive area of thrombolytic therapy. Thus the present concepts of
fibrinolysis are fragmentary and a simplified scheme of the system
is shown in Figure 3-
COMPONENTS OF THE FIBRINOLYTIC ENZYME
PLASMINOGEN
This inactive precursor of plasmin is a beta-globulin contained
in the euglobulin fraction of plasma. It has a strong affinity for
fibrinogen, so that most purified fibrinogen preparations are
contaminated with it. However, separation can be achieved by gel
filtration, and purification procedures following this reveal a
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protein with a molecular weight of approximately 80,000. Besides
being present in the blood, it is widely distributed throughout the
body tissues, excretions and secretions. The liver is probably
responsible for it's production (Sherry, 1965) although immuno-
flurescent studies suggest that bone marrow cells and particularly
eosinophils may also contribute (Barnhart and Riddle, 1963K
The molecular weight of plasminogen and plasmin appear to be
different. This is manifest by clear differences in the sedimentation
and frictional coefficients and the electrophoretic mobilities. A
single arginyl-valine bond is apparently split when human plasminogen
is converted to plasmin by either streptokinase or urokinase.
Following activation a conformational change also appears to take
place and there is some evidence that suggests the splitting off of
a peptide moiety during activation (Summaria et al, 1971)•
However, the major chemical event appears to be a single arginyl-
valine bond split which results in a two chain molecule, connected
by a single disulphide bond.
PLASMIN
Plasmin is relatively non-specific proteolytic enzyme which
hydrolyses many proteins including coagulation factors V and VIII.
It also attacks several of the components of the complement system
and other plasma proteins, although it is believed that its main
biological activity in normal circumstances is directed towards the
digestion of fibrin. It has a molecular weight of approximately
75,000 but its precise structure has as yet not been clarified. The
active site of human plasmin contains both serine and histidine residues.
PLASMINOGEN ACTIVATORS
Fig. 3 A simplified scheme of fibrinolysis
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Human plasmin is similar in specificity to trypsin in that it
catalyses the hydrolysis of alpha-amino substituted lysine and
arginine esters. The significant actitivity, in terms of fibrinolysis
appears to be that directed towards the splitting of arginine or
lysine carbonyl bonds (Troll and Sherry, 1955; Beck and Jackson, 1966)
PLASMINOGEN ACTIVATORS
The plasminogen to plasmin conversion involves removal of part
of the plasminogen molecule by the splitting of arginine and valine
bonds by plasminogen activators. In this way "active sites" are
exposed. Activators exist in two forms, some activators act
directly on the plasminogen molecule and are present in blood,
tissues and body fluids, secretions and excretions. Pro-activators
are substances which first must be transformed to their effective
form by lysokinases present in tissues, vascular endothelium and
bacteria such as streptococci. Plasmin itself may also activate
plasminogen by a process of autocatalysis (Alkjaeisig et al, 1958)
Plasma Plasminogen Activator
When sufficiently sensitive methods are used, plasminogen
activator can be detected in plasma under normal conditions.
Increased levels are found under circumstances of stress, anxiety,
after exertion or following adrenaline infusions. Flute (i960)
was able to distinguish two types of plasma activator by
electrophoresis of plasma. One was temperature stable, the other
was temperature labile. The nature of these activators is unclear.
The labile fraction was rapidly destroyed by heating and acid pH.
Most of it was precipitated in the euglobulin fraction of plasma
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and advantage is taken of this in the commonly performed assay for
plasma activator, the euglobulin lysis time. Negligible amounts are
found in serum euglobulin (KcFarlane and Pilling, 1946) as it is
adsorbed on to fibrin during clotting (Lassen, 1958). From a
practical point of view the lability of plasma activators cannot be
overemphasised.
There now seems little doubt that the blood vessel walls are the
major source of plasma activator as originally suggested by Nolf
(1904). Vascular connective tissue was noticed to have high activa¬
tor content by Astrup (l96l) and Kwaan and Astrup (1964), but the
use of the technique of fibrinolysis autography developed by Todd
(1958) has demonstrated that the intimal surfaces of veinfT venules
and capillaries are largely responsible for its production (Todd,
1959» 1964; Warren, 1964). It is possible that an especially
large contribution of activator in the circulation is contributed
by specific organs such as the kidney (Buluk and Furman, 1962;
Niewiarowski et al, 1964) and uterus (Maki et al, 1965)-
The physiological control of plasma activator release has
recently attracted much attention. However, as yet, little is known
about the factors controlling the release and maintenance of
circulating levels. There is diurnal variation in plasma activator
concentration with the peak during the day and a trough at night
(Fearnley et al, 1957)* It is probably degraded in the liver and
lungs and may be excreted in the urine.
Many physiological and pharmacological stimuli increase the
circulating activator content. Kwaan and McFadzean (1956, 1957)
suggested that its release may be under neurological control.
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Following this postulate numerous attempts were made to study this
aspect of its control but the results were controversial and
contradictory as it was found that there was marked variability
from individual to individual both of resting levels and response
to stimulation. Moreover, reproducible stimuli were rarely used.
A new approach to this subject was introduced by Cash (1966) and
Cash and Woodfield (1968) who, by using standardised exercise
procedures, demonstrated that the fibrinolytic reactivity in any one
individual when expressed as a percentage increase of the resting
level was reproducible, but was variable between individuals. In
particular, a group of 'poor responders' was isolated. These authors
concluded that if rapid dynamic changes of fibrinolysis are required
the ability of the individual to augment the concentration of
plasminogen activator could be an important factor in maintaining
homeostasis (Cash and Woodfield, 1967)- Further studies of the
systemic plasminogen activator response to catecholamines revealed
that it is probably derived from two separate components (Cash,
Woodfield and Allan, 1970) which may share the same adrenergic
receptor site. A relatively minor one may be secondary to vasoactive
changes, whereas the second major component is quite independant of
this phenomenon.
Tissue Activator
Most tissues of the body contain a plasminogen activator which is
localized in the microsomes of cell cytoplasm. Unlike plasma
activator it possesses marked stability to heat, drying, acidification
and chloroform treatment and is bound firmly to structural proteins.
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Extraction and partial purification have been achieved due to its
solubility in potassium thiocyanate (Astrup and Stage, 1952) thus
allowing quantitative determination of its concentration in various
tissues. It may be released from cells after tissue injury. Little
is known of the chemical properties of tissue activator, but it
behaves in a different way to streptokinase.
Its physiological role is probably concerned with the mainten¬
ance of tissue repair. Fibrin participates in tissue repair by ser¬
ving as a matrix for the formation of reparative connective tissue.
Tissue activator may be of biological significance in the prevention
of excess reparative tissues, as resolution and removal of the
fibrin appears to be required to re-establish normal structure.
Urokinase
Fibrinolytic activity of the urine was recognised by
MacFarlane and Pilling (1947) and an activator of plasminogen -
urokinase - was demonstrated by Williams (l95l)» Urokinase has now
been purified and seems to activate plasminogen to plasmin by first
order kinetics. Its molecular weight is approximately 50,000. Its
role in the regulation of endogenous fibrinolysis has been difficult
to evaluate due to the difference of opinion as to its origin. As
the content in renal pelvic urine is the same as excreted urine
(Bjerrehisus, 1952), it seems unlikely that the lower urinary tract
contributes significantly to its production. Urokinase excretion
is increased after physical exercise and cardiac surgery, and is low
in renal insufficiency, cardiac failure, and carcinomatosis. The
work of Kucinski et al, (1968) showing an immunological difference
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between plasma activator and urokinase would suggest that its
origin is exclusively renal. However, the intrarenal site of
urokinase is not clear. Using fibrinolysis autography, activator
activity can be detected in glomerular and peritubular capillaries
of the renal cortex, but its greatest concentration is in the
medulla where presumably it is concentrated. Recent work with
tissue cultures has suggested that a soluble activator probably
originates in the juxtamedullary apparatus (Painter and Charles, 1962;
Prokopowicz et al, 1964).
The physiological function of urokinase is also uncertain. Its
primary role may be concerned with the maintenance of the patency of
renal tubules and the lower urinary tract.
Activator in other body fluids
Activators of plasminogen are present in tears, saliva, milk,
seminal fluid and cerebrospinal fluid. Their physiological
importance is unknown, but may be much the same in principle as
urokinase.
Non-physiological activators
Streptokinase identified in 1933 has been purified for use in
thrombolytic therapy. Plasminogen is not activated by streptokinase
unless proteins from the globulin series are also present (Mullertz
and Lassen, 1953)* From this was inferred the presence of a pro-
activator in human blood.
Other non-specific substances which may cause activation in
vitro include peptones, urea, heparin and protamine while liquid
cultures of Aspergillus oryzae and cell free filtrates of
staphylococci contain plasminogen activators.
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INHIBITORS OF FIBRINOLYSIS
One of the control mechanisms of fibrinolysis is believed to be
concerned with inhibitors against activators and plasmin. In addi¬
tion a great number of inhibitors of exogenous origin are known.
Physiological antiactivators
Inhibitors of activator may be essential for fibrinolysis
regulation, but their separate identity from anti-plasmin is still
questioned, as although some evidence exists for their presence
it is not yet absolutely conclusive. The formation of an anti-
activator during incubation of blood in glass was described by Flute
(i960) and found to be enhanced by calcium ions. The existence of
antiactivator has recently been reinforced by the work of Bennet
^1970). Thus it seems probable that the anti-activator in
plasma plays an important role in reversibly complexing with
circulating activator, thus maintaining a low level of free
plasminogen activator in solution.
Physiological antiplasmins
There are at least four antiplasmins in blood. The alpha - 1
and alpha - 2 antiplasmins in the globulin fraction are the best
characterised. Alpha - 2 antiplasrains, with molecular weight of
845,000 is an immediately effective competitive inhibitor of plasmin,
while the alpha - 1 antiplasmin has a molecular weight of 47,000 reacts
slowly by forming a stable complex with plasmin ( Summaria,
et al, 197l)« The trypsin inhibiting capacity of plasma, has
only negligible activity against plasmin. Another anti-plasmin may
exist in the gamma globulin fraction of plasma proteins (Morian et al,
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1964). Platelets also possess antiplasmin activity and this may be
of importance in the resistance to clot lysis, in vivo.
Miscellaneous exogenous antifibrinolysins
Several unrelated substances are known to inhibit plasmin action
directly or indirectly by virtue of antiactivator activity. These
include soya-bean trypsin inhibitor, basic amino acids, henarin,
heavy metals, trasylol, epsilon amino caproic acid (E.A.C.A.), amino-
methyl cyclohexane carboxylic acid (A.M.C.H.A.) and para-amino
methyl benzoic acid (P.A.M.Q.A.).
THE PLASMIN DEGRADATION OF FIBRINOGEN AND FIBRIN
During the degradation of fibrinogen and fibrin by the fibrinoly¬
tic enzyme plasmin, the substrate molecule is split into several
soluble polypeptide fragments known as fibrin/fibrinogen degradation
products (F.D.P.). The nature of the products formed in vitro, by
this reaction depends on the time it is allowed to proceed. Early
lysis products are of high molecular weight, remain clottable with
thrombin, possess powerful anticoagulant properties and are still
susceptible to further lysis by plasmin. Continued lysis results
in smaller molecular weight non-clottable fragments, with negligible
anticoagulant action and resistance to further lysis.
Characterisation of F.D.P.
Five distinct fractions, name A,B,C,D and E were originally
obtained by Nussenzweig et al (l96l) after subjecting fibrinogen
digests to D.E.A.E. cellulose chromatography. Two of these D and E
precipitated with anti-fibrinogen serum but the remainder appeared
- 18 -
to have lost antigenic similarity during digestion. Fletcher et al
(1962, 1966) found that only D and E fragments could be reliably
produced with prolonged digestion and these workers were able to
estimate the molecular weight of these plasmin resistant fragments
at 88,000 and 33iOOO respectively. On the other hand Jamieson and
Pert (1963) using starch gel electrophoresis found 10 different
bands.
From observations based on the biological and physical properties
of F.D.P. , Marder, Shulman and Carroll (1969) have suggested that the
lysis of fibrinogen and fibrin is a sequential process in which three
distinct phases are apparent. By using immuno-electrophoresis,
ultracentrifugation and gel filtration techniques they were able to
characterise the nature of the products formed at each stage of
digestion. Moreover, by introducing pevikon-block electrophoresis
they separated sufficient quantities for purification, concentration
and subsequent immunological studies (Marder, James and Sherry, 1969).
In the first stage, a number of small molecular weight peptides are
rapidly split from the fibrinogen molecule which has a molecular
weight of 3^,000,thus leaving a single, large clottable fragment
of M.W. 240,OOO - 270,000, which was termed fragment X. The second
stage appeared slower and the sequence of events less clear than in
the first. The clottability of the products is lost and the anti¬
coagulant properties increased as measured by prolongation of the
thrombin time. It is Marder's view that during the second stage,
fragment X is cleaved into two giving rise to fragments with
molecular weights of 155iOOO and 90?000 called fragments Y and D
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respectively. The third stage is the slowest and results in the
formation of plasmin resistant fragments named D and E (M.W. J0,000 -
50,000).
There still remains some disagreement concerning the proteolytic
reaction, especially the second and third stages. For example
Fletcher et al (1966) proposed that further lysis of fragment X
resulted in a large number of products of progressibley smaller
molecular weights. However, subsequent work with G-200 Sephadex
column chromatography provided substanial evidence for the existence
of two distinct intermediate degradation products (Marder, Shulman
and Carroll, 19671 1969) and does not lend support to the view that
numerous intermediate products other than fragment X appear
during plasmin digestion. It thus seems that plasmin causes an
asymmetrical fragmentation of the fibrinogen molecule,as represented
in Fig. 4.
One of the interesting features of this work is that little
is known about the details of fibrin degradation. It has been
assumed that this is likely to be identical to fibrinogen. This
assumption may not be entirely correct.
Biological Properties of F.D.P.
Products formed in the early stages of fibrinogen degradation
are strongly anticoagulant, a property originally attributed to
inhibition of the action of thrombin (Triantaphyllopoulos, 1958;
Niewiarowski and Kowalski, 1958). However, with increased under¬
standing of the fibrinogen to fibrin conversion, it is now possible




Fig. 4 Schematic representation of the asymmetrical
fragmentation of the fibrinogen molecule by plasmin
(after Marder, V.J., 1971)-
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F.D.P. Polymerisation of fibrin is inhibited (Alkjaersig et al,
1962; Latallo et al, 1962) as F.D.P. complexes with normally formed
fibrin polymers to form abnormal polymers of diminished tensile
strength (Bang et al, 1962; Hirsh et al, 1965) which may themselves
be incoagulable (Lipinski et al, 1967). They also complex with
fibrinogen, fibrin monomer and activated coagulation factors
(Kowalski, I960; Miller and Sanchez-Avalos, 1968), and may inhibit
platelet aggregation (Kowalski et al, 1964; Larrieu et al, 1966) as
previously mentioned. This anticoagulant action is of obvious
importance in clinical situations of excessive fibrinolysis second¬
ary to intra-vascular coagulation, where a life-threatening bleeding
tendency sometimes develops.
F.D.P. may also possess actions of pharmacological importance
in that they potentiate the hypotensive effect of bradykinin, and
hypertensive effect of angiotensin in the rat, and the action of
adrenaline on the rat myometrium (Malofiejew, 1971)•
Quantitation of F.D.P.
F.D.P. were originally detected by measurement of their
anticoagulant effect (Worowski et al, 1964) but this method is non¬
specific and has proved to be insensitive. The introduction of
immunological methods for the quantitation of F.D.P. has created
great interest, as it may provide an approach to assess actual in
vivo fibrinolysis. Anti-fibrinogen serum has been employed in all
immuno-assays for F.D.P. as they retain certain antigens common to
native fibrinogen. Such methods as precipitation by flocculation
(Ferreira and Muratj 1963) immuno electrophoresis (Nilehn and
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Nilsson, 1964) and radio-immunoassay (Catt et al, 1968) have been
used, but the tanned red cell haemagglutination inhibition immuno¬
assay (T.R.C.H.I.I.) has gained widest popularity (Merskey et al,
1966). With the T.R.C.H.I.I. accurate semiquantitation of F.D.P.
content has become a reality. More recently a non-immunological
method has been introduced, based on the ability of fibrinogen and
certain F.D.P. to clump specific strains of staphylococci
(Allington, 1967", Hawiger et al, 1970). This method also provides
a sensitive quantitative assay for F.D.P. and it has been compared
with the T.R.C.H.I.I. by several groups (Thomas et al, 1970; Thuot
and Larrieu, 1971)• Both tests are equally sensitive to fibrinogen
and higher molecular weight early derivatives. However, the
T.R.C.H.I.I. is far more sensitive to the lower molecular weight
products D and E. Certain technical difficulties still remain with
the T.R.C.H.I.I. and above all, the method is somewhat laborious.
These aspects will be dealt with in more detail in the technical
developments section of this thesis.
Clearance of products of fibrinolysis
The mechanisms available for clearing the products of fibrinoly¬
sis include the reticulo-endothelial system, neutrophil leukocytes
and the kidney. On the basis of immunoflurorescent studies in
rabbits after infusion of endotoxin or thrombin, the reticulo¬
endothelial cells of the liver and spleen were implicated in the
removal of fibrin (Lee and McCluskey, 1962). In states of low grade
intravascular coagulation it was suggested that the R-E system
removed the bulk of fibrin. Under certain circumstances however,
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neutrophils contribute to this removal (Barnhart and Cress, 1967)*
It also seems that when renal damage is present, urinary excretion
also takes place (Clarkson et al, 1971)*
IN VIVO FIBRINOLYSIS
Several theories have been advanced to explain the mechanism
of thrombolysis by plasma activator JLn vivo. Each has taken into
account the fundamental observations that the dissolution of fibrin
can occur without the appearance of free plasmin in the circulating
blood, i.e. fibrin is attacked but fibrinogen is spared. Deposition
of fibrin provides a focus for fibrinolysis and Fearnley (1953) and
Sherry et al (1959) have proposed that activator diffuses into the
interstices of the clot, is actively adsorbed on to fibrin, and
converts plasminogen, entrapped with its closely associated fibrino¬
gen, into plasmin. Anti-plasmins diffuse into the thrombus less
readily. Local lysis thus ensues and any free plasmin managing to
escape is neutralized by circulating anti-plasmins. A different view
was put forward by Arabrus and Markus (i960) who suggested that fibrin
is able to dissociate plasmin from a plasmin-antiplasmin complex.
Wolf (1968) postulated that plasminogen activator and anti-activator
exist as a loosely formed complex which dissociates during the
diffusion of plasma through a thrombus. As anti-plasmins and anti-
activators diffuse less rapidly due to their large size asymmetrical
shape, activator is freed and plasminogen activation occurs unimpeded.
While each theory is attractive they are not necessarily mutually
exclusive. However, further work is necessary before firm conclu¬




Serum factors agglutinating red blood cells of another species
are called heteroagglutinins. They were first discovered by Landois
(.1875) but were investigated in more detail by Landsteiner (1900).
They are best defined as antibodies combining with a quite different
antigen than used for immunisation. Heteroagglutinin(s) in normal
human sera against sheep erythrocytes have since been extensively
studied. Stuart et al (1935) found agglutinins against sheep red
cells in 63»8 per cent of 760 samples studied; Bunnell (1933) 56.3%
out of 1600 sera. The titres varied from 16 to 400. Paul and Bunnell
(1932) and Davidsohn(l933) noted a correlation of the titre and the
age of the subject: finding low titres among infants and children,
with a gradual increase to the age of 10 years. Thereafter the titre
fell with increasing age. The titres were significantly higher in
females than in males.
The agglutination of other animal erythrocytes in normal sera
has not been studied quite as extensively. However, the studies of
Salo (1966) demonstrated that the titres are highest in rabbit and
descend in the following order: guinea pig, horse and sheep. As a
rule chicken erythrocytes are not agglutinated by normal human sera.
In 1932 Paul and Bunnell reported a study of 275 sera from
patients with various diseases. High agglutination titres against
sheep erythrocytes were found in four cases of infectious mononuc¬
leosis (I.M.). This observation has since been confirmed by many
investigators. The anti-sheep agglutinin in sera from patients with
I.M. differs significantly from that found in normal sera. Papain
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treatment of sheep cells increases the titre of anti-sheep agglutinins
in normal sera, whereas it has little or no effect on the titre of
I.M. sera.
DEAE-cellulose chromatography, gel filtration on sephadex G 200
and 2-mercaptoethanol treatment have suggested that the bulk of the
heterophile agglutinin in normal sera is IgM. However, there appears
to be a small IgG component (Salo, 1966).
The heteroagglutinins in normal sera are regarded as a group of
cross-reacting antibodies. Thus the agglutination titres against
rabbit red cells have been reported to be low in sera with low
agglutination titres to sheep erythrocytes. The same correlation is
shown for high titrc samples (Stuart et al, 1935)* Early studies
suggested that the same antibody reacted with different anitnal red
cells because of the presence of a common partial receptor on the
cell surface. Subsequent absorption studies would support the
principle of a oartial common receptor.
In 1911 Forssman oroduccd high titres of sheep haemolysins and
agglutinins by immunisation of rabbits . ith aqueous suspensions of
guinea pig organs. This observation initiated an intensive ieriod
of investigation of the occurrence, distribution and nature of these
types of heterophile antigens, i.e. antigens shared by unrelated
species. Forssman antigens have been found in the tissues of many
mammals, birds and fish as well as a wide spectrum of micro-organisms.
Of specific interest to the work reported in the present study is
that although the sheep is Forssman antigen positive, the rat is
negative as is man.
A multiplicity of other heterophile antigens have been discovered
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since 1911 and the existance of similar antigens in micro-organisms
and mammalian tissue has been proposed in some infectious diseases,
notably serum sickness and infectious mononucleosis. Recent studies
have demonstrated cross-reactions between group A streptococcal
antigens and mammalian tissue components, and between pneumococcal
polysaccharides and the transplant antigens of certain strains of
mice. Moreover, heat-killed group A streptococci induce in mice,
rats, guinea-pigs and rabbits a state of hypersensitivity to skin
allografts which is indistinguishable from that resulting in pre-
treatment of the recipients with allogeneic tissue. Thus it has
been suggested that the stimulation of the heterologus antigens may
operate in conditioning the hosts response to tissue transplants.
An alternative explanation for the production of heterophile
antibodies has been the suggestion that some morbid processes may
result in alterations of autologous antigens to the point where they
resemble foreign antigens. These altered antigens then stimulate
the formation of antibodies which combine with cross-reacting foreign
antigens. It has been shown that rabbits injected with autologous
but denatured gamma globulin, formed antibodies which reacted with
foreign gamma globulin (McCluskey et al, 1962). A similar mechanism
has been postulated for the marked increase in heterophile antibody
titre following thermal injury in animals and patients (Kano et al,
1967).
Both mechanisms have been invoked by Iwasaki et al, (1967)
Rapaport et al (1968) and Kano and Milgrom (1970) to explain their
findings of a significant increase in serum heterophile antibody
titre to sheep, guinea-pig and rat erythrocytes coincident with an
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episode of renal allograft rejection. Although these observations
have not been confirmed by O'Kane et al (1969)) marked increases
in heterophile antibody to rat erythrocytes have been recorded
following skin grafts (Etheredge and Najarian, 1970) and to sheep
erythrocytes during serum sickness (Davidsohn, 1930).
The importance of these various observations in clinical
situations are considerable. In many of the conditions in which
tissue damage related to immunological injury occurs F.D.P. are
currently being investigated; also the use of the T.R.C.H.I.I. in
which sheep cells are used could lead to a serious misinterpretation
of the data in those samples with high titre heterophile antibodies.
The possibility also exists of examining whether a correlation can
be found between urine F.D.P. content and the heterophile




COAGULATION AND RENAL DISEASE
During the last 15 years increasing evidence has accumulated
which suggests that intravascular ooagulation may be associated in
the natural history of certain renal disorder. The evidence is
based mainly on immuno-fluorescent and electron microscopic studies
and on changes in circulating coagulation factors accompanying some
specific diseases in man, but particularly in experimental animals.
It was widely recognised before the introduction of the electron
microscope and immunological staining procedures that a substance
commonly referred to as fibrinoid was present within glomeruli in
several types of acute glomerular diseases, such as acute glomeru¬
lonephritis, toxaemia of pregnancy, glomerulonephritis associated
with systemic lupus erythematosus, polyarteritis nodosa, thrombotic
thrombocytopenic purpura and experimentally induced hypersensitivity
states in animals. Fibrinoid was also noted in a large variety of
pyogenic and other inflammatory and degenerative lesions, but much
controversy existed as to its nature and origin. Part of the
controversy arose from differing staining properties of this mater¬
ial when subjected to specialised staining procedures which were
unable to discriminate between degenerating collagen, altered
ground substance, and deposited fibrin. However, the development,
by Coons and Kaplan (1950), of a method for the detection and
localisation of antigen by means of fluorescent antibodies provided
the basis for a more accurate assessment of the nature of fibrinoid.
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Fluorescein labelled human anti-fibrinogen serum prepared in rabbits
was used by Gitlin, Craig and Janeway (1957) to study fibrinoid in
biopsy and autopsy specimens from patients with rheumatoid arthritis,
systemic lupus erythematosus, dermatomyositis, glomerulonephritis,
polyarteritis nodosa and thrombotic thrombocytopaenic purpura (Craig
and Gitlin, 1957)• Their findings indicated that in these lesions
the fibrinoid and hyaline material was composed, at least in part,
of fibrin. Moreover, the extent of fibrin deposition was found to
be much greater than revealed by conventional staining methods,
(Gitlin and Craig, 1957)« Similar views were expressed by Lendrum
et al (1962) after a meticulous study of vascular lesions by standard
and personally developed staining piocedures. The reasons and
mechanisms for the fibrin deposition was not, however, pursued.
Vassalli, Simon and Rouilier (19^3) performed a logical series
of experiments by inducing intravascular coagulation in animals and
studied the electron microscopic lesions within the glomeruli. Three
substances thought to activate the coagulation process by different
means were infused intra-aortically into separate groups of rabbits:
liquoid (sodium polyanetholsulphonate), whose action was presumed
to be mediated via platelets, thrombin which promotes the conversion
of fibrinogen to fibrin, and thromboplastin an activator of
prothrombin via the extrinsic coagulation system. The ultrastruc-
tural appearances were similar in each group; not only did glomer¬
ular thrombosis occur, but a variety of abnormalities commonly
present in human renal diseases were observed. Moreover, in a
significant number of animals sacrificed later, progression to
glomerular sclerosis had occurred. A most striking finding was the
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variation in extent and severity of the lesions produced in different
animals by similar stimuli. More severe abnormalities were
consistently seen in animals simultaneously infused with a
fibrinolytic inhibitor, such as epsilon amino caproic acid (E.A.C.A.).
These observations were extended to other experimental models
which more closely approximated human immunological renal diseases.
Using a form of Masugi glomerulonephritis (Masugi, 1934) induced by
the injection of rabbit anti-kidney serum produced in sheep, Vassalli
and McCluskey (1964) demonstrated glomerular lesions similar to
those seen after intravascular coagulation. During the latent phase
of five days only minor glomerular endothelial cell swelling was
observed associated with the deposition of sheep-globulin along
the basement membrane. For the next 10-15 days glomerular inflamma¬
tory reaction of increasing severity was seen. Severe proliferative
changes uniformly distributed through all glomeruli often with
crescent formation and polymorph infiltration gave way after 15 days
to progressive glomerular sclerosis. Rabbit^-globulin and fibrin
were present along the basement membrane in the acute phase. Fibrin
was also seen in the capillary lumina and Bowman's space. In
animals treated with the oral anticoagulants many of these histo¬
logical and imrauno-fluorescent abnormalities did not develop.
It was concluded that :
1. The immune reaction within the glomerulus initiated the coagu¬
lation process and resulted in the formation of fibrin and
fibrinoid,
2. The fibrinoid consisted of^-globulin (and presumably complement)
as well as fibrin,
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3. The phagocytosis of this material by endothelial, mesangial
and epithelial cells was responsible for their swelling and
proliferation,
4. The coagulation process was an essential factor in the
development of progressive sclerosis.
Much of this animal work has subsequently been confirmed by other
workers. Humair, Potter and Kwaan (1969a, 1969b) produced similar
abnormalities in rats by intravascular coagulation and with a form
of Masugi nephritis. However, urokinase, a plasminogen activator
occuring naturally in the urine, was found to be superior to anti¬
coagulation in preventing the inflammatory glomerular lesions.
Thus, in these experimental models, lesions were produced in
the kidneys which closely resembled glomerulonephritis, and renal
graft rejection as seen in humans. Their relevance to man,
however, has yet to be determined.
Since the introduction of more routine immunofluorescence
techniques to the study of human renal biopsy material, the presence
of fibrin in diseased glomeruli has become increasingly recognized.
Following the initial adaptation of the method of Coons and Kaplan
(1950) to renal tissue (Mellors and Ortega, 1956) other observations
have concerned the role of immunoglobulins and complement components
in the pathogenesis of glomerulonephritis. Two generally accepted
theories as to its causation have been proposed by Dixon (1968),
once again on the basis of animal experimentation. The fluorescence
pattern of^-globulin and complement takes one of two forms. In the
first there is a uniform linear distribution along the glomerular
capillary basement membrane which is attributed to the binding, at
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this site of antibodies against glomerular basement membrane
(anti-G.B.M. antibodies) with the specific antigen. In the second
type freely circulating antigen-antibody complexes lodges within
the basement membrane and gives rise to a characteristic granular or
lumpy appearance. While discrete examples of each type of glomeru¬
lonephritis have been described in humans, in the large majority of
cases no such distinct pathogenetic mechanism is found.
Fibrin has been found frequently using immuno-fluorescene in
human glomerulonephritis (Sturgill and Westervelt, 1965; Michael
et al, 1966) in rejecting human renal homotransplants (Busch et al,
1967; McKenzie and Whittingham 1968), but it has also been found
in many other, presumed non-immunological renal lesions and thus it
must be regarded as a non-specific feature of glomerular damage.
Although a role of fibrin deposition in the natural history of
glomerulonephritis and renal homograft rejection remains a matter of
debate, some nephrologists have been impressed with the evidence
and have used anticoagulation to combat its local formation. This
form of therapy has abundant precedent in laboratory animals
(Silverskiold, 1940; Kleinerman, 1954; Vassalli and McCluskey, 1964)
has usually taken the form of heparin infusion, oraldicoumarol or
warfarin administration. Encouraging results have been obtained,
and in man, Kincaid-Smith, Saker and Fairley (1968) have used anti¬
coagulation in glomerular diseases which often gives rise to rapid
and permanent loss of renal function. The same group (Kincaid-Smith,
Laver and Fairley, 1970) are also enthusiastic about the benefit
derived from such therapy in other forms of proliferative
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glomerulonephritis, and in human renal homotransplant rejection
(Kincaid-Smith, 1970)• Much of this work has been done in an uncon¬
trolled fashion and where more rijjidly controlled studies have been
reported, the results are not as impressive although in occasional
cases dramatic response seems to occur (Herdman et al, 1970; Arieff
and Pinggera, 1972).
Following the successful development of a T.R.C.H.I.I.
for F.D.P. determinations using human erythrocytes, which forms part
of the work contained in this Thesis (vide infra), Clarkson et al
(1970, 1971) were able to show that intraglomerular fibrin deposition
was a constant feature in certain forms of glomerulonephritis and
during renal homotransplant rejection. No information, however, was
obtained during these studies to ascertain the mechanisms involved
in this process, and specifically whether evidence of immunological




Despite the success of the early studies on the urinary F.D.P.
content of urine following renal horaotransplantation (Clarkson et al,
1970)i in his laboratory, it was clear that certain technical
difficulties existed : in particular the presence of urinary
agglutinins to the sheep red cells used for the T.R.C.H.I.I.
Occasionally they proved difficult to absorp and at all times it
was necessary to run an absorption procedure before the F.D.P.
assay could be undertaken. This meant that the urinary F.D.P. assay
was laborious and time-consuming, and not ideally suited for the
planned extensive serial studies on a large group of patients with
glomerulonephritis. The question also arose as to origins of the
urinary heterophile (sheep) haemagglutinin. Was it related to the
immune process or simply reflected the degree and type of proteinuria?
Was it a more specific index of immune glomerular damage than F.D.P.?
The essential aims of the work contained in this Thesis were
directed towards these problems. In the first place studies were
undertaken to develop a T.R.C.H.I.I. for F.D.P. using human red cells
which could be stored, as the sheep cells, for prolonged periods of
time. By using homologous cells the problem of the heterophile
haemagglutinin would be evaded. Other approaches to the assay of
urinary F.D.P. were also examined. In the second place studies
were designed to establish an optimum assay for the quantitation
of heterophile haemagglutinins in urine. Finally, if successful)
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these assays were to be rur in parallel in a preliminary investi¬
gation of the urinary F.D.P. and heterophile haemagglutinin content
of urine in healthy controls and patients with glomerulonephritis




The preparation of human red






STUDIES ON THE PREPARATION OF PRESERVED AND
SENSITISED HUMAN RED CELLS FOR THE ASSAY OF
SERUM FIBRINOGEN/FIBRIN DEGRADATION PRODUCTS.
- 3? -
INTRODUCTION
The original tanned red cell haemagglutination technique, devised
by Merskey et al (1966), made use of sheep red cells on to which
human fibrinogen had been attached. This led to the problem of
absorption of sheep cell agglutinins before each assay. One approach
to circumnavigating this problem has been to investigate the possibil¬
ity of finding low reacting sheep red cells (vide supra), the more
direct approach, when analysing human sera for F.D.P. would be to
replace sheep by human red cells. Merskey et al (1969) introduced
human red cells for the T.R.C.H.I.I. but it has been shown to be a
particularly difficult adaptation, due to the high incidence of auto-
agglutination when preserved in the usual way with formaldehyde.
This problem has proved to be so great that workers using human red
cells have been forced to avoid the preservation stage. Thus it has
been necessary to prepare, at weekly intervals, new batches of tanned
and sensitised cells. Such an approach is exceedingly time-wasting
and makes standardisation tedious and difficult. The following
section deals with attempts to make available human red cells for the
T.R.C.H.I.I. with long term storage characteristics similar to the
sheep cell F.D.P. assay.
The preparation of sensitised human red cells can be conveniently
divided into three separate procedures : (a) red cell fixation, (b)
treatment with tannic acid and (c) sensitisation. These three
features have been the subject of separate detailed investigations
and will be discussed as such.
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RED CELL FIXATION STUDIES
The attachment of proteins to intact erythrocytes can be
achieved by means of specific coupling agents such as bisdiazobenzidine
(Pressman et al, 1942; Hamashige and Arquilla, 1963), or tannic acid
(Boyden, 1951; Stavitsky and Arquilla, 1958; Vallo et al, 1964;
Merskey et al, 1969)• The most important disadvantages of these
techniques have been summarised by Herbert (1967a) who stressed the
limited duration that the cells could be stored and the considerable
variation in the sensitivity of different batches. Preservation
of cells is of great importance as a large single batch can be
prepared, which will last for at least twelve months, and is partic¬
ularly important with indirect haemagglutination tests (Ling, 1961;
Herbert, 1967a).
■ - - V.-v •->
Most previous methods for the preservation of red cells in this
area of technology have included a formaldehyde fixation procedure
(Flick, 1948; Cole and Farrel, 1955; Fullthorpe, 1957; Csizmas, I960;
Ling, I96I5 Wide, 1962; Merskey et al, 1966; Herbert, 1967a; Das,
1970a; Haanen et al, 1971a).
Ling (1961) in his comparative study on human cells concluded
that pyruvic aldehyde was the best fixative agent. Bing et al (1967)
commented that glutaraldehyde was a better reagent than formaldehyde
for preservation of sheep cells. A small study was therefore designed
to find which aldehyde might be suitable for human red cells destined
for the T.R.C.H.I.I. F.D.P. estimation.
Human group 0 RH negative cells, obtained at routine donor
sessions into acid citrate dextrose anticoagulant, were allowed to
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settle for 2-5 days by gravity, washed three times in 50 volumes
of saline and the haematocrit established after centrifugation at
1000 G for 5 minutes. Fixation with formaldehyde was attempted by
three different methods : Wide's (1962) modification of the method
of Veinbach (1958) and the methods described by Ling (1961) and
Herbert (1967b). Pyruvic aldehyde fixation was performed according
to Ling (l96l) and glutaraldehyde fixation was done according to
the standardised method (vide infra).
30 batches of glutaraldehyde, 5 batches of formaldehyde and 4
batches of pyruvic aldehyde were prepared separately on different
occasions. The cells were tanned and sensitised the same time under
identical conditions (vide infra) and the antifibrinogen titre
determined along with negative controls. The results are shown in
Table I which shows that glutaraldehyde fixation alone provided
consistent batches of cells with no trace of autoagglutination.
Although the cells fixed with formaldehyde or pyruvic aldehyde
appeared satisfactory on initial testing, a significant proportion
developed autoagglutination within a month of storage at 4 C
(Table XV).
These results led to the selection of glutaraldehyde as a preser¬
ving agent for human cells and to examine this particular fixation
procedure in detail. The basis of this procedure is given below.
Preservation Procedure
Human group 0 Rhesus negative red cells were obtained from
blood collected at routine donor withdrawal into Acid Citrate
Dextrose (4 parts to lpart). It was allowed to settle by gravity



















for 2-5 days, the plasma was then removed and the cells concentra¬
ted washed three times in 50 volumes of isotonic saline. After the
final wash and centrifugation at 1000 g for 5 minutes, the packed
cell volume was measured and the cells then transferred to a
receptacle immersed in iced water.
A 2% red cell suspension was prepared in 1% glutaraldehyde in
phosphate/buffered saline, (see appendix) mixed well and incubated
for 30 minutes at 4°C with occasional further mixing. The cells
were then washed in 50 volumes of distilled water. After the last
wash, a 10% (V/V) suspension was prepared in distilled water
containing sodium azide (l mg/ml) and stored at 4'c.
The glutaraldehyde fixed cells were bright red after fixation
and gradually became brown with succeeding washes. They do not lyse
in distilled water. They are of normal shape, do not clump and
retain their antigenic characteristics. Sensitisation of the cells
with a protein antigen was possible even after 2 years of storage
at 4°C.
Forty separate batches of glutaraldehyde fixed human red cells
were prepared over a period of 2 years and no autoagglutination was
apparent in any of these batches.
Although the preservation technique, as described, appeared to
be entirely satisfactory it was felt of some importance to study
what variables might influence the success of instituting this
technique in other laboratories. Accordingly the effects of
glutaraldehyde concentration, cell concentration, duration of
incubation, temperature, buffer pH and storage were studied.
- 4l -
The effect of relative increase in glutaraldehyde and cell content
on the fixation of human red cells.
A 2%, k%y 6%, 8% and 10% cell suspensions were prepared in
1%, 2%, 3%, 4% and 5% glutaraldehyde, respectively. All mixtures
i o
were incubated for 30 minutes at 4 C, washed, tanned and coated
in a standard way (vide infra). The results are summarised in
Table II and demonstrate that no differences were recorded in the
sensitivity of the batches prepared in these different ways.
The effect of incubation time on the fixation of human red cells
with glutaraldehyde.
A 2% red cell suspension was prepared in 196 glutaraldehyde and
divided into three parts. Each was then incubated for different
incubation times, (30, 60 and 120 minutes) at 4°C. The fixed cells
were then tanned and coated with fibrinogen (vide infra). The
results are shown in Table III and demonstrate that glutaraldehyde
fixation is a rapid process, but a prolonged incubation does not
appear to be harmful.
The effect of temperature on glutaraldehyde fixation
A 2/6 red cell suspension was prepared in 1% glutaraldehyde and
divided into 3 parts. Each was incubated for 30 minutes at either
, o o o
4 C, 22 C and 37 C. The fixed cells were washed, tanned and coated
under identical conditions. The results in Table IV show no
evidence of an effect of these temperature variations on the anti¬
body titre to anti-fibrinogen sera.
The effect of buffer pH on glutaraldehyde fixation
A 2% cell suspension was prepared in 196 glutaraldehyde either
The effect of relative increase in glutaraldehyde
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in phosphate buffered saline or citrate phosphate buffer. With
variation of pH ranging from 6.4 to 8.0, the cell mixture was
o
incubated for 30 minutes at 4 C and then tanned and coated with
fibrinogen under identical conditions (vide infra). The results in
Table V show that the variability of buffer and pil had no effect
on the antibody titre.
Storage of glutaraldehyde fixed cells
Different batches of human red cells were fixed with 1% glutar¬
aldehyde on different occasions and stored at 4°C in sodium azide.
On one day the various batches were removed from the refrigerator,
tanned and coated with fibrinogen (vide infra). The antibody
titres to antifibrinogen sera were then performed on each batch.
The results are summarised in Table VI and show that during a period
of storage no deleterious effects were demonstrated.
STUDIES ON THE TREATMENT OF GLUTARALDEHYDE FIXED HUMAN RED CELLS WITH
TANNIC ACID
Erythrocytes can be coated with antigens by various means for
their use in passive haemagglutination reactions. Although many
polysaccarides adsorbed on to red cells after only brief direct
contact (Keogh et al, 1948; Neter, 1956), proteins usually require
the alteration of the cell surface or the use of coupling agents.
Boyden (1951) discovered that proteins could be adsorbed onto
red cells after tannic acid treatment, but the mode of action is not
yet clear. Pirofsky et al (1962) observed that tanning not only
enhanced the attachment of antigens, but also increased their
agglutinability and thus their sensitivity in serological reactions.












































ANTIBODYTI RE OFFRESH CELLS
































































































Herbert (1967a) commented that the chief factor affecting the
sensitivity of antigen coated tanned cells was the efficiency of the
tanning procedure rather than the quantity of antigen attached to the
cells and that this role of tannic acid could be compared to an enzyme
such as papain.
The Tanning Procedure
Glutaraldehyde fixed human 0 Rh negative red cells were washed
3 times in 50 volumes of P.B.S. and the haematocrit was established
by centrifugation of the cells at 1000 G for five minutes. The cells
were then suspended in P.B.S. as a 2% (V/V) concentration. One
volume of this cell suspension was then mixed with 1 volume of fresh
1 in 40,000 tannic acid (see appendix ) in P.B.S. and incubated
o
in a water bath at 56 C with occasional mixing. Following incubation
the cells were washed three times in 50 volumes of P.B.S.
The tanned fixed cells were immediately coated with human
fibrinogen (see appendix) by the method found to give optimal results
(vide infra), or the cells were suspended as 10% (V/V) in P.B.S. con¬
taining sodium azide ( 1 mg/ral) and stored at 4°C.
The variables influencing this basic procedure were studied in
detail.
The effect of varying tannic acid concentration
Glutaraldehyde fixed cells were washed 3 times in 50 volumes
of P.B.S. and a 2% (V/V) cell suspension was made in the same buffer.
1 volume of cell suspension was then mixed with 1 volume of tannic
o
acid in P.B.S. of different concentrations and incubated at 56 C for
30 minutes. The cells were then washed and coated with fibrinogen
- 44 -
(vide infra) and antifibrinogen titres performed.
The results are shown in Table VII and indicate that a maximal
antibody titre was obtained with a tannic acid concentration between
1 in 20,000 - 1 in 40,000. The titre gradually decreased with the
decreasing tannic acid concentration. No benefit was observed with
increasing levels of tannic acid, indeed autoagglutination developed
with high concentrations. These observations on human glutaraldehyde
treated red cells are comparable to the findings of Wide (1962) and
Shioiri (1964) who studied the tannic acid treatment of sheep
erythrocytes.
The effect of relative increase of both tannic acid and cell
concentration
In order to prepare a large batch of tanned cells which avoids
the use of large containers and considerable quantities of washing
fluid, this aspect of the possible variables was also investigated.
Glutaraldehyde fixed cells were suspended in P.B.S. in a cell
concentration of 2%, 4%, 8% and 10% (V/V), in quadruplicate. Each
aliquot was then mixed with tannic acid at the concentration of 1 in
40,000, 1 in 20,000, 1 in 10,000 and 1 in 8,000 respectively and
.0
incubated at 56 C for 30 minutes. Following incubation the cells
were washed in P.B.S. and coated with human fibrinogen (vide infra).
Antifibrinogen titres were then recorded.
The results are shown in Table VIII. The important finding was
that of 10% (V/V) suspension of cells was satisfactorily tanned by
adding a relatively strong solution of tannic acid (l in 8,000). This




























































































































The effect of varying the time of tannic acid treatment
Different authors have used different incubation periods for the
tanning reaction. Thus Boyden (1951), George and Vaughan (1962) and
Herbert (1967b), considered 10 minutes to be sufficient. Other
workers used 30 minutes (Wide, 1962) or 1 hour (Merskey 1966, Das,
1970a), For human cells Ling (1961) allowed 15 minutes, whereas
Murakami (1965) allowed 30 minutes, Mertens et al (1969) and Merskey
(1969) suggested 1 hour.
Using the standard tanning procedure (vide supra) aliquots of
cells were incubated from 15 - 120 minutes, coated with fibrinogen
and antifibrinogen titres recorded. The results are summarised in
Table IX and demonstrate that the incubated periods studied were not
critical.
The effect of different buffer and pH variations on the tanning
Ling (1961) used 0.15M phosphate buffer at pH 6.0 for tanning
human erythrocytes, whereas Murakami (1965) and Merskey (1969) used
phosphate saline buffer at pH 6.4. Mertens et al (1969) used phos¬
phate citrate buffer at pH 6.4.
Glutaraldehyde fixed cells were washed 3 times in P.B.S. and a
2% cell suspension was made in different buffers at different pH.
One volume of a cells suspension was mixed with 1 volume of tannic
acid (l in 40,000) in the same buffer and pH as the cells and the
mixture incubated at 56°C for 30 minutes. Following the incubation
period the cells were washed in the same buffer and pH and then
coated with human fibrinogen and antibody titres performed (vide







































infra). The results are shown in Table X from which it is concluded
that cells can be tanned by using either P.B.S. or C.P. buffers
at pH 6.4 cr 8.0.
The effect of storage on tanned cells
Three batches of tanned cells prepared on different dates were
washed in P.B.S. and coated with human fibrinogen under identical
conditions by the standard method. Antibody titres of the coated
cells were run in parallel and the results are shown in Table XI.
It was observed that the age of the cells had no significant
influence on the results.
STUDIES ON THE BATING OF GLUTARALDEHYDE FIXEB TANNED RED CELLS (HUMAN)
WITH FIBRINOGEN
The Sensitisation Procedure
Glutaraldehyde tanned human 0 Rhesus negative cells were washed
3 times in 50 volumes of C.P. buffer and the haematocrit established
by centrifugation at 1000 G for 5 minutes. A 4% cell suspension was
then prepared in C.P. buffer and 1 volume was added with 1 volume of
a solution of human fibrinogen (10-tLg clottable protein/ml) in C.P.
buffer, mixed well and incubated for 30 minutes at 37* C. The
sensitised cells were then washed 3 times in 5° volumes of C.P. buffer
and finally made up as a 10% suspension (V/V) in diluting fluid
containing sodium azide (l mg/ml) and stored at 4°C.
This procedure was adopted as a result of the studies described
beloif.
























































ANTIBODYTI RE OFFRESH TANNEDCELLS



































The effect of variations in fibrinogen concentration on the sensitis-
ation procedures
Adsorption of the antigen onto cells depends on the concentration
of antigen present in the buffer - cell mixture during the sensitis-
ation procedure. A very small amount, less than 1% of the available
antigen, is usually adsorbed onto tanned erythrocytes (Scheibel 1956,
Ling et al, 196l). Herbert (1967a) observed that cells could be
sensitised satisfactorily using a wide range of antigen concentrations
but other authors (Heller et al,1954, Stavitsky .ndlngraham 1964) noted
non-specific panagglutination with excess antigen. No studies have
been performed on glutaraldehyde fixed human red cells coated with
fibrinogen and it seemed appropriate to investigate this problem.
Glutaraldehyde, tanned cells were washed 3 times in 50 volumes
of C.P. buffer and a 4% (V/V) suspension prepared in the same buffer.
Equal volumes of cell suspension and human fibrinogen (1-100 "fag
clottable protein/ml in C.P. buffer) were mixed and incubated at 37°C
for 30 minutes arid then washed in C.P. buffer. The results of varying
the fibrinogen concentration between 1 - 100 41-g/ml is shown in Table
XII. Although a wide range of antigen concentrations can be used, the
antibody titre was diminished below the concentration of loM-g/ml,
but a fibrinogen concentration of 50 fag or lOOi^/ml resulted in
agglutination of the negative controls. A fibrinogen concentration
of lOfyyQ was therefore used to sensitise the tanned human cells
throughout this study.
The effect of varying the type of buffer and pH during sensitisation
Glutaraldehyde tanned cells were washed and a 4% cell suspension
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(V/V) prepared in different buffers (P.B.S. and C.P.) at different
pH's (6.4 and 8.0). One volume of cells was added to one volume
of fibrinogen solution (lQ^g clottable protein/ml in corresponding
buffers), mixed and incubated for 30 minutes at 37°C. The coated
cells were washed 3 times in 50 volumes of the same buffer used for
the sensitisation and 10% suspension (V/V) prepared in the same
buffer containing bovine albumin 2% (V/V) and sodium azide (l mg/ml).
The results of antifibrinogen titres are shown in Table XII and
demonstrate that the antibody titre was not significantly effected
by the type of buffer or pH range used. However, in the haemagglut-
ination inhibition test (T.R.C.H.I.I.) for F.D.P., citrate buffer
pH 6.4 tended to give a highei sensitivity, thus C.P. buffer (pH 6.4)
was used in the present study not only to obtain higher sensitivity
but also to prevent clot formation which has been shown to be an
occasional problem when phosphate buffer has been used.
The effect of varying the _tinie of incubation during sensitisation
Glutaraldehyde tanned cells were sensitised in the standard
way, but the incubation time was varied from 15 - 120 minutes. The
cells were washed in 50 volumes of C.P. buffer. The antifibrinogen
titres are shown in Table XII and indicate that satisfactory sensi¬
tisation can be obtained in 15 minutes. Any further increase in the
incubation time did not influence the sensitivity. In this study a
30 minute period was taken for routine sensitisation.
The effect oj varying the incubation temperature during sensitis¬
ation.
Glutaraldehyde tanned cells were sensitised as before, with the
EFFECT OF VARIATIONS IN FIBRINOGEN CONCENTRATION, BUFFER AND PH
TIME OF INCUBATION, TEMPERATURE AND RELATIVE INCREASE OF
FIBRINOGEN AND CELL CONCENTRATION ON THE ANTIBODY TITRE































































































(+) = partial or incomplete agglutination Continued
(+) m complete agglutination




10 C.P. 6.4 15 37 4
1
2048 x 103 -ve
10 C.P. 6.4 30 30 4
1
2048 x 103 -ve
10 C.P. 6.4 60 37 4
1
2048 x lb3 -ve
10 C.P. 6.4 120 37 4
1
2048 x io3 -ve
TEMPERATURE
10 C.P. 6.4 30 22 4
1
2048 x 103 -ve
10 C.P. 6.4 30 37 4
1
2048 x 103 -ve
RELATIVE INCREASE OF BOTH CELL AND FIBRINOGEN
10 C.P. 6.4 30 37 4
1
2048 x 103 -ve
20 C.P. 6.4 30 37 8
1
2048 x ib3 -ve
40 C.P. 6.4 30 37 16
1
2048 x ib3 -ve
TABUS XII
-ve = firm end point with distinct button
~
^9 "
/ O ° \
exception that the incubation temperature was varied (22 C or 37 C).
The results of the antifibrinogen titres are shown in Table XII. The
procedure was not influenced by the range of temperature studied.
The effect of proportional increase in both fibrinogen and cell
content during sensitisation
The following experiment was designed to prepare a large volume
of sensitised cells, but avoiding the use of large quantities of
washing fluid. The tanned cells were washed in C.P. buffer (pH 6.4)
and 4 to 16% cell suspension (V/V) prepared in C.P. buffer added to
fibrinogen solutions with increasing concentrates (10 - koiig of
clottable protein/ml) in C.P. buffer. The mixtures were incubated
o
at 37 C for 30 minutes and then washed 3 times in C.P. buffer.
The results of the antifibrinogen titres are shown in Table XII
and demonstrate that cells can be sensitised satisfactorily by
proportionally increasing the concentration of fibrinogen. Thus a
16% suspension (V/V) of cells was satisfactorily sensitised by
40/^g/ml of fibrinogen. This observation has some practical signif¬
icance to those engaged in this work, for it reduces a considerable
amount of tedious work, and in so doing ^educes costs. It has also
been shown that further cuts are possible by simply decanting the
supernant off at the end of the tanning stage and adding the fibrin¬
ogen immediately for sensitisation.
Comparative antifibrinogen titres of human and sheep red cells coated
with fibrinogen
Human and sheep cells were fixed with glutaraldehyde and
sensitised with or without tanning under identical conditions. The
- 50 -
antifibrinogen titres are shown in Table XIII which demonstrate that
the titre of sensitised tanned human cells was 4-8 times higher
than similarly treated sheep cells and that the directly sensitised
human cells (untanned) were 16 - 32 times more than equivalent sheep
cells. It was also observed that the tanned sheep cells required less
antigen (l llg/ml) to attain the highest antibody titre. The results
also show that the cells autoagglutinate when higher concentrations
of fibrinogen (50 - 100/^-g/ml) are used for sensitisation of either
human or sheep cells.
These results using a fibrinogen/antifibrinogen system are in
close agreement with Steele and Coomb's (1964) findings with other
antigens. They noted that human cells were 4 times more sensitive
than sheep cells.
COMPARATIVEANTIFIBRINOGENTIT EFFIBRINOG NSE SITISED HUMANANDSHEEPRCELLS


























































































+=completeautoagglutination (-)=moderateautoagglutin tion (+)=slightautoagglutination
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STUDIES ON THE PREPARATION OF SENSITISED HUMAN RED CELLS FOR THE P.P.P.
ASSAY WITHOUT TANNING.
There is no doubt that one of the problems of the T.R.C.H.I.I.
for F.D.P. assays has been the ability in many laboratories to prepare
satisfactory reagents, notably the sensitised red cells. The exist¬
ing procedures involving preservation, tanning and coating are
laborious and extremely time consuming and it is probable that much
of the difficulties have arisen during this arduous and exacting
stage.
Ling (1961) and Bing et al (1967) reported that antigen attach¬
ment was possible immediately after fixation; thus omitting a
tanning stage. Studies were undertaken to assess whether this
reported technical feature could be confirmed and adapted to the
attachment of fibrinogen to human red cells for the F.D.P. assay.
Using the simple basic experimental design described in detail
in previous chapters the optimal fibrinogen concentration, buffers,
pH, incubation time and temperature were delineated. The results
of these studies are summarised in Table XIV. They show that it is
indeed possible to take human group 0 Rhesus negative red cells,
preserve with glutaraldehyde (1%) and obtain apparently satisfactory
coating of fibrinogen to enable satisfactory F.D.P. estimations,
without including a tanning stage. In summary, using a preservation
procedure described previously, the optimal conditions for direct
sensitisation appeared to be as follows; glutaraldehyde fixed cells
were washed 3 times in C.P. buffer, 1 volume of a 4% suspension (V/V)
in C.P. buffer and 1 volume of human fibrinogen solution (30^-g of
INVESTIGATIONS ON THE EFFECT OF VARIATIONS IN
FIBRINOGEN CONCENTRATIONS, BUFFER AND pH, TEMPERATURE



























2 37 C.P. 6.4 37 60 4
1
38 x 10J -ve




10 37 C.P. 6.4 37 60 4 J 3
32 x lO-* -ve




30 37 C.P. 6.4 37 60 4
1
3128 x 10J -ve
50 37 C.P. 6.4 37 60 4
1
^
128 x 10J -ve
100 37 C.P. 6.4 37 60 4
1
1
128 x 10J -ve
BUFFER AND pH
30 37 C.P. 6.4 37 60 4
1
3128 x 10J -ve
30 37 C.P. 8 37 60 4
1
364 x 10J -ve
30 37 P.B.s. 6.4 37 60 4 - 3
32 x 10J -ve
30 37 P.B.S. 8 37 60 4 1 3






































clottable protein/ml in the same buffer) were mixed and incubated
o
for bO minutes at 37 C with occasional further mixing. The cells
were then washed 3 times in 50 volumes of C.P. buffer and stored
as a 10% cell suspension (V/V) in diluting fluid.
The storage of these cells when compared to glutaraldehyde, tan¬
ned, sensitised cells are summarised in Table XV. It can be seen
that the antifibrinogen titre of the directly sensitised cells (non-
tanned) , although identical to the tanned batches when initially
tested, after approximately 3 months began to lose their sensitivity.
It was concluded that tanning results in more effect binding of the
antigen to the red cell membrane and that the time used in this
procedure is well spent, as cells obtained retain excellent
sensitivity for at least 2 years.
THE F.b.P. HAEMAGGLUTINATIQN INHIBITION IMMUNOASSAY USING HUMAN RED
CELLS.
In the previous studies attempts to develop methods which
permit the introduction of sensitised human red cells that may be
stored for many months for the T.R.C.H.l.I. for F.D.P. estimation
have been described in detail. In terms of antibody titration
values and stability, the results of these studies were particularly
successful. However, before clinical studies with this new reagent
could be considered it was important to observe their behavior in
the inhibition immunoassay situation. The apparatus (Microtitre
system) and other reagents required, (preparation of test sera,
details of antibody titration, patterns of agglutination obtained,
controls incorporated into each assay and the calculation of F.D.P.
Antibody titre of fibrinogen sensitised human cells (tanned and
untanned) after storage for variable length of time (reciprocal titre).
A. FIBRINOGEN SENSITISED TANNED CELLS FIXED WITH DIFFERENT ALDEHYDE
DURATION OF STORAGE IN MONTHS
Batch No. Initial 1 2 3 4 5 6 • 9 12 15 18 21 24 27
TANNED (XI J ITAP A T DPHYDK FIXED CELLSvalju lniuiLL/Lllii/L
H-l 2048T 1024T 2048T 2048T 1024T 1024T 1024T 2048T 2048T 1024T 1024T 1024T 1024T 512T
H-2 2048T 2048T 2048T 2048T 2048T 2048T 1024T 1024T 2048T 1024T 1024T 1024T 512T 1024T
H-3 2048T 2048T 1024T 2048'T 1024T 1024T 2048T 2043T 1024T 1024T 1024T 1024T 1024T 512T
H-4 2048T 2048T 1024T 2048T 2048T 1024T 2048T 1024T 1024T 1024T 1024T 1024T 512T 512T
H-5 2.048T 2048T 2048T 1024T 2048T 2048T 1024T 2048T 1024T 1024T 1024T 1024T 1024T 1024T
H-6 2048T 2048T 1024T 1024T 2048T 2048T 1024T 2048T 1024T 1024T 1024T 1024T 512T 512T
H-7 2048T 2048T 2048T 1024T 2048T 2048T 1024T 1024T 1024T 1024T 1024T 1024T 1024T 1024T
H-8 2048T 1024T 2048T 2048T 1024T 1024T 2048T 1024T 1024T 1024T 1024T 1024T 512T 512T
HL 2048T 2048T 2048T 1024T 2048T 1024T 2048T 1024T 2048T 1024T 1024T 1024T 1024T 512T
HS 2048T 1024T 2048T 1024T 1024T 2048T 1024T 2048T 1024T 1024T 1024T 1024T 512T 1024T
TANNED PYRUVIC ALDEHYDE FIXED CELLS
P.S. 512T A A A A A A
TANNED FORMALISED CELLS
F.S. 2048T A A A A A A
B. FIBRINOGEN SENSITISED UNTANNED FIXEE CELLS
Glutaraldehyde 128T 128T 64T 64t 32T 32T 16T 16T 8t 8T 4T IT
Pyruvic aldehyde 16T A A A A A A





values) have been described in detail by previous workers (Merskey
1969; Das 1970b) and are outlined in the appendix of this thesis.
The purpose of this chapter is to summarise the basic principles of
the inhibition immunoassay and describe some experiments designed to
consider certain important variables which might influence F.D.P.
quantitation.
Principle of the test
When diluted antifibrinogen sera is incubated with test samples
containing excess fibrinogen or F.D.P. the antisera is neutralised
completely. If fibrinogen coated cells are now added, no agglutin¬
ation occurs. The reaction between antisera and coated cells has
therefore been inhibited. If the amount of fibrinogen or F.D.P.
is insufficient, then only partial neutralisation of the antisera
occurs leaving sufficient to react with the sensitised cells and thus
agglutination occurs.
This is the basic principle of all haernagglutination inhibition
reaction and by using specific nti-human fibrinogen sera and
fibrinogen controls for calibration, the dilution at which the
settling pattern changes from inhibition to non-inhibition enables
an unknown test sample to be quantitated.
T.R.C.H.I.I. for F.D.P. quantitation
Three standard fibrinogen solutions of varying concentration
(58 mg%, 100 mg% and 136 mg% clottable protein) were diluted 100
fold in diluting fluid and then serially diluted in the same way as
the test sample. The optimal concentration of antisera for the
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assay was determined or calculated from the antibody test obtained
from running antisera against sensitised cells (see appendix).
In practice the antisera used was approximately 10 times more
concentrated than the maximum dilution which produced unequivocal
passive agglutination.
Titration of fibrinogen standards and test samples were made
serially as l/2, 1/3, 1/4, 1/6, 1/8 using diluting fluid. Specific
attention was paid to such details as meticulous rotating of the
micro-dilutor 20 times in each well, to obtain satisfactory mixing.
Separate dilutors were used for the l/2, 1/4, l/8, l/l6, 1/32 series
and the l/3, 1/6, 1/12, 1/24 and 1/48 series.
One volume (0.025 ml) of antisera, suitably diluted, was now
added to all the diluted samples in each well. Mixing was achieved
by aggitation of the microtitre plates followed by a period of 4
hours incubation at 22°C (room temperature). One volume (0.025 ml)
of a 2.5% suspension of sensitised red cells was then added to every
well, thoroughly mixed, incubated at room temperature overnight and
the settling patterns recorded the following morning. Positive
and negative controls were set up in every assay batch.
Although a considerable number of variables which might effect
the T.R.C.H.I.I. for F.D.P. have already been extensively studied
(Das 197Cb), at least 4 features were regarded as having had less
than satisfactory attention or none at all. Accordingly experiments
were performed in order to define these variable.
The effect of variations in the concentration of the stabilizing
agent in the diluting fluid
In this experiment bovine and human albumin were used As
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stabilising agents and added to citrate buffer at different
concentrations (0.25% to 6%). The T.R.C.H.I.I, was performed on
standard fibrinogen solutions and on normal as well as pathological
sera. The effect on the inhibition is shown in Table XVI which
reveals that the inhibition titre increases when the concentration
of stabilising agent is increased to 2%. Further increases in protein
concentration reverse this trend. Moreover, in pathological sera no
inhibition could be detected due to appearance of a prozone
phenomenon. At an albumin concentration of 0.25%> auto-agglutination
occurred with standard fibrinogen solutions. There was no signifi¬
cant difference between the results obtained from bovine and human
albumin. Thus the work reported in this thesis, 2% bovine albumin
was incorporated in the diluting fluid as a stabilizer.
A comparison of Phosphate Duffer Saline and Citrate Phosphate Buffer
at different pH on the sensitivity of the T.R.C.H.I.I.
Comparative studies were performed to investigate the effect of
C.P. and P.B.S. buffers at pH 6.4 or 8.0 on the inhibition titre.
The results are shown in Table XVII. There appeared to be little
doubt that C.P. buffer at pH 6.4 gave significantly higher inhibition
titres as well as better agglutination patterns. Thus C.P. buffer
at pH 6.4 was used throughout this study to prepare the diluting
fluid.
The effect of temperature on the sensitivity of the T.R.C.H.I.I.
To investigate the effect of incubation temperature on this
inhibition titre, 2 microtitre plates containing similar test samples
and standard fibrinogen solutions were incubated at different temper-































































































{U. g . ml)
Inhibition Quantity of
Titre F.D.P. in serum
(U- g /ml)
C.P. 6.4 1600 0.6 16 9.6
C.P. 8 A 12 7.2
P.B.S. 6.4 A 4 2.4




atures (4°C or 22°C) for the same incubation period. The results
are shown in Table XVIII. The inhibition titre was higher in those
plates which were incubated at 22°C. Moreover, the presence of cold
agglutinins in some test sera completely masked the inhibition titre
when the microtitre plates were incubated at 4°C. Although the
action of the cold agglutinins could be partially reversed by a
second incubation at room temperature or 37°C, this was not always
successful and accordingly room temperature was routinely adopted
for this study.
The effect of varying the interval between addition of antisera and
cells on inhibition titre.
The following experiment was designed to study the effect on
the inhibition titre by varying the time between addition of anti-
sera and sensitised cells. The test samples including the standard
fibrinogen solutions, were diluted in diluting fluid in 8 separate
plates. Antisera was added to each plate and the contents mixed.
Fibrinogen sensitised cells were then added after fixed incubation
periods of 15, 30, 60, 120, 180, 240 minutes and overnight at
room temperature. The results are shown in Table XIX. The
inhibition titre increased with increasing the incubation period.
Thus overnight incubation provided the highest inhibition titre.
Moreover, it was noted that to obtain really good unequivocal
inhibition patterns in the standard fibrinogen solutions and test
samples, the incubation period should be at least 2 hours.
Effect of incubation











Serum I A 16
Serum II 12 16
A indicates autoagglutination
TABLE XVIII





















































































DISCUSSION AND CONCLUSIONS OF STUDIES ON THE PREPARATION OF PRESERVED,
SENSITISED HUMAN RED CELLS FOR THE ASSAY OF F.D.P.
The present investigation was designed to find a substitute for
formaldehyde as a preserving agent for human red cells in the T.R.C.H.
I.I. for F.D.P., as formaldehyde enhances the tendency to autoagglut-
inate human red cells. It has been demonstrated that glutaraldehyde
is the best fixative for human cells: they react satisfactorily for
at least 2 years and the sensitivity of the antigen coated cells
remains high. Glutaraldehyde fixed human erythrocytes can be
sensitised directly without tannic acid treatment and the sensitivity
of such preparations although modest,is satisfactory for routine use.
However, compared to glutaraldehyde tanned cells, the storage
stability is less satisfactory. This latter finding is similar to
those of Bing et al (1967)» who studied the attachment of proteins
other than fibrinogen to glutaraldehyde fixed sheep cells.
It was interesting to record that glutaraldehyde-tanned cells
appeared to have a consistently higher sensitivity than most sheep
cell preparations prepared in the same way. This observation
confirms the work of Steele and Coombs (1964) who studied antigens
other than fibrinogen.
The sensitivity of the cells appeared to depend primarily on the
tanning procedure. Thus tanned cells were 32 times more sensitive
than untanned. Satisfactory tanning can be achieved over a wide
range of tannic acid concentrations (l: 10,OOO to 160,000), but
concentrations higher than 10,000, of the preparation used in this
study increased, caused a high incidence of autoagglutination.
- 58 -
Optimal sensitivity was achieved by using a concentration between
1: 20,000 to 40,000. This aspect of the study supports the findings
of Shioiri (1964) who used proteins other than fibrinogen.
Sensitivity and autoagglutination were also found to be
influenced by the concentration of fibrinogen used during the
coating procedure. The optimal concentration, providing maximal
sensitivity and avoiding autoagglutination, was found to be between
10-20/{tg/ml. This order of protein concentration is in line with
the results of Boyden (l95l)» Wide (1962), Steffen and Rosak, (1963).
The incubation time for fixation, tanning and coating of human
cells did not appear to be critical and in practice this was main¬
tained at 30 minutes. Glutaraldehyde fixation and tanning were
performed at pH 8.0 and coating at 6.4.
The cells can be fixed at 4°C, 22°C or 37°C. Although this
»o ,
was done at 4 C for routine use, for direct sensitisation this was
o
best achieved by fixation at 37 C. The temperature for tanning can
o -O
vary from 22 C to 56 C and the incubation time could be as short as
o o
15 minutes. The sensitisation can be achieved both at 22 C and 37 C.
The concentration of fibrinogen required for the coating of tanned
cells was lOitg/ml but 30Hg/ml was needed for direct sensitisation
of untanned fixed cells.
These investigations demonstrate that the human cells prepared
fulfilled all the criteria required. Thus the following character¬
istics were observed.
1) Both coated and uncoated cells could be preserved for prolonged
periods.
2) Antibody titres were more than a million and thus the sensitivity
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in the inhibition reaction was very high.
3) The antibody titre remained almost near to its original titre
even after prolonged storage despite repeated washings, which
indicate that the antigens were firmly bound to the cells.
4) No interference of non-specific and cold agglutinins were encoun¬
tered during this study - as the tests were performed and incub¬
ated at room temperature (22°C). Thus no absorption procedures
were required prior to the assays, with the exception of
occasional urine samples.
5) Negative controls always gave well defined settling patterns.
Moreover, during storage the inhibition settling pattern gradually
improved.
6) The haemagglutination inhibition titre on the same test sera was
highly reproducible.
The T.R.C.H.I.I, described proved to be sensitive and very
reliable. It was capable of detecting as little as O.^iig/ml of
fibrinogen. The elimination of an absorption step, which is
essential for the sheep cell assay, enabled a trained technician to
quantitate as many as 50 serum samples per day.
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CHAPTER 7.
STUDIES ON THE AGGLUTINATION OF SHEEP
RED CELLS BY HUMAN SERA.
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STUDIES ON THE HETEROPHILS HEMAGGLUTININS TO SHEEP CELLS IN
NORMAL HUMAN SERA.
Several authors have reported on the problems of obtaining
complete absorption of heterophile agglutinins in normal human sera
prior to performing F.D.P. assays when using tanned and sensitised
sheep cells (Cash et al, 1969 and Mertens et al, 1969)• This
problem has not received the attention it deserves as it may well
explain some of the anomalous results between different laboratories
when studying the same group of patients.
One important source of variability could theoretically be the
sheep red cells used for absorption purposes. Accordingly, the
following set of experiments were designed to examine the optimal
conditions for sheep red cells agglutination by human sera and to
investigate the possibility that some sheep red cells might react
poorly to heterophile agglutinins and in so doing wcbuld prove to
be less than ideal for absorption purposes. At the same time
it was hoped to isolate a 'high reacting' sheep cell preparation





Preparation of test sera
Test serum samples were prepared as for F.D.P. estimations:
10 mis of blood were collected in a glass tube containing 0.2 ml of
aprotinin (5000 K.I. units/ml). The mixture was incubated at 37°C
for four hours and the sera separated after centrifugation at 3400
R.P.M. for 10 minutes. Thrombin was then added to the serum to give
a final incubation for 30 minutes at 37°C and centrifuged at 3400
R.P.M. for five minutes. The resultant sera was either tested
immediately or stored at -40°C.
The test system
The microtitre system was used throughout, using 0.025 nil
volumes. One volume of test sera was titrated in serial doubling
dilutions, followed by adding one volume of diluent and finally 1
volume of a 2.5% suspension of sheep red cells. The contents of the
raicrotitre plates were mixed by shaking and then incubated at 4°C
overnight (approximately 16 hours). The patterns were read at room
temperature.
A system of scoring the agglutination titres arithmetically
was used to summarise and analyse the data (Race and Sanger, 1954).
A score of 5 was given to each serial dilution, thus the agglutin¬
ation end points read at l/l scored 5» 1/2 = 10, l/4 = 15, l/l6 = 25i
1/32 - 30.
The intermediate agglutination (jh) scored as 3 and(+) scored 2.
The absorption procedure
Two volumes of test samples were added to 1 volume of washed
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i o
packed red cells, mixed and incubated for 30 minutes at 4 C. After
incubation the samples were centrifuged at 3*400 R.P.M. for 5 minutes
° o
at 4 C, separated and stored at -40 C.
RESULTS
The effect of incubation temperature
Test sera was diluted (doubling dilutions) in separate plates
and the sheep red cells added. Two plates, one for fresh and the
other for tanned cells, were incubated overnight at 4°C and the
other two plates at room temperature. The results are shown in
Table XX which demonstrates that agglutination titres are higher
i °
at 4 C incubation than at room temperature.
These results support the conclusion that the heterophile
antibody to sheep's cells in human sera reacts like a cold
agglutinin and that absorption should be done at 4°C.
The importance of stabilising agent in the diluent
Comparative studies were made of tanned sheep cells in phosphate
buffered saline at pH 6.4 or 8.0, in saline and distilled water.
The results demonstrated that the cells autoagglutinated in saline,
distilled water and buffer (Table XXI). However, this was prevented
when a stabilising agent such as horse serum was added to the buffer.
No difference was observed between the pH range 6.4 - 8.0.
The effect of Trasylol (Aprotinin) and Thrombin
As it was hoped in future studies (vide infra) to assay the
heterophile haemagglutinin titres in the sera, it was important to
ascertain whether this could be done on sera obtained for F.D.P.
studies, i.e. sera containing Trasylol and
^tHeterophile agglutination titre in relation
to incubation temperature^ (Receiprocal titres)
r —
INCUBATION INCUBATION
| AT 4°C AT ROOM TEMPERATURE (22°C)
Sheep red cells Sheep red cells
Tanned Fresh Tanned Fresh
Serum 24 8 4 0 0
Serum 25 32 16 16 8
Serum 26 32 7 8 2
Serum 27 16 8 4 4
Serum 29 128 8 16 4
TABLE XX
The effect of diluent with or without stabilisation on tanned sheep
cells
DILUENT







Cells 1 A A A A (-ve)
Tanned Sheep
Cells 11 A A A A (-ve)
Tanned Sheep
Cells 111 A A A A (-ve)
Tanned Sheep
Cells IV A A A A (-ve)
Tanned Sheep
Cells V A A A A (-ve)
Tanned Sheep
Cells VI A A A A (-ve)
A indicates autoagglutination in negative control




12 normal sera were collected either in plain glass tubes or
tubes containing 0.1 ml of trasylol. The sera were separated out
and then tested for heterophile haemagglutinins against sheep red
cells. The results demonstrate that the heterophile agglutination
scores, were not significantly effected by these agents (Table XXII).
The effect of cell concentration on the heterophile haemagglutinins
titre.
1% and 2.5% cell suspension (V/V) were added to diluted test
samples and incubated overnight at 4°C. The results are shown in
Table XXHL The titres were not significantly altered by using these
two concentrations of cells. However, the end-points were difficult
to differentiate when a 1% cell suspension was used. Therefore,a
2.5% cell suspension was used for all future tests.
The reproducibility of the test
Thirty coded normal sera were tested fresh and after storage at
-40°C for more than 6 months. The results are shown in Table XXIV
which shows that the results were reproducible and that storage has
no deleterious effects, as there was no statistically significant
difference betwreen each set of results (pj>0.l).
A comparison of the heterophile agglutination score in human sera to
fresh and tannic acid treated sheep red cells
A single batch of cells was selected and tested fresh and after
tannic acid treatment against 50 normal sera. The results are shown
The effect of Thrombin and Trasylol on the reactivity of sheep eryth¬













1. 32 32 33 32
2. 32 28 30 27
3. 35 32 32 30
4. 30 32 30 30
5. 30 30 28 28
6. 28 28 27 25
7. 30 28 27 27
8. 28 28 23 25
9. 27 27 27 27
10. 30 30 28 27





The effect of cell concentration on the heterophile haemagglutination
reaction
Serum
1% cell suspension (V/V) 2.5% cell suspension (V/V)
Sample
Titre Score Titre Score
MS 56 C 1/128 38 1/64 38
NS 10 1/64 35 1/32 30
NS 11 1/64 33 1/32 27
CS 1/64 30 1/64 27
TABLE XXIII
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in TableXXV which shows that the tannic acid treated cells gave sign¬
ificantly higher scores when compared with fresh cells (p^O.OOl).
The variability of sheep red cells in their reaction to haemagglut-
inins in normal sera.
A panel of 10 batches of sheep cells (4 Merino and 6 Finnish
Landrace) were preserved in formaldehyde followed by treatment with
tannic acid. (Table XXVI). Sera from 25 healthy volunteers were test¬
ed simultaneously against these cells and the results are shown in
Table XXVI. There was no significant difference between the mean
titre scores of cells Sll, S12, S17, Sl8, S19 and S27 (all Finnish
Landrace). There was a highly significant lower reactivity between
each member of this group (Finnish Landrace) and S24, S25i S26,
(p<^0.001) and S28 (p<C0.002) (all Merino).
' I
Further analysis of the data revealed that although the
red cells from sheep S24, S25 and S26 appeared to be "over all"
poor reactors, this did not apply to certain individual reactions.
An example of this phenomenon is shown fey the performance of
serum R against S25 cells which reacted more strongly than Sll
cells, whereas S26 cells, which usually mirrored the reactions
of S25 cells, failed to agglutinate.
Heterophile agglutination scores before and after tannic acid treat¬






1 25 40 26 20 20
2 20 35 27 10 10
3 20 40 28 15 30
4 10 20 29 5 5
5 5 15 30 10 20
6 10 40 31 20 30
7 25 40 32 20 30
8 10 15 33 20 30
9 25 40 34 15 5
10 20 4o 35 25 4o
11 10 35 36 10 25
12 25 35 37 10 15
13 15 40 38 20 35
14 15 35 39 10 25
15 20 35 40 io 25
16 0 0 41 15 40
17 0 0 42 15 4o
18 25 35 43 15 4o
19 10 25 44 10 40
20 15 30 45 0 5
21 20 30 46 20 30
22 15 25 47 15 20
23 0 0 48 15 15
24 15 40 49 5 20
25 0 0 50 15 35
TABLE XXV

















































































































































































































































































Absorption studies by using "good" and "poor" sheep cell
further substantiated the finding presented above.
DISCUSSION AND CONCLUSIONS
The initial experiments in this section were primarily
designed to define the optimal conditions in which the heterophile
haemagglutinin in human sera reacts with sheep red cells. In
summary, it would appear that the test system can be made specific
and reproducible. It is best performed using a 2.5% red cell
I o
suspension at 4 C. An important finding for subsequent clinical
studies in this Thesis was the absence of interference by Trasylol
and bovine thrombin. This resulted in the preparation of
glutaraldehyde fixed, sheep red cells for future studies. They
proved to be stable and highly reproducible and therefore,
an ideal tool for long-term investigations (vide infra).
An extensive search of the literature has failed to reveal
previous reports on differences in reactivity between sheep cells
to haemagglutinin(s) in normal human serum, although this phenomenon
has been observed in sera from patients with infectious mononucleosis
(I.M.) (Zarafonetis and Oster, 1950). Moreover, Cox and Vermillion
(1956) suggested that the problem was sufficiently important to
warrant the preservation of sheep red cells in order to obtain
standardised techniques for the serological diagnosis of I.M.
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Although the 2 UK, AA Finnish Landrace sheep gave titres
significnatly higher than the others, particularly the 2LK, AB
Merinos, and it is possible that the variation of agglutination
titres may be partly explained by inherent genetic differences in
the cell membrane, the sample size was not sufficient to justify a
distinction being made between the effects of breed and blood group.
It is also likely that an additional heterogenicity was created by
variability in the strength of binding of different populations
of anti-sheep cell haemagglutinins.
The practical significance of these results is of particular
interest for it is suggested that sheep cells with a known low
reactivity to anti-sheep cell haemagglutinins should be selected
as the ideal inert carriers of antigen or antibody in all types of
haemagglutination immunoassays. In doing so it may prove possible
to abandon the time-consumming exercise of absorption prior to
carrying out the immunoassays. In those circumstances where this
does not prove possible, absorption should be done with known
highly reacting cells which must be done at 4°C. The data also
suggests that the conflicting reports of the rise in titre of anti-
sheep cell haemagglutinins associated with allograft rejection
(Rapaport et al, 1968; O'Kane et al, 1969) may be explained on the
differences in reactivity of the sheep cells used in the different
centres. It seems likely that the introduction of a panel of sheep
cells in future studies would be mere revealing.
As a direct result of these methodological studies a stuitable
sheep cell preparation was obtained and the optimal conditions for
the reaction ascertained for the subsequent clinical investigations.
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CHAPTER 8.




The prime motivation for the F.D.P. technical developments,
already described in detail, was towards a linear study inrenal disease*
The design of this study necessitated the assay of a large number
of samples, and using the T.R.C.H.I.I. this would prove to be a
particularly laborious exercise.
In 1971 we were given the opportunity of carrying out a series
of studies on a new approach to the problem - a direct latex agglut¬
ination test, developed at the Wellcome Research Laboratories. This
method had several attractions: it was rapid, and considered to be
sensitive to fragment E, which did not apply to the existing latex
technique known as the Fi-test (Thomas et al, 1970). This latter
feature is believed to be due to a coating of antisera directed
against the anti D and E, rather than anti-fibrinogen.
In view of the potential usefulness of this reagent, known as
the Thrombo-Wellcotest, both for this project and general clinical
application its performance has been tested against the T.R.C.H.I.I.




Serum and urine test samples were prepared as described
previously (Clarkson et al, 1970 and Das et al, I967K All
concentrated urine samples were centrifuged at 3t4O0 R.P.M. for 10
minutes at 4°C in a 6L M.S.E. Mistral centrifuge prior to assay. The
T.R.C.H.I.I. was performed using the modification of Das (1970b)
of the Merskey technique (1966). The Thrombo-Wellcotest reagent
was kindly supplied by Wellcome Reagents Limited, Bechenham,
Kent, England, as was a suspension of latex particles coated with
anti F.D.P. and normal rabbit IgG. Test samples and standard
(human fibrinogen; Kabi Pharmaceuticals) were doubly diluted in
a glycine buffer (0.1 M in 1% NaCl containing 0.1% sodium azide at
pH 8.2. Two drops at a total of 0.05, of test material or standard,
were placed into a marked ring on a clean glass slide. Two drops
of the latex suspension were then added, mixed using a glass rod
and incubated at room temperature for 2 minutes. Macroscopic
agglutination was visualised against a dark back-ground.
RESULTS
Sensitivity to fibrinogen, Fragments D and E
The direct latex test was shown to be sensitive to as little as
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4^g/ml of fibrinogen. Specific products (kindly supplied by
Doctor V. Marder, Temple University, Philadelphia, U.S.A.) revealed
a sensitivity to fragment D of 4/^'g/ml and fragment E of 0.5^9/ml*
Reproducibility
Standard fibrinogen solutions, at different concentrations,
citrated plasma, pooled sera and test samples of both serum and
urine were tested on different occasions. The results are shown
in Table XXVII which demonstrates satisfactory reproducibility.
Precision and sensitivity of the test in relation to incubation time
The precision as well as the sensitivity of the test could
be imporved by increasing the incubation time from the usual 2
to 15 minutes. This is summarised in Table XXVIII.
The precision was increased by using two drops instead of 1
drop as recommended. This simple adaption prevented false agglutin¬
ation reactions in icteric and haemolysed sera. The results are
shown in Table XXIX.
Reproducibility of the te3t
Test samples
(Quantity of F.D.P. (Jig/ml)
Day - 1 Day - 2
Serum 3781 64 it g/ml 644 g/ml
Serum 3756 644. g/ml 6 .4 g/ml
Serum 3306 644 g/ml 644. g/ml
Serum 3818 4 g/ml 12 4g/ml




Plasma 4096 CL g/ml 409 4 /ml
Urine 7508 5124. 3/-' -1 512/4.g/ml
Urine 7525 102-':4- g/ml 1024 4-g/ml
Urine 7569 12 4- 0/i"il 121 l(. nil
Urine 7608 A. g/ml A-g/ml
Urine 9047 2564g/ml 2564g/ml
Urine 1932 4. g/ml 12 4. g/ml
Urine 9125 6 4-g/ml 64 il g/ml
Urine 9130 164-g/ml 164. g/ml
H.F. 1.25"Hg/ml
(w/v) 5124g/ml 512 4g/ml
H.F. 2.5tr>g/ml
(v/v) 1024 4 g/i ;1 1024 K. g/ml
I H.F. 5.0%g/ml
j (w/v)
2044 4g/ml 2044 Ag/ml
1
TABLE XXVII
Sensitivity and precision of the test in relation to incubation time
Time required to enhance nacroscopical Agglutination (incubation Time)
Quantity of clott
-able protein





4' 150" 75" 120" 8'
H.F. 100mg/l00 ml 4* 90" 75" 4' 7'
H.F. 58mg/lOO ml - l40" 75" 105" 4i-
Plasma 5' 90" 60" 2j' 5' 7'
Dig Fibrinogen



















Urine 50" 8" 3' 15'
Serum 60" 90" 7'
TABLE XXVIII
Precision of the test increased by two drops method
Number of
test samples
Number of no false
reaction by 1 drop
method
Number of false reaction
by 1 drop method - which was









A comparison of the latex and T.R.C.H.I.I. reactivities during in
vitro fibrinogenolysis
Streptokinase (1000 units/ml), plasminogen (0.25 casinolytic
units/ml) and purified human fibrinogen (10 mg/ml) were prepared in
o
tris buffer. The mixture incubated at 37 C and at different times,
from zero to 66 hours, 1 ml aliquots of the digest were removed and
the enzymatic reaction arrested by adding 0.1 ml of Aprotinin
(5000 U/ml) and the thrombin time (Thomson, 1970), a fibrinogen
estimation (Ellis and Stransky, 1961), T.R.C.H.I.I. and Latex test
performed.
The results are summarised in Fig. j .
The apparent higher sensitivity of the Latex test to later
digests, compared to the T.R.C.H.I.I., was thought to be related to
the use of antisera in the T.R.C.H.I.I. directed against whole
fibrinogen, thus being relatively insensitive to anti-E. This
conclusion was supported by the known high sensitivity to the E
fragment of the Latex test and the observation that when a specific
anti-E serum was used in the T.R.C.H.I.I. then continued sensitivity
was retained throughout the period of digestion (Fig. 6).
Comparison of the T.R.C.H.I.I. and Latex Test on Clinical Material
A plot of the results from both techniques on 144 sera and 37
urines is shown in Fig. There was a very satisfactory correlation
between the two methods (r = 0.8942 : despite the use
of antisera to whole fibrinogen in the T.R.C.H.I.I.
Non-specific latex particle agglutination
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Fig. 5 F.D.P. quantitation using the Latex Test,
T R.C.H.I.I., thrombin time and fibrinogen
estimations on serial aliquots of an in vitro
human fibrinogen plasmin digest.
(Minutes) (Hours)
INCUBATION TIME
Fig. 6 Results of the T.R.C.H.I.I. on in vitro human
fibrinogen digests using antisera prepared to
whole human fibrinogen, fragment D and (fragment E.
4 8 16 32 64 128 256 512 1024 2048
LATEX TECHNIQUE (yug/m!)
Fig. 7 A correlation between the Latex test and T.R.C.H.I.I.
on the F.D.P. values in sera (circles) and urines
(squares), (r = 0.094, p/LO.OOl).
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agglutinated the latex particles coated with normal rabbit IgG.
However, in patients with rheumatoid arthritis this rose to 25%:
the highest titre recorded being l/8. In urine specimens, whether
from healthy subjects or patients with glomerulonephritis, this rose
to 50% in fresh specimens but could be reduced to 25% after freezing,
thawing and centrifugation. The highest titre recorded was 1/64.
Complete removal of this non-specific latex agglutinating material
was possible if 1 volume of urine was incubated with 1 volume of nor¬
mal rabbit IgG coated latex for 30 minutes at 4°C.
DISCUSSION AND CONCLUSIONS
Latex agglutination tests have been used since 1956 when Singer
and Plotz introduced latex particles as carriers for gamma globulin.
It has been used most frequently in rheumatology and pregnancy test¬
ing. Hirsch et al, 1965 used the Fi-test (antifibrinogen serum
coated latex made by Hyland Laboratories) for the estimation of
plasma fibrinogen. Since then many others have used the Fi-test
for the detection of F.D.P. in serum but with less than satisfactory
results (Merskey, et al, 1966; Castelan et al, 1968; Melligar, 1970;
Thomas et al, 1970; Marder et al, 1971)• Allington 1971 introduced
fibrinogen coated latex for estimation of serum F.D.P. using an
agglutination inhibition test technique similar to the T.R.C.H.I.I.
The Fi-test has the disadvantages of low sensitivity which has
varied from 10 - 20-^g/ml and cannot detect late products (Castelan
et al, 1968; Thomas et al, 1970; Marder et al, 1971)• Allingtons
technique, although more sensitive and reliable than the Fi-test,
is technically cumbersome (Allington, 1971) and has proved to be
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insensitive to the E fragment (Marder et al, 1971)•
From the results of this study there seems to be little doubt
that the latex F.D.P. test, developed at the Wellcome Research
Laboratories, has many attractions for those concerned with the
semiquantitation of F.D.P. in serum. In vitro studies above reported
have clearly demonstrated that the sensitivity to all digested
fragments is good and in terms of fragment E more sensitive than
the T.R.C.H.I.I. using whole anti-fibrinogen sera. From a clinical
point of view only 20 minutes are required to produce a results,
and it must therefore represent a satisfactory technique. The
presence of non-specific latex agglutination substances in sera is
unlikely to be of significance as it has not been recorded above a
titre of 1/8 which corresponds to an F.D.P. of 32^g/ml. The close
correlation between the T.R.C.H.I.I. and latex F.D.P. test on
individual serum samples was also encouraging and indicates that
laboratories can convert to this assay readily. Although ideally
suited as a 'one-off' rapid bedside technique the method is somewhat
laborious as there is no readily available and suitable automatic
dilution equipment at the moment, and it seems likely that the
T.R.C.H.I.I. will continue to be used on those research studies which
involve the assay of a large number of specimens. This conclusion
was incorporated in the work described in this Thesis.
Merskey et al, (1966) recorded the presence of a significant
number of apparent false positive reactions in normal sera when using
the Fi-test. This phenomenon was noted in the present studies but
it was found that the incidence could be greatly reduced by using
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glycine buffer as a diluent in place of normal saline. The mechanism
of this reaction is unknown, but by incorporating the glycine buffer
the incidence of non-specific latex agglutination in normal sera was
reduced to 1%. In practice it seems reasonable to institute a latex
control test using normal rabbit IgG coated latex in those sera
reading between 20 - 40^ g/ml, as this was the maximum non-specific
titre recorded.
The position with regard to the latex F.D.P. assay for urine
appears to be quite unlike the serum. Because the latex test has an
overall, slightly lower sensitivity than the T.R.C.H.I.I. the need
to concentrate the urine specimens before assay is imperative. This
procedure greatly increases the non-specific latex agglutination
problem so that almost 50% cannot be assayed. Freezing, thawing and
centrifugation reduced this to approximately 25% only.
Although the residual non-specific substance(s) could be
absorped using normal rabbit IgG coated latex this extra procedure
made the whole process extremely laborious. Thus it would appear
that for urine F.D.P. assays, the L&tex Test is not ideal and in
view of the importance of running large batches of assays on indiv¬
idual patients (Clarkson et al, 197i) it is felt that the latex
approach is unlikely to replace the T.R.C.H.I.I. for urine assays.
It is of interest to record that the non-specific latex agglut¬
inating substance(s) in sera and urine did not appear to be sensitive
to mercaptoethanol treatment and their was no correlation between the
non-specific latex agglutinating titres and the sheep red cell heter-
ophile antibody titre in either serum or urine.
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SECTION III
STUDIES ON THE URINARY HETEROPHIL® HEMAGGLUTININ AND













At the present time perhaps the most fruitful area in clinical
medicine,in which the measurement of F.D.P. appears to offer assistance
in the management of individual patients lies in general nephrology
and renal transplantation, and in urine rather than serum. Abnormal
urine F.D.P. excretion has been shown to arise in glomerulonephritis
and during the rejection of renal homografts (Clarkson et al, 1970;
Haanen et al, 1971 and Bouma et al, 1971)• In proliferative forms of
glomerulonephritis urine F.D.P. excretion appears to correlate closely
with disease activity (Clarkson et al, 1971)i and particularly
interesting has been the response to certain therapeutic manoeuvres,
both in the rejecting renal homograft (Clarkson et al, 1970) and
active proliferative glomerulonephritis (Vermylen et al, 1971 and
Clarkson et al, 1972). These events are likely to be immunological in
origin (vide supra).
One of the outstanding features of all these studies has been
the relative insensitivity of serum F.D.P. to marked activity within
the kidney tissue. This in part may be due to reduced glomerular
perfusion during the active phase of the disease processes, the fact
that much of the intra-renal fibrin is likely to be extravascularly
situated (Davison et al, 1973) and due to a dilution factor, as the
renal mass accounts for only 25% of the total cardiac output. In
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considering how to apply the assay of heterophile haemagglutinin as
a marker of non-specific immunological damage in the kidney, it was
concluded that its application would be best directed in the first
instance towards urine rather than serum. Moreover, the non-invasive
nature of a urine analysis has considerable practical attractions, so
that patients can be under continued surveillance with the minimum
of discomfort and inconvenience.
The following account describes a series of preliminary studies
in which an attempt is made to ascertain whether heterophile haema-
gglutinins are excreted in healthy subjects, those with renal
homografts and in glomerulonephritis, and whether this correlates
with the urine F.D.P. excretion in these patients. Efforts are also
made to ascertain the mechanisms of these phenomena and to delineate




The normal urines (100,aged 19 - 58 years) were obtained from
laboratory personnel and the author's colleagues and friends. They
were not 24 hour-collects, but obtained at random during the working
day.
The patient groups were those attending the Nuffield Transplant
Unit, Western General Hospital, Edinburgh under the care of
Professor Sir Michael Woodruff and Mr. B. Nolan; the Medical Renal
Unit, Royal Infirmary, Edinburgh under the care of Doctor J.S.
Robson and Doctor Anne Lambie; the Paediatric Renal Unit, Royal
Hospital for Sick Children under the care of Doctor William Uttley
and several other General Medical Units in the S-E Region of Scotland.
Aliquots from 24 hour collects were obtained during in-patient periods,
but while at home patients sent early morning urine specimens to the
laboratory, through the postal services. No proteolytic inhibitors
were used during sample collection as this has been shown to be
unnecessary (Clarkson et al, 1971)•
The diagnoses in the patients with glomerulonephritis was
established by light, electron and fluorescent microscopy in the
University Department of Pathology under the direction of Doctor
Mary K. Macdonald. The urinary total protein estimations were
performed in the University Department of Clinical Chemistry, under
the direction of Professor G. Whitby. The biuret method used as
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described by Hiller et al (1943). The IgG, IgM and content of
the concentrated urines were quantitated by the Mancini technique
(1965) using commercially obtained plates (Hyland). Using standard
sera the limit of sensitivity of this tech) I [ue was, - 3 mg5°,
IgM - 2.5 mg% and IgG - 5 n»g%.
The activity of the disease in each patient was assessed in the
light of information available at the time of the urinary study.
Cases were considered to be in an active phase if any one or more of
the following clinical pathological features were present: decreas¬
ing creatinine clearances, progressive rise in the concentration of
serum creatinine, proteinuria in excess of 1 g Per 24 hours, red
blood cell casts in the urine, focal or diffuse proliferation of
endothelial and mesangial cells, and intraglomerular fibrin. The
disease was considered inactive or resolving if none of these
clinical features were present or if histology showed only foci of
glomerular sclerosis with or without capsular adhesions.
All urine specimens were first dialysed against tap water and
concentrated overnight, using polyethylene glycol (10 - 20 times),
as previously described (Clarkson et al, 1970). They were then
stored in plastic tubes at -36°C until assayed. All specimens were
centrifuged at 3,400 R.P.M. for 30 minutes after thawing prior to
assay. In those patients in which serial samples were studied, all
were thawed and assayed at the same time in order to maintain
identical assay conditions. The assay of urinary F.D.P. and heter-
ophile haemagglutinins (using high reacting sheep cells) were run
independently and blindly on coded samples as described in previous
chapters and appendix. No prior laboratory or clinical information





URINE F.D.P. AND HETEROPHILS (SHEEP) HAKMAGGLUTININ CONTENT IN
HEALTHY VOLUNTEERS
In the 100 normal subjects studied the concentration of urinary
F.D.P. never exceeded 0.2^/^-9/ml which is in agreement with the
findings of Clarkson et al (1970; 1971)• On no occasion was
heterophile antibody to sheep cells detected in normal concentrated
urine.
URINE F.D.P. AND HETEROPHILE (SHEEP) HAEMAGGLUTININ EXCRETION IN
GLOMERULONEPHRITIS AND HOMOTRANSPLANTATION
A series of 60 selected urines were obtained from the deep
freeze and assayed 'blindly' in order to ascertain the degree of
correlation between their F.D.P. and heterophile antibody contents.
The results are as shown in Fig. 8. Although there was a highly
significant correlation (p O.OOl) the 'r-value' was less than 0.5
and it was assumed to be due to the presence of high F.D.P. and
low heterophile antibody content in some urines and vice versa. This
was confirmed when individual patients urines were studied over a
prolonged period, an example of which is shown in Fig. 9. Neverthe¬
less, there was sufficient evidence to suggest that although the
results from individual samples might be misleading, when patients
were studied serially over a period of time then active proliferative
glomerulonephritis was associated with the presence of intermittent





Fig. 8 A correlation between F.D.P. and heterophile (sheep)
antibody (haeraagglutinin) content in 60 selected urines
obtained from patients with proliferative glomerulonephrits| #J











Fig. 9 The pattern of urinary F.D.P. and heterophile (sheep)
antibody from a patient with proliferative glomerulonephritis.
(Note Some urine specimens contain low F.D.P. and high
heterophile antibody and vice versa).
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heterophile (sheep) haemagglutinin excretion; a phenomenon never
observed in normal controls. Moreover, this was paralleled by the
intermittent appearance of abnormal urine F.D.P. excretion in those
patients.
These pattern of changes were sharply contrasted in those
patients with minimal lesion glomerulonephritis. In this condition
(six cases studied serially for 10 - 22 d^ys) there was less than
2^g/ml of urine F.D.P., which confirms the findings of Clarkson et al
(I97l)i but abundant evidence of heterophile (sheep) haemagglutinin
excretion. Moreover, this returned to normal as the patient
recovered during steroid therapy (Fig. 10).
The data obtained from patients with active proliferative
glomerulonephritis appeared to parallel the findings in patients
undergoing acute or subacute renal homograft rejection. Ten trans¬
plant patients were studied serially and all clinical episodes of
graft rejection were associated with the expected elevation in urine
F.D.P. excretion but also an appearance of urinary heterophile
haemagglutinin (sheep). Fig 11 shows an example in which the daily
events occurring 42 days following renal transplantation are recorded.
By the 20bfl day there was evidence of rejection, as the urine volume
began to fall and serum creatinine was rising. Prior to this,
however, there was a rapid rise in the titre of heterophile antibody
and an associated elevation in urine F.D.P. Of equal significance was
the fall in these latter parameters as the rejection episode was
successfully treated, so that by the 31st day the urine volume had





10 The pattern of urinary F.D.P. and heterophile (sheep)
haemagglutinin in a patient with minimal lesion
glomerulonephritis showing less than 2 g/ml of urine
F.D.P. but abundant heterophile haemagglutinin excretion.
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Fig. 11 Daily urine volume, urinary heterophile (sheep) antibody
(haemagglutinin), F.D.P., total protein, and serum
creatinine in a patient after renal transplantation
followed by rejection episode, which was clinically
evident on the 22nd. day, with the evidence of fall of
urine volume and rise of serum creatinine. Prior to this,
there was a rapid rise of both heterophile antibody and
F.D.P. Fall of these parameters as the rejection episode
was successfully treated.
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URINARY HETEROPHILS (SHEEP) IIAEMAGGLUTININ AND F.D.P. CONTENT IN PRO¬
LIFERATIVE GLOMERULONEPHRITIS DURING INDOMETHACIN ADMINISTRATION.
Although controlled trials have yet to be reported, indomethacin,
an anti-inflammatory drug, has been claimed to be of benefit in the
management of proliferative forms of glomerulonephritis (Michielsen et
al, 1969)« Clarkson et al (1972) have reported that in some patients
receiving indomethacin there was a marked reduction in urine F.D.P.
content during indoinethacin administration. Based on previous studies
(Clarkson et al, 1971) it was suggested that a reduction in disease
activity might have occurred. It, therefore, seemed appropriate to
study the urinary heterophile antibody content in a limited series of
patients before and during indomethacin treatment.
In 5 of the 7 patients studied there was a fall in urinary
heterophile haemagglutinin content during indomethacin treatment, but
it did not occur as rapidly as the fall in urinary F.D.P. In all of
these patients the clinical activity of the disease either improved
or remained stationary during indomethacin administration. An
example of such a response is shown in Fig. 12. In one of the 2
remaining patients both the urinary F.D.P. and heterophile (sheep)
haemagglutinin excretion failed to be influenced by indomethacin
administration (Fig.13 ). This patient's renal function continued
to deteriorate. Perhaps most interesting of all was the seventh
patient: while there was an excellent F.D.P. response during indome¬
thacin therapy this was not paralleled by the heterophile haemagglutinin
excretion (Fig.l4 ). it may be significant that this patient's renal
function continued to deteriorate and eventually long-term renal
dialysis followed by homotransplantation was necessary.
Fig. 12 The pattern of urinary heterophile (sheep) antibody
and F»D.P. excretion in a patient with proliferative
glomerulonephritis whose renal function improved
during indomethacin administration (Note— Fall of both
F.D.P. and heterophile antibody, but heterophile
antibody did not fall at the same rate as the fall of
urinary F.D.P.)
Fig. 13 The pattern of excretion of urinary heterophile (sheep)
antibody and F.D.P. in a patient with proliferative
glomerulonephritis during indomethacin administration
whose renal function continued to deteriorate (Note -
Continued excretion of both F.D.P. and heterophile
antibody).
'//////// IHDOMEJHACIN < 75mgW////////////,
DAYS
Fig. 14 The pattern of excretion of urinary heterophile (sheep)
antibody and F.D.P. in a patient with proliferative
glomerulonephritis whose renal function continued to
deteriorate during indomethacin administration.(Note -
There was an excellent F.D.P. response to treatment
but continued elevation of heterophile (sheep)
antibody.)
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TOTAL PROTEIN. IgM, IgC AND HLTLHOPIIILE HAEMAGGLUTININ CONTENT IN
ISOLATED URINES FROM POST-TRANSPLANT AND GLOMERULONEPHRITIS PATIENTS
One of the fundamentally important aspects in understanding the
presence of heterophile haemagglutinin in urine is to consider that
it may arise as a simple leakage of plasma through a damaged and highly
permeable glomerular basement membrane. As such, it would be of little
interest and could not be regarded as being involved in an immune
tissue destructive process. The first approach required to examine
this possibility would be to consider the correlation between total
protein content and heterophile haemagglutinin of urines.
All assays were performed on dialysed/concentrated urines (vide
supra). The results of such a study are shown in Fig.15 in which
it can be seen that no correlation was observed. However, a
correlation was recorded between the urinary heterophile (sheep)
haemagglutinin and IgG and IgM concentrations in trhe homotransplant( Fig 16*17)
urines, and between the IgG only in the proliferative glomerulone¬
phritis urines (Fig. 18 ). In minimal lesion glomerulonephritis there
was also a correlation between both of these parameters (Fig. 19 & 20).
C^3 AND HETEROPHILE HAEMAGGLUTININ CONTENT IN ISOLATED URINE SAMPLES
I .OM POST-TRANSPLANT AND GLOMERULONEPHRITIS PATIENTS
Both active proliferative glomerulonephritis and renal homotrans-
plant rejection are regarded as destructive processes of immunological
origin and therefore likely to involve localised glomerular complement
and in particular C3 deposition (Gotoff et al, 1965, Michael et al,
1969)• It therefore seemed of value to assay the urinary C3 content


















Fig. 15 Evidence of no correlation between total protein
content and heterophile (sheep) antihbdy of




y = 3'5016 ♦0 1985 x
Fig. 16 A correlation between urinary heterophile (sheep)
haemagglutinin and urinary IgM in transplant patients
(r = 0.6885, p<O.OOl).
TRANSPLANTPATIENTS
r=05551 P<001
Fig.17Acorrelationbetw enthur n ryhet rophi(s ep)haemagglut ninand IgGintra splantpatients(=0.5551?p<O.OOl).
PROLIFERATIVEGL MERULONEPHRITIS r=0-6139 P<0-001 URINARYIgG(mg%)
Iig.18Acorrelationbetweenthuri aryh terophile(sheep)a magglutininand IgGinproliferativeglomerulonephritis(=0.6139,^O.OOl).
MINIMALLESIONG.N. r=0-620A P<001 y=03617-021.33x URINARYTOTALP OTEIN(mg%)
Fig.19Acorrelationbetweeurinaryt talproteindh rophile(sh ep) haeraagglutinininminimallesiolomerulonephritis(=0.6204,p<,O.OOl).
MINIMALLESIONa . r=0(.985 P<OOI URINARYIgG(m V.)
Fig.20Acorrelationbetweenur naryI Gdh t r phile(sh ep)ha magglutinin inminimallesionglomerulonephritis(=O.4985,p^O.OOl).
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correlate these findings with the heterophile haemagglutinin and F.D.P.
content. It also seemed appropriate to consider the correlation between
urinary C 3, IgG and IgM in these isolated samples from different
patients. All assays were performed on dialysed/concentrated urines
(vide supra).
The results are summarised in Table XXX - It can be seen that
there was a positive correlation between the urinary heterophile (sheep)
haemagglutinin, F.D.P. and C3 content. There was also a nositive
correlation between the C3 and IgM and C3 and IgG (Figs. 21 & 22).
COMBINED SERIAL STUDIES ON FIVE SELECTED PATIENTS
The apparent success of the studies on a selection of urine
samples from many different patients made it worthwhile considering a
detailed combined investigation on a number of consecutive urine
samples from 5 highly selected patients;-
1. Minimal lesion glomerulonephritis
2. An episode of renal homotransplant rejection
3. Active proliferative glomerulonephritis failing to show an F.D.P.
and heterophile (sheep) haeraagglutinin response to indomethacin
4. As (3^) but showing F.D.P. and heterophile (sheep) haemagglutinin
responses
5. As (3«) and (4.) but showing a satisfactory F.D.P. and unsatisfac¬
tory heterophile (sheep) haemagglutinin responses.
The results of serial assays of urine F.D.P., heterophile (sheep)
haemagglutinin, IgG, IgM and C3 on these patients are shown in Fig. 23 -
No significant IgM or C3 excretion was detected in the minimal lesion
















Urinary IgG (mg %)
Fig. 21 A correlation between urinary C3 and IgG in
isolated urine samples from post-transplant
glomerulonephritis patients (r = 0.6979* p<C0.00l).
r= 0-6927
Urinary C3 (mg %)
Fig. 22 A correlation between urinary C3 and IgM in isolated
urine samples from post-transplant and glomerulonephritis
patients (r = 0.6927, p<O.OOl).
PARAMETERS NUMBER STUDIED r-VALUE p-VALUE
/ S.H.A. 96 0.8319 < 0.001
C / F.D.P. 96 0.6431 < 0.001
c3 / IgM 64 0.7291 < 0.001
TABLE XXX
Correlation between urinary F.D.P., Heterophile (sheep) haemagg-
lutinin (S.H.A.), IgM and in a selection of isolated samples
from patients with proliferative glomerulonephritis and renal
transplantation.
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present. The unremarkable F.D.P. content confirmed previous
observations. The transplant rejection episode was associated with a
elevation in all parameters assayed. 24)
The 3 highly selected proliferative glomerulonephritis patients
receiving indomethacin showed particularly interesting results. Three
parameters gave parallel information, namely the excretion of hetero-
phile (sheep) haemagglutinin, IgM and C3 Thus in the patient who
showed evidence of an excellent F.D.P. response to indomethacin there
was a continued excretion of heterophile (sheep) haemagglutinin, IgM
and C3 (Fig. -r). This patient's renal function continued to
deteriorate, as did the patient whose combined measurements showed
no change during indomethacin administration (Fig. 26)- The patient
whose renal function improved on indomethacin treatment showed a
dramatic fall in the excretion of F.D.P., heterophile (sheep)
haemagglutinin, IgM and C3.(Fig. 27).
Fig. 23 Combined serial studies on urines from a patient with
minimal lesion glomerulonephritis showing no detectable
IgM or C3 although heterophile (sheep) haemagglutinins
as well as total protein and IgG were present.
Fig. 24 Combined serial studies on urines from a transplant patient
with a rejection episode. (Note - There was elevation in
all parameters assayed, i.e. Heterophile (sheep) haemagglutinin,
F.D.P., total protein, C3, IgM, IgG and blood urea. A fall













Fig. 25 Combined serial studies on urines from a patient with
proliferative glomerulonephritis receiving indeomethacin
showing an excellent F.D.P. response to treatment. (Note -
Continued excretion of heterophile (sheep) haemagglutinin,
IgM, C3, IgG and total protein. This patient's renal




















Fig. 26 Combined serial studies on urines from a patient with
proliferative glomerulonephritis showing no response
to treatment. (Note - Continued excretion of F.D.P.,
heterophile (sheep) haemagglutinin, IgM, IgG and C3).
INDOMETHACIN 75mg./d.
Fig. 27 Combined serial studies on urines from a patient with
proliferative glomerulonephritis whose renal function
improved on indomethacin treatment. (Note - dramatic




QUALITATIVE STUDIES ON URINARY HE1EROPHILE HAEMAGGLUTININ
Urinary haemagglutinins to sheep, rabbit and rat cells
Gluataradehyde fixed sheep (high reacting: Finnish Landrace,
and low reacting Merino), rabbit (New Zealand White) and rat (Sprague-
Dawley) erythrocytes were prepared and the titres of urinary
agglutinins ascertained against a panel dialysed/concentrated urine
samples, obtained from patients with glomerulonephritis (45
proliferative, 53 minimal lesion) and post-renal transplantation (30).
The results are summarised in Tables XXXI . It was observed that
rabbit erythrocytes gave an overal higher titre than any of the other
cells in urines from transplant and proliferative glomerulonephritis
(] <l0.00l). Moreover, rabbit cells detected agglutinins in a higher
proportion of these urines tested (p<^0.00l). Sheep (high reacting)
cells appeared to react more frequently with proliferative glomeru¬
lonephritis urines, compared to rat, but the situation was reversed
in the transplant urines (p^O.Ol). In minimal lesion, however, the
high reacting sheep cells detected a greater number of positive urines
than either rabbit orrat cells, and the titres were accordingly
higher (p^O.OOl). Low reacting sheep cells were found to be of
little value.
Urinary heterophile haemagglutinin absorption studies
Two types of absorption studies were undertaken: cross absorption
using heterologous and homologous red cells (sheep, rabbit, rat and
human group 0, A and B) and the combined used of guinea-pig-kidney
Urinary haemagglutinins against sheep, rabbit and rat erythrocytes in
glomerulonephritis and transplant
A. Proliferative glomerulonephritis
CELLS SCORE (ARBITRARY UNTTS/ML
TOTAL
NUMBERS




high reacting 5 19 16 3 2 45
Sheep
low reacting 36 7 2 0 0 45
Rabbit 0 10 19 14 2 45
Rat 15 17 11 2 0 45
B. Transplant
Sheep
high reacting 14 10 2 4 0 30
Sheep
low reacting 23 5 2 0 0 30
Rabbit 0 17 6 5 2 30




C Minimal lesion glomerulonephritis
Sheep
high reacting 0 20 13 12 53
Rabbit 40 11 0 2 53
Rat 45 7 l 53
TABLE XXXI (Contd.)
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emulsions and partially boiled ox red cells. This latter approach
was to determine whether the reaction was a Paul-Bunnel type and the
methods used were as described by Barrett (l94l). A known positive
Paul-Bunnel serum was used as a control.
Three urines were selected with known high titre heterophile
haemagglutinins (2 proliferative glomerulonephritis and 1 post-
transplant) and absorped with aliquots of all cells: 1 part urine,
1 part packed cells incubated at 4°C overnight. After the absorption
procedure they were then tested against sheep, rabbit and rat cells.
The results are summarised in Tables XXXII and XXXIII which shows
that high reacting sheep cells absorbed completely the agglutinin to
low reacting sheep cells, little or no effect was recorded when
tested against rabbit and rat cells. Individual erythrocytes absorbed
completely the agglutinin of their own sisecies. Rabbit and rat
Partially
erythrocytes^absorbed the agglutinin to each others cells, thus
showing narked cross-reactivity. Human group 0, A and B Rhesus neg¬
ative cells failed to influence the titre recorded against sheep,
rabbit and rat cells.
Absorption studies on similar urines using boiled ox erythrocytes
and guinea-pig kidney gave inconclusive results. Some behaved
weakly like the Paul-Bunnel positive sera whereas others failed to
absorp, or showed weak absorption with guinea-pig kidney emulsions.
It was concluded that their behaviour was not of the Paul-Bunnel type
(Table XXXIV).
Reactivity of Urinary ileterophile Haemagglutinin after 2M Mercaptoe-
thanol treatment.
Five selected urines (2 transplant and 3 proliferative glomer¬
ulonephritis) were treated with 2M mercaptoethanol as follows:
0.5 ml of urine was added to 0.5ml of 0.O2M mercaptoethanol in iso-
Absorption studies on urinary heterophile haemagglutinin by








Sheep (H.R.) Rabbit Rat
P.G.N.-1 A-ve 10 12 8
B-ve 10 13 8
O-ve 10 12 7
Control 12 15 10
P.G.N.-2 A-ve 12 13 10
B-ve 12 14 10
O-ve 12 13 10
Control 13 14 11
TX. - 1 A-ve 12 18 11
B-ve 11 18 12
O-ve 12 19 11
Control 14 20 12
H.R. - indicates high reacting.
P.G.N. - indicates Proliferative glomerulonephritis
TX. - indicates Transplant
TABLE XXXII



















































































H.R.-ighreacting L.R.-owreacting P.G.N.-roliferativeg om rulonephritis TX.-ransplant
Differential absorption for Paul-Bunnel antibody in the urine of









P.G.N.-1 20 20 13
P.G.N.-2 15 12 2
P.G.N.-3 22 22 22
P.G.N.-4 12 10 0
P.G.N.-5 23 22 15
P.G.N.-6 12 8 8
P.G.N.-7 8 8 8
P.G.N.-8 10 8 8
P.G.N.-9 4 4 4
P.G.N.-10 4 4 2
TX.-l 13 12 6
TX.-2 8 8 4
TX.-3 12 12 4
TX.-4 4 2 0
3 • 1 VJ1 2 2 0
Normal Serum 18 0 13
Control Paul-
Bunnel Serum
2560 2560 1280 j
TABLE XXXIV
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osmotic phosphate buffer (pH 7.4). A control, using the test
material plus phosphate buffer alone i.as also incorporated. Both
o
were incubated at 37 C for 2 hours and dialysed overnight against
i °
phosphate-salxne buffer at 4 C. The samples were then tested
against glutaraldehyde fixed sheep, rabbit and rat cells. The results
are summarised in TableHfXXVwhbh suggests that the heterophile
haemagglutinins in the 2 transplant urines were mainly IgM whereas
the bulk in the three active proliferative glomerulonephritis urines
appeared to be IgG.
Taken toghether these qualitative studies on the urinary heter¬
ophile haemagglutinin content in transplantation and active prolif¬
erative glomerulonephritis suggest that there is no single haemagglut¬
inin involved but several. The reactivity to rat cells excludes
Forssman antibody. Finally, future studies should perhaps turn
to the use of rabbit erythrocytes although high reacting sheep
cells may continue to be of choice in the minimal lesion type of
glomerulonephritis .
Reactivity of urinary heterophile (sheep, rabbit and rat) haema-
gglutinins (scores) before and after 2M mercaptoethanol treatment
Urines
Sheep Rabbit Rat






2 18 2 13 2
• to 6 0 8 0 7 2
P.G.N. 1 8 8 8 7 4 4
P.G.N. 2 10 7 8 8 4 4





It is an interesting fact that during the period
when studies were reported on serum F.D.P. in renal
disease, the results were controversial and disappointing.
It now seems almost certain that the primary problems
were the marked dilution effect after the rena). venous
blood mixed with the rest of the circulating blood volume,
the known powerful mechanisms for clearing systemaically
circulating F.D.P. and the probability that much of the
intra-renal fibrin deposition is likely to be extravas-
cularly sited. By introducing urinary estimations of
F.D.P., however, the Edinburgh group, using the human
cell preparations described in this Thesis, were the
first to show a close correlation between disease
activity in the proliferative forms of glomerulonephritis,
as assessed biochemically and histologically, and the
excretion of F.D.P. (Clarkson, et al., 1971; Davison et
al, 1973)• They were also able to demonstrate, in some
patients, dramatic responses to therapy (Clarkson et al,
1972). Thus marked changes in urinary F.D.P. excretion
were recorded which were not evident from serum estima¬
tions. These observations also appeared to be valid in
the rejecting renal homotransplant situation (Clarkson,
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et al, 1970).
In what, it is proposed is essentially a preliminary
study, described in this section, the same pattern of
events has emerged, although a quite different parameter
has been quantitated. Thus, all previous investigations
directed to the assay of heterophile haemagglutinins in
the renal transplant rejection situation have been con¬
cerned with serum values. These results have also proved
to be disappointing and controversial (Rapaport et al,
1968; Tiong and Morris, 197"?) • It is also of interest
that a recent report has included the finding of increased
serum heterophile haemagglutinin titres in occasional
patients with 'nephritis' (Svehag et al, 1973). Once
again, it would seem that the application of urinary
heterophile haemagglutinin assays, rather than serum,
has revealed considerably more information than hitherto
available. Moreover, the approach of correlating this
data with urinary F.D.P. excretion has also been of
interest.
The initial results of this study would suggest
that in proliferative glomerulonephritis and following
human renal homotransplantation there is an overal
parallelism between the excretion of urinary F.D.P. and
heterophile haemagglutinins. However, this does not
appear to apply in all situations and the one which has
clearly been demonstrated in this study is the response
to the administration of indomethacin in proliferative
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glomerulonephritis. It has been shown, conclusively,
that there is a subgroup of patients whose F.D.P.
response appears to be satisfactory, and as such would,
according to previous studies (Clarkson et al, 1972) be
expected to stabilise or improve their renal function.
In the event this did not occur and it was noted that
their abnormal heterophile haemagglutinin excretion
continuedj unaffected by the indomethacin.
From a clinical point of view this latter observa¬
tion may prove to be of some importance, as it may
represent a new subgroup of patients whose therapeutic
requirements may be significantly different from other
patients. Thus, with respect to the total data now
available from Edinburgh on the responses to indomethacin
in proliferative glomerulonephritis at least 3 major
subgroups have emerged :-
Group 1 - Failure of F.D.P. and heterophile haemagglut¬
inin excretion to fall.
Group TT - Parallel fall in both parameters.
Group YTT ~ Fall in F.D.P. but continued excretion of
heterophile haemagglutinin.
If these subgroups are confirmed and if the clinical
impression that Groups 1 and 111 are destined to contin¬
ued renal functional deterioration, then future trials on
indomethacin in proliferative glomerulonephritis should
be so designed to exclude them. The existing technology
makes this possible.
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The 'Group 1It phenomenon' is also of considerable
theoretical interest, for it would suggest that intra
renal fibrin deposition may not be the key aetiological
factor in the progressive glomerular damage in man, and
that the animal studies of Vassalli and McCluskey (1964)
and Humair et al, (1969a, 1969b) may not be a satisfactory
model. This conclusion, it is suggested, is supported
by the collateral observation of continued C3 and IgM
excretion in this type of patient during indomethacin
adminis trat ion.
There are other significant practical conclusions
which may be drawn from these studies, that are of
particular relevance to those responsible for providing
laboratory services to Nephrology Units. From the
laboratory point of view there are certain advantages to
the serial monitoring of patients' heterophile haemagg-
lutinin excretion rather than F.D.P. The former technique
is a direct one-stage agglutination reaction and as such
is much easier to perform and control than the compli¬
cated and laborious two-stage haemagglutination inhibition
immunoassay required for F.D.P. determinations. Moreover,
the reagents required for urinary heterophile haemagglut-
inin estimations are readily available in any laboratory
area, whereas good quality reagents for the T.R.C.H.I.I.
(F.D.P.) are so difficult to prepare that many labora¬
tories have abandoned this approach and sought refuge in
obtaining commercial supplies. Such a move has proved
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to be costly, and excessively so when it is appreciated
that meaningful data on individual patients can only be
obtained from serial studies on a large number of urine
samples. Finally, preliminary studies in this laboratory
have shown that unlike the T.R.C.H.I.I. (F.D.P.) the
heterophile haemagglutin in technique can be readily
modified to suit automation using a Technicon Single
Channel Autoanalyser. It is believed that the further
development of this approach will enable an individual
laboratory to assay urinary heterophile haemagglutinins
at a rate of 30 samples per hour. Thus, although it
must be emphasised that in the foreseeable future it will
still be necessary to assay urinary F.D.P., as the data
presented in this Thesis are essentially preliminary
in nature, there are already sufficient reasons why those
responsible for laboratory work might wish to see a con¬
version from urinary F.D.P. to heterophile haemagglutinins.
Moreover, from a clinical standpoint the latter may prove
to be a more relevant marker of on-going immune damage.
When considering the origins of urinary heterophile
haemagglutinin in proliferative glomerulonephritis and
during transplant rejection the author finds himself on
less certain ground. Certainly the data presented
demonstrates that the haemagglutination does not arise
from the cross-reaction of urine F.D.P. Moreover,
studies on purified preparations of F.D.P. (fragments D
and E, kindly supplied by Doctor P. Gaffney) did not
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agglutinate sheep, rabbit or rat cells. The absence of a correlation
between the urinary total protein content and heterophile haemagglut-
inin titre, and the good correlation between the urinary IgG and IgM
and heterophile haemagglutinin titre, combined with the knowledge
that in sera this reaction is related to the IgG and IgM fractions
would support the conclusion that the urinary heterophile haemagglut¬
inin is indeed a heterophile antibody. But, ife its appearance related
to a leaking basement membrane, and as such is a feature of 'dilute
plasma', or does it arise following the known glomerular deposition of
IgG and IgM in these conditions (Berger, 1969; McCluskey, 1971;
Macaiovic et al, 1972). To conclude that the latter is at least
part of the mechanism in proliferative glomerulonephritis and renal
transplant rejection implies that urine heterophile antibody does not
arise entirely as a passive leak constituent in the proteinuria,
but is closely related to the immune damage process.
Perhaps the most useful studies, in this project, which give at
least a clue to this problem are those in which serial estimations of
urinary F.D.P., heterophile antibody, IgG, IgM and C3 were performed
on a highly selected group of patients. Thus it is proposed to discuss
this data in some detail.
The complement system consists of 9 main proteins and a number
of cofactors which when activated, through cell bound components,
leads to cytolysis (Humphrey and Dourmashkin, 196b) and/or the release
of soluble factors with biological activity. Thus activation leads
to all the features of inflammation. 'Classical' activation occurs
following antigen-antibody combination, but an 'alternate pathway'
exists (Gotze and Muller-Eberhard, 1971) and recent studies would
- 97 -
suggest that this pathway may indeed be important in certain types
of proliferative glomerulonephritis, (Hunsicker et al, 1972). The
evidence that complement is involved in human glomerulonephritis is
good (Lancet, 1972). This includes immunofluorescent techniques
which have shown it to be present in the glomerulus during active
disease, and in particular the third oomponent of complement, known
as C3 Thus at the present time, histological data suggests that
botu in active proliferative forms of glomerulonephritis and in the
rejecting renal allograft, IgG, IgM, C3 and fibrin are deposited in
the renal glomerulus, (McKenzie and Wliittinghara, 19635 Porter et al,
1963; Berger, 1969; McCluskey, 1971 a«d Mac aaonvic et al, 1972).
It is now well established that urinary proteins are composed
of antigens of different size and origin: some related to serum
proteins, others kidney or renal tract proteins (Manuel and Revillard,
1970). Moreover, experiments have shd>wn a glomerualr sieve effect
and tubular reabsorption influences the final composition of
urinary proteins. In general, proteins with a molecular weight of
less than 88,OOO pass, without major alterations, through the
glomerular membrane , whereas raacromolecules are excluded and not
normally found in urine. Thus albumin, IgA (secretory) and intact
IgG represent the major part of plasma proteins detected in normal
urine (Poortmans and Jeanloz, 1968), whereas IgM has not been found
(Turner et al, 1970)» and some of the IgG has undergone degradation
to Fc type of fragments (Berggard and Bennich, 1967).
The results of the serial studies on the patients with prolif¬
erative glomerulonephritis receiving indomethacin would suggest that
the presence of heterophile antibody, IgM and C3 are largely related
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to an active disease process rather than passive leakage of plasma
proteins. This is deduced by their rapid fall in urinary excretion
during indomethanin administration in the presence of an altogether
less dramatic fall in IgG and total protein excretion. It therefore
seems unlikely that the dramatic fall in heterophile antibody, IgM
and C3 was due to a sudden change in protein selectivity. This
is supported by the finding of continued unchange excretion of^ o-
macroglobulin, which has a molecular weight close to IgM. Moreover,
the molecular weight of IgG is close to that of C3 and if the
changes arose from selectivity alterations alone then the fall in
C3 should have been paralleled by IgG; this did not occur. Thus it
is proposed that the urinary excretion of heterophile antibody in
proliferative glomerulonephritis and in the rejecting renal allograft
is likely to be part of an immune intrarenal destructive process, and,
moreover, as such may be a more reliable index of this activity
than urinary F.D.P. excretion.
One of the many interesting further questions which arises from
these studies is whether the heterophile antibodies found in the
urine are directed against partially damaged renal tissue, and as
such give rise to further and progressive renal tissue destruction.
Such a concept is not new, as the role of a secondary autonomous
phase with the production of autoantibodies against autologous
damaged kidney antigens has been already postulated (Houba et al,
197*l)i although without evidence. This hypothesis for heterophile
antibody gains further acceptance in the light of recent studies
which show that serum heterophile (rat) antibody in patients following
renal transplantion can be absorped by human kidney tissue (Svehag et
- 99 -
al, 1973)* Moreover, Fors.gman antibody, when inoculated into
normal guinea pigs produces vascular inflammatory lesions. (Taichman
and Chi-Cheng Tsai, 1972). This tissue damaging process appears to
be complement mediated (May and Frank, 1972). Thus it seems
possible that the heterophile antibodies may be directed against
altered glomerular antigens and that in turn the interaction of these
antigens with the heterophile antibodies may be part of a vicious
circle of destruction.
One of the further interests in this study was the position of the
heterophile antibody in the minimal lesion glomerulonephritis. It is
assumed that this arises from leaking IgG and is not related to a
specific immune process.
The qualitative studies on the urinary heterophile haemacgiutinin
would suggest that they are IgG and IgM. The results of using sheep,
rat and rabbit erythrocytes strongly imply a heterogenicity of
antibodies with respect to antigenic determinants. The absorbtion
studies, however, were not clear cut, and so do not confirm previous
results on serum heterophile antibodies in renal transplantation when
it was shown that there was a significant cross-reaction with the B







There have been three main themes in this project: the
development of a new T.R.C.H.I.I. (F.D.P.) in which human red cells
replace sheep erythrocytes 5 the development of a standardised assay
for urinary heterophile haemagglutinins; and the application of these
two technologies in glomerulonephritis, and renal transplantation.
In the first series of studies it was discovered that by the
introduction of glutaraldehyde, instead of formaldehyde, satisfactory
human red cells could bp prepared for the T.R.C.H.I.I. (F.D.P.).
This development provided a key reagent for extensive studies on
urinary F.D.P. In the second techological study techniques were
developed which provided stable and reproducible reagents for the
assay of urinary heterophile haemagglutinins. A new finding in this
study was the existence of high reacting and low reacting sheep
erythrocytes. The isolation of this former group proved to be
essential for the success of the renal studies.
Finally, these techniques were used to study urinary excretion
of F.D.P. and heterophile haemagglutinins in glomerulonephritis and
renal homotransplantdtion. These studies confirmed the concept that
the origin of urinary F.D.P. in proliferative glomerulonephritis and
renal transplantation is likely to be immune. But, that a group of
patients can be demonstrated in the former conditon, which was hither¬
to unrecognised. It is concluded that the introduction of urinary
heterophile haemagglutinins quantitation represents a new and valuable
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Preservation of Human 0 cells fixed with glutaradehyde
Materials
Glutaraldehydc - 25% in distilled water (Koch Light Lab. Ltd.)
Phosphate Saline Buffers - pH 8.0 (P.D.S.)
1 volume of 0.15M Na HF04 (Anhydrous)
9 volumes of 0.15M NaCl
5 volumes of distilled water - pH adjusted to 8.0 with N/l HC1.
Saline Solution - 0.15M NaCl in distilled water.
Sodium Azide - (British Drug House Ltd.)
100 mg/ml in distilled water.
Preparation of glutaraldehyde mixture - 1% glutaraldehyde in
P.B.S. was prepared by adding 4 parts of 25% glutaraldehyde to
96 parts of P.B.S. (V/V) and the mixture chilled by immersion
in iced water until use^j
Preservation of Buman 0 cells fixed with formaldehyde by three differ¬
ent methods
Materials
Formaldehyde - 40% B.P. (Evans Medical Ltd.)
Phosphate Buffered Saline - pH 7«2
761 ml of O.15M NaoHP04 (Anhydrous)
Cm*
239 ml of 0.15M KHoP04
1000 ml of 0.15M NaCl
The pH was adjusted to 7»2 with N/l HC1 or NaOH.
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The conditions adopted for formalization of human 0 cells by
three different methods are described in Table XXXVI
Preservation of Human 0 Cells fixed with Pyruvic aldehyde according
to Ling (l96l).
Materials
Pyruvicaldehyde - 40% (Sigma Chemicals Ltd.)
Phosphate Duffer - pH 8.0
945 ml of 0.15M NaHP04 (Anhydrous)
55 ml of 0.15M KH0P04
u
pH adjusted to 8 with N/1 HC1
Treatment of Cells
1.5 vol. of a 25% pyruvic aldehyde solution (by adding distilled
water to 40%) was brought to a pll of 7«0 by the addition of a
1% Sodium Carbonate Solution. 0.7 vol. of 0.15M phosphate buffer
(pH 8.0) was added, followed by 1 vol. of 50% suspension of cells
1 o ,
in Saline. The suspension was incubated at 4 C for 24 hours with
occasional mixing and then washed three times in Saline and a
10% suspension was made in Saline containing 0.1% sodium azide»
Tanning procedure :
Tannic Acid (May and Baker Ltd.)
A fresh stock solution of tannic acid in distilled water (10 mg/ml)
was used, and working solutions of 1 in 40,000 made by further
diluting in buffer (P.B.S.).
Procedure for coating cells with fibrinogen
Citrate Phosphate Buffer - pH 6.4 (C.P.)
Fixation of human 0 cells with formaldehyde























First step - 30






Time 18 - 22 hours 18 hours First step - 2
days




Citrate Phosphate Buffer - pH 6.4 (C.P.)
350 ml of 0.15M Na^HPO^ (Anhydrous)
650 ml of 0.15M KH2PG4
1000 ml of 0.10M tri-sodium citrate
pH adjusted to 6.4 with 0.5N citric acid
Human Fibrinogen -(Kabi Pharmaceuticals Ltd. 97% clottable
protein)
A freshly prepared stock of fibrinogen solution containing 20
rag/IOO ml in distilled water was used, and working solutions of
10^/g/ral were made in C.P. for coating of cells.
Diluting Fluid
A 2% solution of bovine albumin (Armour Pharmaceuticals Ltd.) in
C.P. buffer pH 6.4 containing sodium azide ( 1 mg/rnl) was used.
Preparation of test sera for F.D.P.
Trasylol (Aprctinin) - Bayer Pharmaceuticals Ltd.
5 ml vial containing 25000
Kallikrein Inactivator Units (K.I.U.)
Topical Thrombin -(Parke Davis & Co.)
5000 units per vial dissolved in physiological saline at a
dilution of 100 units/ml and was stored at -40°C.
Preparation of test sera
10 mis of blood was withdrawn by clean venepuncture with minimal
venous occlusion, using a disposable plastic syringe. The blood
was transferred into a glass tube containing 0.2 ml of aprotinin
(5000 K.I. units per ml). The mixture was incubated at 37°C
for 4 hours. The upper two thirds of serum was separated after
- 117 -
Cantrifugation for 10 minutes at 3400 R.P.M. Thrombin was then
added to give a final concentration of 10 units per ml which was
o
followed by a further 30 minutes incubation at 37 C and then
centrifugation at 3400 R.P.M. for 5 minutes. The resultant serum
o
was either used immediately or stored at -40 C.
Antibody titration :-
Special Apparatus
The microtitre system (Cooke Engineering Co., U.S.A.) was
used throughout the performance of the test. The microtitre
kit consists of permanent "Lucite V" plate, calibrated micro-
pipette dropper, Takasy microtitrators and a reading mirror.
Materials j~
Tris Buffer - pii 7.8
0.15M solution of tris (hydroxymethy1) - amino methane
(Koch-Light Laboratories) pH adjusted to 7»'°> with N/l HC1
Standard Fibrinogen - Human Fibrinogen (Kabi Pharmaceuticals Ltd.)
at three concentrations 1.25i 2.5 and 5 mg/ml (W/V) in tris buffer
pH 7.8 was incorporated in the test system. The amount of clottable
protein in these standards was calculated by the method of Ratnoff
and Menzies (1951) as modified by Alkjaersig (i960) and the mean
value was taken.
A small aliquot of 0.4 ml was kept in a Teklab tube and stored
1 °
at -40 C as a stock solution. The stock solution of each of the
three concentrations was diluted 100 folds in diluting fluid before
incorporated in the test. In the test the diluted fibrinogen was
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further diluted along with the test samples.
Anti-human fibrinogen serum from rabbit - (Behringwerke AG, Patch No.
1154 P)
The neat antiserum was diluted 1 in 500 in diluting fluid (C.P.)
and stored as aliquots of 0.5 ml at -40°C. Working solutions were
made by thawing the aliquot and further diluting in diluting fluid.
Monospecificity was determined by immunodiffusion and immuno-
electrophoresis against human plasma and fibrinogen.
Antibody Titration
The antifibrinogen serum (which was diluted previously 1: 500
and kept as stock solution at -40°C), was thawed anddiluted further
in diluting fluid (doubling dilutions) as follows:-
By using a micropippete dropper,one volume (0.025 ml) D.F. was
placed in each well of a given row by omitting the first well.
Two volumes (0.05 ml) of antisera (1: 500 dilutions) were then
placed in the first well and the microdilutor was then inserted
into it and then rotated 20 times. The microdilutor was then
transferred to the next well of the row carrying along 0.025 ml
of antisera and mixed by swirling the microdilutors 20 times
to ensure good mixing and thus produced doubling dilution. It
was then transferred into the next well and the same process was
repeated, the result was 1: 4 dilution of the original antiserum.
By repeating this process 8, 16, 32 and so on folds of dilutions
of antiserum were obtained. One volume (0.025 ml) of diluting
fluid and one volume (0.025 ml) of 2.5'A> suspension of fibrinogen
sensitised cells were then added in each well containing the
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diluted antisera. The contents of the wells were then mixed
by tapping or shaking the plate. The plates were then covered
with parafilm or by another plate to prevent evaporation and
incubated at room temperature (22°C) at least for four hours or
better
5 left overnight without disturbance. The results
were noted by observing the settling pattern of the cells at the
bottom of the wells with the help of a reading mirror.
Itositive and negative control was incorporated as such -
positive control includes one drop of diluting fluid, one drop
of ant;sera (stock solution of 1/500 dilutions) and one drop
of a 2.5% suspension of sensitised cells.
Negative control constitutes two drops of diluting fluid and one
drop of 2.5% suspension of sensitised cells.
Antibody Titre:-
The highest dilution which showed complete agglutination (+)
was taken as the end point and called the antibody titre. The
antibody titre was expressed as a reciprocal concentration of
antiserum where complete agglutination occurred.
Patterns of Agglutination
Complete agglutination was designated as positive (+) where
the cells form a smooth mat at the bottom of the well.
Incomplete or partial agglutination was designated as (+) inhere
the cells partly formed a smooth mat around an indistinct
dispersed button of cells.
Mo agglutination was designated as (-) where the cells settled
as a firm distinct button at the centre of the wells.
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Calculation of F.D.P.
The amount of F.D.P. present in an unknown sample is calculated
from the inhibition titre obtained by a known amount of clottable
protein present in the standard fibrinogen solution.
Therefore, the amount of F.D.P. in the unknown is calculated
as follows :-
Fibrinogen/fibrin degradation products
= sensitivity of the standard x inhibition titre of the
solution- test.
Sensitivity = The quantity of clottable protein in standard
fibrinogen
The inhibition titre of standard fibrinogen
Materials for Fibrinogen Assay
Darbitone - Saline Buffer - pH 7»22
Sodium barbitone - 5-71G
Sodium chloride - 2.93G
Distilled water - 960 ml
pH adjusted to 7«22 with N/l HC1 (approximately 25 mis) and the
volume made up to 1 litre with distilled water.
Calcium - Thrombin
1 vol. of bovine Thrombin (10 units/ml)
1 vol. of 1.12M Calcium chloride (CaCl )
Mixed together and stored in 0. 5 ml aliquots in a Teklab tube
at -40°C
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Folin and Ciocalteu's Reagent (British Drug Houses Ltd.)
1 part of Folin Ciocalteu's Reagent was diluted with 2 parts
of distilled water.
Solution of Epsilon Amino-caproic Acid (E.A.C.A,) in Saline
E.A.C.A. - 710 mg
Physiological Saline (0.9%) - 1,000 mis.
Fibrinogen Assay
Two methods were used.
a) Fibrinogen assay described by Ratnoff and Menzies (1951) as
modified by Alkjaersig (i960).
This method was used as the standard reference with which other
fibrinogen or its derivatives could be compared. In the test, the
fibrinogen is clotted with thrombin in a medium containing sufficient
E.A.C.A. to prevent proteolysis and incubated overnight. The
resultant clot is precipitated, separated and hydrolysed with sodium
hydroxide and boiling. The amount of tyrosine released by hydrolysis
is estimated with Folin Ciocalteu's reagent and the fibrinogen
concentration calculated from a standard tyrosine curve.
The tests were performed in triplicate in 5' x unsiliconised
test tubes. The following reagents were added one after another -
6.0 ml E.A.C.A. Saline, 0.2 ml of 2.5% Calcium Chloride Solution,
0.1 ml of thrombin (100 units/ml in saline) and 0.2 ml of test
solution and then mixed thoroughly. To ensure complete clot, the
o
tubes were left overnight at 4 C. The tubes were then centrifused
at 3*400 R.P.M. at 4°C for 5 minutes after addition of 0.5 ml of
glass beads (diameter 0.15 mm) which aids the subsequent precipitation
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of the fibrin. The supernatant was discarded and the glass beads
and entrapped fibrin were washed 3 times with saline and then
hydrolysed by the addition of 0.4 nil of 10% sodium hydroxide and
boiled for 20 minutes in a water bath. The tubes were then cooled
'
...
and 2 ml of 0.5N sodium hydroxide and 0.6 ml of Folin and Ciocaltei' s
reagent (diluted 1: 2 in distilled water) were added in sequence and
mixed, and the tubes centrifused at 3i*±00 R.P.M. at room temperature
for 2 minutes. The tyrosine released by hydrolysis is assessed by
measuring optical density in an Unitsam S.P. 600 at 650 m, using the
red filter against the non-clotted tube as the blank. The tyrosine
released is calculated from a previously prepared standard tyrosine
curve, and converted to fibrinogen concentration by multiplying
by 11.7. This technique is time consuming and tedious, and not
easily adapted for routine work.
b) Fibrinogen assay as described by Ellis and Stransky (1961)
This provided a rapid reproducible assay, easy to perform and
was used for routine purposes. In this study, the assay was performed
for fibrinogen estimation in control fibrinogen as well on seriai
aliquots of an in vitro human fibrinogen plasmin digest. The
optical density resulting from the formation of fibrin is measured
in citrated plasma, as well test samples recalcified and clotted with
thrombin. By comparison with a previously prepared standard curve,
the fibrinogen content of the test can be calculated.
0.5 ml of test is added to 5»5 mi barbitone saline buffer
(pH 7*22) in a glass test tube, mixed by inversion. 3-0 ml aliquots
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of this solution are added to one unicara cells for the test and the
other for the blank. 0.05 ml of calcium thrombin solution is then
added to the test cell and mixed by inversion. After incubation at
room temperature for 20 minutes, the optical density of the test cell
is compared with the blank in an unicam S.P. 600 at 470 m with a
blue filter.
Heterophile haemagglutinin in sera
Materials :
Phosphate Saline Duffer pH 6.4
350 ml of 0.15M NaHP04 (anhydrous)
650 ml of 0.15M KIipP04
1000 ml of 0.15M NaCl
pH adjusted to 6.4 with N/l HC1
Diluting fluid





tri-sodium citrate - 0.80G
sodium chloride - 0.42G
Distilled water - 100 ml
pH adjusted to 6.1 with 10% citric acid.
Autoclaving at 10 pounds for 10 minutes.
Sheep Cells
A panel of 10 animals, with a wide genetic variability, was
selected from Marino and Finnish Landrace breeds. Selection was
based on blood groups R, r', HX, LK and haemoglobin AA, DD and AD
(Tabie xXXVIl).
Details of the blood groups and breeds of




Sll r/AA/LK Finnish Landrace
S12 R/AA/LK Finnish Landrace
S17 r/AB/HK Finnish Landrace
Sl8 r/AA/HK Finnish Landrace








Jugular vein blood was withdrawn into Alsever's solution (l part +
1 part) stored at 4"C for 3-4 days and preserved in formaldehyde
followed by treatment with tannic acid (Das, 197Ca). See Table XXXVI
Heterophile haemagglutinin in urine
Erythrocytes from three different species in high and low
reacting sheep, white New Zealand rabbit and Sprague Dawley rat,
were used to quantitate the heterophile haemagglutinin in the urine.
Sheep blood was collected by venepuncture of the jugular vein,
rabbit and rat blood by cardiac puncture and then mixed in Alsever's
solution (l part blood and 1 part Alsever's solution) and stored at
o ,4 C for 3-4 days. The cells were presevered in glutaraldehyde
as described for- human 0 cells (vide supra). The fixed cells were
suspended as 10% in distilled water containing sodium azide (lmg/ml)
I °
and stored at 4 C unitil use.
Performance of the test
Microtitre kit (Cooke Engineering Co., U.S.A.)
Diluent - distilled water - 1000 ml
sodium azide - 1G
The concentrated urine was prepared as described (vide supra) and
was centrifused at 3^400 R.P.M. for 30 minutes. The clear
supernatant was separated as aliquots in Teklab tubes. One
drop of diluent was placed in each well of a plate except the
first, where two drops of test urine was added.
Three controls were included in the test, i.e. pooled normal
sera, normal urine and negative control. After titration of the
test, as described above4 One drop of diluent and one drop of
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2.5% suspension of fixed erythrocytes were placed in each well
(according to the designated wells for different species
erythrocytes) and the mixture in the wells was mixed by
shaking the pj.ate. The plates were then incubated overnight
o
at 4 C, and read on the following morning. The arbitrary score
was given according to the pattern of agglutination as described
(vide supra).
Serial concentrated urines (9 samples) from a transplant patient
with a rejection episode, were tested for heterophile haemagglut-
inin against glutaraldehyde fixed sheep (Fig.-28) ancj rabbit
(Fig. 29 red cells. One to three rows prerejection and 4-9
rows rejection samples, the 10th row is normal urine, 11th
row is controlled normal sera and the 12th row is negative
control. The figure also shows that the rabbit erythrocytes
detect heterophile haemagglutinin in urine sample 4 more
strongly then the sheep cells and gave a higher haemagglutinin
score than sheep cells in sample 9« The pattern of agglutin¬
ation can be seen in Figure and their score in Table XXXVIII.
Paul-Bunnel Test with Differential Absorption
The method of Barrett (l94l) with some modification was used to
determine whether the reaction is a Paul-Bunnel type, i.e. that it is
absorbed by Ox cells hut not by guinea-pig kidney.
Reagents: l) Two mis of concentrated urine or serum previously
inactivated by heating at 56°C for 30 minutes.
2) A 20% autoclaved Ox red-cell suspension
1. r. ( • • • • • • •
2.
r. , • • • • • • •
3.
«• ( • • • • • • •
4. K* • • • • • • •
5. m • • # • • • •
6. m # • • • • • •
7. m m • # • • • •
8. m m # • • • •
9.




• • • • • •
11. # # « • • • •- •
12. K*- • •
/ • v • 1
Fig. 28 Microtitre plate showing haemagglutination pattern
of urinary heterophile (sheep) haemagglutinin. Rows
1-9 are urine samples from a transplant patient with
a rejection episode, (rows 1 - 3prerejection and 4-9
rows rejection samples). The tenth row is normal urine,
whereas the eleventh row is a control serum and the
twelfth row a negative control.
1. (< • • • • • • • •
2. «• • • • • • • •
3. K • • • • • • • •
4. K # • • • • • • •
5. m • • • • • • •
6. !($ • • • • • •
7. «• • • • • • • •
8. ((• • • « • • • •
9. • • • • • • • •
10. (< • • • • • • • •
11. m * & • • • • •
12. 11J, • • •
• • • •
Fig. 29 Microtitre plate showing haemagglutination pattern
by urinary heterophile (rabbit) haemagglutinin. 1-9
rows are urine samples from a transplant patient with a
rejection episode, ( 1 - 3 rows are prerejection and 4-9
rows are rejection samples). The tenth row is a normal
urine, the eleventh row a control serum and the twelfth
row a negative control. (Note rabbit erythrocytes have
detected agglutinins in higher proportion of the tested
samples and have given overall higher titre than sheep).
Haemaggiutination Score of serial urine samples from
a transplant patient with rejection episode.
Test Sample Sheep Rabbit
1. Urine from a 0 0
transplant patient
2. " " 0 2
3. " " 0 2
4. " " 2 7
5. " " 18 20
6. " " 12 17
7. " " 22 24
8. " " n*~i-Ji- 22
9. " " 5 12




12. (Negative Control) 0 0




3) A 20% guinea-pig kidney emulsion.
Absorption procedure
Three 0.5 ml volumes of test sample are delivered into three
small tubes designated as A, B and C. 0.6 ml of guinea-pig
kidney emulsion is added to tube B, 0.6 ml of ox-red cells
to tube C and 0.5 ml of saline to tube A. The contents of the
i °
tubes are then mixed and incubated overnight at 4 C. The tubes
are then centrifused and the supernatant retained. In the
absorption procedure, the test samples become diluted 1: 2. The
absorbed and unabsorbed test samples are then run for heterophile
haemagglutination test using 2.5% glutaraldehyde fixed sheep
cells (vide supra).
Thrombin time as described by Thomson (1970) with some modification
This method was used to measure the anticoagulant activity of
in vitro digested products of fibrinogen.
Materials :-
Sodium citrate B.P. J.8% (Boots Pure Drug Co. Ltd.)
Thrombin (Bovine thrombin - 10 units/ml in saline).
Citrated normal plasma - by clean venepuncture, 10 mis blood
was withdrawn, placed in citrated tubes (9 parts blood to 1 part
sodium citrate) and thoroughly mixed. Plasma was separated by
centrifugation at 3i400 R.P.M. for 15 minutes.
Method :-
Test material (0.1 ml) and citrated normal plasma (0.1 ml)
were placed in a glass tube and incubated for 1 - 3 minutes in an
automatic coagulometer thermostatically controlled to 37°C. The
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clotting time was initiated by adding 0.1 ml of iced cold
thrombin and the subsequent clotting time noted and compared with
the clotting time of a control in which saline 0.1 ml substituted
for the test material. The test was always done in triplicate
and the mean was taken.
Materials for Cuchterlony immunodiffusion plate or immunoelectrophor-
esis.
1. Barbitone - acetate buffer pll 3.6 and ionic strength 0.1M.
Sodium barbitone - 50G
Sodium acetate - 50G
N/IIC1 - 32 ml (approximately)
Sodium barbitone and sodium acetate (trihydric) was dissolved
in 4L distilled water and the pll was adjusted to 8.6 using
N/l HC1 and the final volume would be 5 litres by adding
distilled water.
2. Agar (Difco)
1.5G agar and 0.1G sodium azide was mixed to a solution
of 50 tnls distilled and 50 barbitone acetate buffer
(0.1M). The mixture was then heated in a boiling waterbath
until the agar dissolved and gave a clear solution. The
o
temperature was then brought down to 65 C and then used
either to prepare Ouchterlony plate or Immunoelectrophoresis
glass slides.
3. Ponceau S solution
0.2% ponceua S stain in 6% sulpho sali cylic acid.
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Ouchterlony immunodiffusion technique (Quchterlony, 1962)
Onchterlony plates were prepared by pouring 15 mis of 1.5%
melted agar into 8.8 cm Petridishes and allowed the gel to solidify
for 4 hours. The wells - one central and six peripheral were cut by
using a commercially available -punch antiserum was placed in the
central well and test materials in the peripheral wells and allowed
to diffuse for 48 hours at room temperature (22°C) in a moist
chamber.
Immunoelectrophoresis
The method described by Scheidigger (1955) was used. Glass slides
(2.5 cm x 7-6 cm) were placed in a commercially available slat and 10
mis of 1.5% melted agar was poured in each portion of the slat (2 ml
for each slide) and allowed to solidify for 4 hours. Wells for
antigen and troughs for antiserum were cut in each slide by using
a commercially available punch. Electrophoresis was carried out
by using barbitone acetate buffer (pH 8.6 ionic strength 0.1M)
inside the tank and electrophoresed for 2 hours by passing a current
at the rate of 7*5 m A per section or 15 m A per slat followed by
immunodiffusion for 48 hours in a moist chamber. The slides then
covered with azide saline for a further 24-48 hours and then dried
with filter paper and washed with tap-water. The slides were then
stained in Ponceau S for 10 minutes and washed in 2% acetic acid
until all excess stain was removed and then dried in air.
Urinary Protein Estimations
The buiret method of Hiller et al (1948) was used for estimation
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of the protein in urine (unconcentrated) as per cent. Urinary protein
is first precipitated with an equal volume of 10% (W/V) trichlor acetic
acid, the precipitate dissolved in 30% (W/V) NaOH and the buiret
colour developed by 5% (V/V) CuS04. The concentration of protein is
determined by a Lovibond Comparator. The protein estimation was
performed in the Department of Clinical Chemistry, University of
Edinburgh.
The Mancini method for quantitation of urinary IgG, IgM, C-3 and
CX- 2 macroglobulin.
The IgG, IgM, C-3 andmacroglobulin content of concentrated
urine, were quantitised by the Mancini technique (1965) using
commercially obtained Hyland plates.
Priniple Antigen placed in a well in antibody containing agargel,
diffuses into the gel and forms a precipitin ring. The total
diameter of this ring is related to the concentration of antigen.
Each immunodiffusion plate contains 12 wells, three of thein
required for three reference sera which are provided with the
test kit. Thus one plate is used to prepare a standard curve
and simultaneously to test 9 unknown specimens. As urine
contains less antigen than serum, the reference serum provided
with lowest quantity of antigen, was further diluted to get a
curve, which could be fitted with a less amount of antigen.
Materials :-
l) Immunodiffusion plates (Hyland) containing antiserum specific
for different antigen (IgG, IgM, C3 and^(2 Macroglobulin).
ll) Capillary pipettes (3»550" x 0.035" - Hyland)
111) Reference standards (Hyland), the lowest standard serum was
- 130 -
further diluted with saline (0.9/i»)»
Performance of the test
The plastic cover of the immunodiffusion plate is removed and
allowed to dry for 30 minutes if the plates contain moisture.
The well is filled with the test specimen or reference serum
by touching the tip of the capillary tube to the bottom of the
well and allowed to flow by gravity so that the well is filled
to the level of agar surface by taking precaution of overfilling
or underfilling. The plate cover is then placed and the plates
o
designated for IgG is incubated for 4 hours at 37 C and the
other plates at room temperature (22°C) in a moist chamber for
24-48 hours.
The diameter of the precipitin ring is measured by using an
eyepiece reticle having a mm. scale. The concentration of
/




Analysis of results for Student's "t" test, coefficient of
correlation and rate of regression and standard deviation were
obtained using the Olivetti programma 101 with the following
equations
1. Student's "t" test
(a) Comparison of means of two samples: ,
g 2 m ~
l —r,—7T, rr-(N - 1)







1 I'"", * (N2 * l)a22
N + N - 2
X u
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Vhere M, is the arithmetic mean of the first sample
1
M is the arithmetic mean of the second sample
2
s^ is the variance of the first sample
0
is the variance of the second sample
N is the number of values in the first sample
1
is the number of values in the second sample





Where d is the arithmetic mean of the difference of pairs
N is the number of pairs of observations
2
SD is the sample variance.
2. Coefficient of linear correlation and rate of regression
The Bravais-Pearson coefficient of linear correlation.
Formula:-
r =
N^xy - C^x) (jy)
yjTT^2 - (<x)C— |X^yD I (Cy)2^!
- 133 -
Where x, y = variables
N = number of observations.
The regression line between two variables x and y according to the
equation :-
y = a + bx
Formulae:-
b = N^xy - C&c) (£y)
N£x" - ($x)"
a = lx - b^x
N
Where x, y ■ variables
N = number of observations.
3. Standard deviation.
Formula used:-
/T— = / n6c2 - (€x)2I N (N - i;
Where x = variate value
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13. PREPARATION OF HUMAN CELLS FOR THE ASSAY
OF SERUM FIBRINOGEN DEGRADATION PRODUCTS USING
HAEMAGGLUTINATION INHIBITION
M.S. Hoq and P.C. Das.
S-E Scotland Blood Transfusion Centre
Royal Infirmary
Edinburgh, EH3 9HB Scotland
Boyden's (1951) original technique in which
tanned red cells are coupled with an antigen
such as fibrinogen, can be adopted as an
agglutination inhibition reaction, using antifi-
brinogen serum, for detection of circulating
fibrin/fibrinogen degradation products (F.D.P.)
(Merskey et al. 1966 ; Das 1970a ; Das 1970b).
Although sheep red cells have been used in
many laboratories with satisfactory results,
difficulties have been encountered in the com¬
plete absorption of heterophile antibody which
is a necessary and time-consuming procedure
before every assay. This antibody is present in
over 90 % of the normal population (Salo,
1966) and its titre increases markedly following
organ transplantation (Rapaport et al. 1968)
and severe burns (Kano et al. 1967).
The following communication describes the
results of a study designed to circumnavigate
this problem by developing tanned red cell
haemagglutination inhibition immunoassay
(T.R.C.H.I.I.) using human group 0 red Rh.
negative cells. In particular, efforts were made
to find a substitute for formaldehyde as human
red cells display a marked tendency to autoag-
glutinate when preserved in this material.
Materials
Glutaraldehyde
- 25 % (Koch Light Lab. Ltd.)
Formaldehyde
— 40 % B.P. (Evans Medical Ltd.)
Pyruvicaldehyde
— 40 % (Sigma Chemicals Ltd.)
Sodium Carbonate
- (British Drug House Ltd.)
Phosphate Saline Buffer
- pH 8.0 (P.B.S.)
1 volume of 0.15 M Na2HP04 (Anhy¬
drous)
9 volumes of 0.15 M NaCl
5 volumes of distilled water. pH adjusted
to pH 8.0 with N/1 HC1
Saline Solution
— 0.15 M NaCl in distilled water
Citrate Phosphate Buffer
- pH 6.4 (C.P.)
350 ml. of 0.15 M Na2 HP04 (Anhydrous)
650 ml. of 0.15 MKH2P04
1000 ml. of 0.10 M tri-sodium citrate
pH adjusted to 6.4 with 0.5N citric acid.
Tannic Acid (May & Baker Ltd.)
A stock solution of tannic acid in distilled
water (10 mg/ml) was used, and working solu¬
tions of 1 in 40,000 made by further diluting in
buffer (P.B.S.).
Sodium Azide (British Drug House Ltd.)
100 mg/ml in distilled water.
Diluting Fluid
A 2% solution of albumin (Armour Pharma¬
ceuticals Ltd.) in C.P. buffer pH 6.4 containing
102
sodium azide (lmg/ml.) was used.
Human Fibrinogen (Kabi Pharmaceuticals Ltd.
91 % clottable protein)
A stock fibrinogen solution containing 20
mg/lOOml. in distilled water was used, and
working solutions of 10 /ug/ml. were prepared
in C.P. pH 6.4.
And Human Fibrinogen Serum from Rabbit
(Behringwerke Ag.)
The neat anti-serum was diluted 1 in 500 in
diluting fluid and stored in 0.5 ml. aliquots at
20°C. Working solutions were made by further
dilution in diluting fluid.
Methods
Red Cell Fixation Procedures
Blood was collected in acid citrate dextrose
(4 parts to 1 part) and allowed to settle by
gravity for 2-5 days. The supernatant plasma
was removed and the cells washed 3 times in 50
volumes of saline. After the final wash, the
packed cell volume was measured following
centrifigation at lOOOg for 5 minutes and the
cells were chilled by immersion in iced water.
Satisfactory formaldehyde fixation was at¬
tempted using 3 different methods :a Wide's
(1962) modification of the method of Wein-
bach, and the techniques described by Ling
(1961) and Herbert (1967). Pyruvicaldehyde
fixation was done according to Ling (1961).
Gluteraldehyde fixation was done as follows : a
2 % red cell suspension was prepared in 1 %
gluteraldehyde in P.B.S., mixed well and in¬
cubated for 30 minutes at 4°C with occasional
further mixing. The cells were then washed 3
times in 50 volumes of saline followed by 3
washes in 50 volumes of distilled water. After
the final wash a 10% (V/V) was prepared in
distilled water containing sodium azide
(lmg/ml.) and stored at 4°C until further use.
Tanning Procedure
All types of fixed cells were washed 3 times
in 50 volumes of P.B.S., the haematocrit
established and a 2 % suspension (V/V) pre¬
pared in P.B.S. One volume of this cell sus¬
pension was then mixed with 1 volume of 1 in
40,000 tannic acid and incubated for 30 mi¬
nutes at 56°C with occasional mixing. Fol¬
lowing incubation the cells were washed 3 times
in 50 volumes of P.B.S.
Sensitization Procedure
All types of tanned and fixed cells were
washed 3 times in 50 volumes of C.P. buffer
and after the haematocrit was established a 4 %
suspension (V/V) was prepared in C.P. buffer.
One volume of cells and 1 volume of a solution
of human fibrinogen (10 ^tg clottable protein/
ml. in C.P. buffer) were mixed and incubated
for 30 minutes at 37°C. The sensitized cells
were then washed 3 times in 50 volumes of C.P.
buffer and finally made up as a 10 % suspension
(V/V) in diluting fluid and stored at 4°C. Three
days later the supernatant fluid was replaced by
an equal volume of fresh diluting fluid.
Serum F.D.P. Immunoassay
The details of the T.R.C.H.I.I. employed in
this study have been described in detail else¬
where (Das, 1970b), with the exception that
the microtitre plates were incubated at room
temperature (20°C) and 2% bovine albumin
was used as a stabiliser in the diluting fluid. The
behavior of the cells in the capillary F.D.P.
technique described by Israel et al. (1968) was
also studied.
Results
Five batches of formaldehyde, 4 batches of
pyruvicaldehyde and 17 batches of gluteral¬
dehyde cells were prepared on separate occa¬
sions, tanned, sensitized at the same time under
identical conditions, and their sensitivity to
anti-fibrinogen sera ascertained along with ne¬
gative controls in which diluting fluid replaced
antisera. The results are summarised in Table I,
which shows that gluteraldehyde fixation alone
provided batches of cells with no trace of
autoagglutination. Moreover, those cells fixed
with formaldehyde and pyruvicaldehyde which
appeared satisfactory on initial testing, deve¬
loped autoagglutination within a month of
storage at 4°C. Gluteraldehyde fixed cells,
however, remained in excellent condition for
more than 6 months, and the sensitivity of all
batches to antibody was in excess of one part
103
Table I
Antibody titre and incidence of autoagglutination in batches of human group 0 cells fixed with a different
agent and subsequently tanned and sensitized with human fibrinogen.
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Effect of variations in fibrinogen concentration, pH, time of incubation and temperature on the antibody
titre, during the sensitization procedure.
Fibrinogen
PH
Temp. Time Cell conc. Antibody Autoagglutination
Cone. (/ug/ml) (0° C) (mins.) (% V/V) Titre in controls
Fibrinogen Concentration
1 6.4 37 30 4 1/512x 103
10 6.4 37 30 4 l/2048xl03 —
100 6.4 37 30 4 — +
pH
10 6.4 37 30 4 l/2048xl03
10 8.0 37 30 4 l/2048xl03
Time of Incubation
10 6.4 37 15 4 1/2048x103
10 6.4 37 60 4 l/2048xl03 —
Temperature
10 6.4 22 30 4 l/2048x103 _
10 6.4 37 30 4 1/2048x103 -
104
per million at initial testing and 6 months later.
Using gluteraldehyde fixed human group 0
cells optimal conditions for subsequent tanning
and sensitization were also studied. Satisfactory
tanning was achieved with either 20,000 or
40,000 tannic acid, the pH could vary between
6.4-8.0, the temperature between 22-56°C and
the duration of tannic acid incubation could be
as short as 15 minutes. There was a similar
latitude in the conditions for sensitization, the
results of which are shown in table II. However,
a fibrinogen concentration of lOOqg/ml re¬
sulted in autoagglutination of the controls, but,
high fibrinogen concentrations could be used if
the cell concentration was proportionally in¬
creased. Thus a 16% (V/V) suspension was
satisfactorily sensitized by 40 qg/ml of fibrino¬
gen.
Further studies revealed that when using
gluteraldehyde it was possible to exclude the
tanning stage and sensitize the cells immediate¬
ly after fixation. This was best achieved by
fixation at 37°C and incubating a 4 % cells
suspension in a fibrinogen solution (30 Aig/ml)
at pH 6.4, for 60 minutes at 37°C. These cells
Figure 1
Comparative F.D.P. values of 25 serum samples
assayed by the microcapillary and microtitre tech¬
niques.
gave a consistent antibody titre up to 1/64,000
and remained stable for more than 3 months.
In the serum F.D.P. assay the human group
0 gluteraldehyde fixed and tanned cells behaved
in a similar manner to sheep cells with reference
to reaction patterns and sensitivity to test sera.
However, prior absorption of the unknown sera
was not necessary, although it was essential to
perform the test at room temperature in order
to avoid interference from cold agglutinins.
These cells also reacted satisfactorily in the
rapid capillary technique described by Israels et
al. (1968) as is shown in figure 1.
Comments
Although a change from preserved sheep to
human group 0 cells in the T.R.C.H.I.I. for the
quantitation of F.D.P. would avoid the time-
consuming problem of prior absorption of test
sera, no reports have appeared describing the
preparation and use of such cells. Merskey et al.
(1969) reported their successful experiences
with human red cells but these were not fixed
and could not therefore be readily stored for
prolonged periods of time.
The results of the present study have shown
that whereas formaldehyde is a satisfactory
fixing reagent for sheep red cells it is totally
inadequate for human cells, as a high proportion
of batches autogglutinate immediately after
preparation and those which appear satisfactory
deteriorate to such an extent that they are
unusable within 1 month. The problem has
been solved by introducing gluteraldehyde
fixation. Cells prepared by this method are
stable and sensitive and indeed direct sensiti¬
zation is possible without tanning. These find¬
ings are similar to those of Bing et al. (1967)
who studied the coating of sheep cells with
proteins other than fibrinogen. Although the
direct procedure produces cells which have a
markedly lowered antibody sensitivity, they
can readily be used in routine haemagglutina-
tion inhibition assays for serum F.D.P.
While rapid results can be achieved using
unfixed human group O cells in a macrovolume
system (Merskey et al. 1969) the cells for this
modification cannot be stored for prolonged
105
periods. This is a significant handicap for those
laboratories not engaged in research exercises
but requiring rapid serum F.D.P. assays at
infrequent intervals. The gluteraldehyde fixed
human group 0 red cells which can be stored
for many months, used in the capillary tech¬
nique will answer this practical need.
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Summary. The interaction (agglutination) of 25 normal sera against a panel of 10
different sheep red cells was studied. There were highly significant differences in the
agglutinability of different sheep cells to any one normal serum, and the cells could
be divided into 'high reactors' and 'low reactors'. Absorption studies confirmed
these observations. The significance of these findings is discussed in the light of
previous studies on anti-sheep cell haemagglutinins in disease and the selection of
sheep cells for all types of haemagglutinin immunoassays.
The introduction of specific, sensitive and semiquantitative haemagglutination inhibition
immunoassays for a variety of proteins, using sheep red cells previously treated with tannic
acid (Boyden, 1951), has been widely adopted, with varying degrees of success (Herbert,
1967). In using this technique for the assay of serum fibrin/fibrinogen degradation products
(FDP), difficulties have arisen, from time to time, with the complete absorption of the natural
anti-sheep agglutinins, prior to running the test serum in the immunoassay (Cash et al, 1969;
Mertens et al, 1969). The following communication describes a series of studies in which
it is shown that the capacity of red cells derived from different sheep to absorb the anti-sheep
agglutinin in any one normal serum varied markedly.
MATERIALS AND METHODS
Sheep Cells
A panel of 10 animals, with a wide genetic variability, was selected from Merino and
Finnish Landrace breeds. Selection was based on blood groups R, r; HK, LK and haemoglobin
AA, BB and AB (Table I). Jugular vein blood was withdrawn into Alsever's solution stored
at 4°C for 3-4 days and preserved in formaldehyde followed by treatment with tannic acid
(Das, 1970).
Test Sera Preparation
The serum was prepared as for FDP estimations: 10 ml of blood was withdrawn into a
glass tube containing 0.2 ml ofaprotinin (5000 K.I. units per ml). The mixture was incubated
at 37°C for 4 hr. Thrombin was then added to the separated serum, to give a final concentra¬
tion of 10 units per ml, which was followed by a further 30 mill incubation at 37°C and then
centrifugation at 3400 rpm for 5 min. The resultant serum was either tested immediately or
stored at — 40°C.
677
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Table I. Details of the blood groups and breeds of




Sn r/AA/LK Finnish Landrace
S12 R/AA/LK Finnish Landrace
S17 r/AB/HK Finnish Landrace
Si 8 r/AA/HK Finnish Landrace




S27 r/BB/HK Finnish Landrace
S2 8 R/AB/HK Merino
Test System
The microtitre system (Cooke Engineering Co.) was used throughout, using 0.025 ml
volumes. One volume of test serum was added, followed by 1 vol of diluting fluid and finally
1 vol of a 2.5% suspension of sheep red cells. The contents of the microtitre plates were
mixed, incubated at 4°C for 16 hr and then read at room temperature. A system of scoring
the agglutination titres arithmetically was used to summarize and analyse the data (Race &
Sanger, 1954). A score of 5 was given to each serial dilution, thus agglutination end points
at 1/1 scored 5, 1/2 = 10, 1/4 = 15, 1/8 = 20, 1/16 = 25 and 1/32 = 30 etc.
Absorption Procedure
Two volumes of test serum were added to 1 vol of washed packed red cells, mixed and
mcubated for 30 min at 4°C. After incubation the samples were centrifuged at 3400 rpm for
5 mill at 4°C, separated and stored at — 40°C until required.
RESULTS
Sera from 25 healthy volunteers were tested simultaneously against the panel of formalized
tanned red cells. The results are shown in Table II. Whereas there was no significant difference
between the mean titre scores of cells S11; Si2, S17, S18, S19 and S27 (all Finnish Landrace),
there was a highly significant lower reactivity between each member of this group and
S24, S25, S26 (P< 0.001) and S28 (P< 0.002) (all Merino). Using formaldehyde preserved cells
it was shown that these differences were highly reproducible, when the same sera stored at
— 40°C were retested some 6 mth later. Further analysis of the data revealed that, although
the red cells from sheep S24, S25 and S26 appeared to be 'overall' poor reactors, this did
not apply to certain individual reactions. An example of this phenomenon is shown by the
performance of serum R: S25 cells reacted more strongly than S, t cells, whereas S26 cells,
which usually mirrored the reactions of S25 cells, failed to agglutinate.
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The basic concept of overall 'good' and 'poor' sheep cell reactors and the occasional
individual exceptions was further substantiated by absorption studies. A single batch of cells
tested 'fresh' and after tannic acid treatment against 50 normal sera demonstrated that tanned
cells gave a significantly higher titre (P< 0.001).
DISCUSSION
Landois (187$) first recorded agglutination ofred cells from different animal species by human
sera. This work was initially extended by Landsteiner (1900), and subsequent studies have
drawn particular attention to the occurrence of sheep cell haemagglutinins in normal human
serum (Paul & Bunnell, 1932; Bunnell, 1933 ; Davidsohn, 1933; Stuart et al, 1935). The anti-
sheep agglutinins in sera from patients with infectious mononucleosis (IM) and normal
controls differ significantly. The antibody in IM is not absorbed by guinea-pig kidney
(Davidsohn, 1937; Lippet & Nogalski, 1953) but is readily absorbed with boiled ox red cells
(Kemp & Baker, 1936). The reverse is found in normal sera. Papain treatment of sheep cells
increases the titre of anti-sheep agglutinins in normal sera, whereas it has little or no effect
on the titre oflM sera (Wollner, 1955; Salo, 1966). This latter property is perhaps analogous
to our findings using tannic acid treated cells and similar to the observations of Munoz
(1967) who studied the reactions of mouse sera on tanned sheep red cells.
An extensive search of the literature has failed to reveal previous reports on differences in
reactivity between sheep cells to haemagglutinin(s) in normal human serum, although this
phenomenon has been recorded in sera from patients with IM (Zarafonetis & Oster, 1950).
Moreover, Cox & Vermillion (1956) suggested that the problem was sufficiently important
to warrant preservation of sheep red cells in order to obtain standardized techniques for the
serological diagnosis of IM.
Although the 2HK, AA Finnish Landrace sheep gave titres significantly higher than the
others, particularly the 2LK, AB Merinos, and it is possible that the variation of agglutination
titres may be partly explained by inherent genetic differences in the cell membrane, the sample
size was not sufficient to justify a distinction being made between the effects ofbreed and blood
group. It is also likely that an additional heterogenicity is created by variability in the strength
of binding of different populations of anti-sheep cell haemagglutinins.
The practical significance of these results is of particular interest for it is suggested that
sheep cells with a known low reactivity to anti-sheep cell haemagglutinins should be selected
as the ideal inert carriers of antigen or antibody in all types of haemagglutination immuno¬
assays. In doing so it may prove possible to abandon the time-consuming exercise of absorp¬
tion prior to carrying out the immunoassay. In those circumstances where this does not prove
possible, absorption should be done with known highly reacting cells. The data also suggest
that the conflicting reports of the rise in titre of anti-sheep cell haemagglutinins associated
with allograft rejection (Rapaport et al, 1968; O'Kane et al, 1969) may be explained on the
differences in reactivity of the sheep cells used in the different centres. It seems likely that the
introduction of a panel of sheep cells in future studies would be more revealing.
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Comparison of resin extraction and ethyl-acetate extraction.
manifest when one compares the extraction procedures
and recovery by assaying thyroxine after adding known
amounts of the hormone to urine. If " assayable thyroxine "
is plotted against the quantity of thyroxine added then the
two should bear a linear relationship if the assay system is
valid. If one considers the result of two such experiments
(see accompanying figure) it can be seen that extraction
procedures using ethyl acetate show a variable relationship
to thyroxine added, whereas a linear relationship obtains
with resin extracts. The plot does not pass through the
origin because the urine already contains some endogenous
thyroxine. .
These results suggest that the resin-column procedure is
.to be preferred to ethyl-acet3te extraction of urine before
thyroxine estimation. Until further information is available,
the term " urinary thyroxine" applied to the material








duration of the disease or between the percentage of t
lymphocytes and titre of thyroid antibodies. It is believed
that t lymphocytes mediate cellular immunity.1 Laryea
et a!.5 observed that lymphocytes from patients with
Hashimoto's disease interfere with human thyroid-cell
function in tissue-culture. Furthermore, Podleski7 has
shown that similar lymphocytes are capable of producing
cytotoxic damage of cells coated with thyroid antigen.
Antibodies to follicular cell components appear later
through cooperation of thymic lymphocytes with bursa-
equivalent (b) lymphocytes.
The fall in titre of thyroid antibodies recorded in children
with lymphocytic thyroiditis treated with thyroxine 9 is
probably coincidental to the spontaneous regression of the
disease process, for it has been shown 5 that in a substantial











Sir,—We read with interest the article by Dr Papapetrou
and his colleagues (Nov. 18, p. 1045). We agree that
Hashimoto's thyroiditis, left untreated, will progress at
different rates to result in hypothyroidism in the majority
of patients.1 Furthermore, we are not surprised that
thyroxine failed to halt the advance of the underlying
process. This we believe to be cell-mediated immunity.2
Larnki et a!.3 from this laboratory have shown a significant
inhibition of migration of peripheral leucocytes from
patients with Hashimoto's thyroiditis when exposed to
thyroid antigens. Moreover, we have found a significantly
raised percentage of non-immune rosette-forming lympho¬
cytes—i.e., t or thymus-dependent lymphocytes—in the
peripheral blood of these patients.'1 No correlation was
found between the percentage of t lymphocytes and the
1. Yolpe, R. Mod. Treat. 1969, 6, 47-1.
2. Voire, R., Edmonds, At., Lamki, L., Clarke, P. V., Row, V. V.
Vroc. Mayo Clin. 1972, 47, 824.
3. L-ire.k:, L., Row, V. V., Volpc, R. J. clin. Endocr. Aleiab. (in the
press).
4. Farid, N. R-, Munro, R., Row, V. V., Volpe, R. Clin. lies. 1972,
20, 919.
RAPID LATEX-SCREENING TEST FOR
URINE F.D.P.
Sir,—Although our own experience with the rapid
latex-screening test (' Thrombo-Wellcotest', Wellcome
Reagents) .for the semi-quantitation of urine fibrin/
fibrinogen degradation products (f.d.p.) would support
some of the specific findings of Dr Hulme and Mrs Pitcher
(Jan. 6, p. 6), we are uncertain, at present, as to its future
application.
In our experience approximately 50% of all concentrated
and 15% of all unconcentrated urines (normal and patho¬
logical) contain non-specific latex agglutinins. This we
have found can be reduced by freezing/thawing and
centrifugation. However, there has remained a significant
number which are resistant to this procedure and require
either filtration through Whatman GF/B glass-fibre paper
or prior absorption using latex particles coated with normal
rabbit IgG. Thus, in order to be absolutely certain that
the reaction is specific for f.d.p. we believe each urine
should be set up against a control (latex coated with
normal rabbit IgG). There is no doubt, however, that if
these precautions are taken then the results of the Thrombo-
Wellcotest correlate very closely with the htemagglutination-
inhibition immunoassay.10
Although it is probable that future studies may show
that the rather aggressive approach of studying daily
urine samples will not be necessary for all patients, it is
likely that busy transplant units will still provide labora¬
tories with substantial work-loads. In this context the
microtitre system, used with the h.a.i., permits a significant
degree of automation. If all the precautions necessary to
avoid non-specific latex agglutination for the Thrombo-
Wellcotest are instituted then the technique becomes
exceedingly laborious and rather expensive. However, for
a quick " one-off" test it could have a place, although the
interpretation of a single observation may pose problems.
Finally, perhaps it should be pointed out that a urine
concentration step may not be an essential feature of the
h.a.i, technique. It was used in the original studies to
ascertain whether excretion of urinary f.d.p. below 2-0 ng.
per ml. was of clinical importance. This question has yet
to be fully answered. The application of the Thrombo-
5. Roitt, i. At., Greaves, At. F., Torrigiani, G., IJrostoff, J., Piayfair,
J. H. L. Lancet, 1969, ii, 367.
6. Laryea, H., Row, V. V., Volpe, R. Clin. Endocr. (in the press).
7. Podleski, \V. K. Clin. cxf. Immunol. 1972, 11, 543.
8. Lcboeur, G., Ducharrnc, J. R. Pediat. Clint N. Am. 195S, 13, 19.
9. Rallison, M. L. Personal communication.
10. Hon, M. S., Cash, J. D. Thrombosis lies, (in tile press).
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Wellcotcsc, which has a lower sensitivity than the h.A.i.,
combined with the absence of concentration, could mean













Sir,—Fakhri and Hobbs 1 demonstrated that antibodies
and lymphocytes may cooperate in mediating tissue damage
in patients with certain autoimmune diseases. They
suggest that lymphocyte-dependent antibodies may be
ixnportant in the pathogenesis of Hashimoto's thyroiditis,
thyrotoxic exophthalmos, retinal, vasculitis, and cceliac
disease.
We have studied the serum of a patient with chorio¬
carcinoma which contained a lymphocyte-dependent
antibody (l.d.a.) specific for cells from the patient's
husband.2 This antibody has many similarities in common
with the antibodies described by Fakhri and Hobbs.
Using a 5lCr-release assay, we found that neither the
antibody alone nor lymphocytes alone .were cytotoxic for
target cells. However, the combination of l.d.a. and
lymphocytes led to target-cell lysis. Neither conventional
complement nor non-specific toxins were involved in
i..d.a.-mediated cytotoxicity. Non-immune lymphocytes
from man and other species could be recruited by l.d.a.
to destroy specific target cells. Similar results have been
reported in several animal model systems.3-'
Fakhri and Ko'obs point to the need for further studies
of the immunoglobulin class of l.d.a., types of inhibitors,
and the nature of the cells participating in l.d.a.-mediated
reactions. Recent studies indicate that l.d.a. migrates in
the v-globulin region during block electrophoresis and
eiutes in the 7S region of the G-200 ' Sephadex ' chromato¬
graphic column.2'5 Goat antisera specific for IgG inhibits
l.d.a. activity, whereas goat antisera specific for IgM does
not inhibit l.d.a. activity. Studies in animals indicate
that l.d.a. is detectable as early as 4 days after immunisa¬
tion.5 Lymphocytes (cells not adherent to plastic) but not
monocytes (cells adherent to plastic) are capable of par¬
ticipating in l.d.a.-mediated reactions.2 l.d.a.-mediated
cytotoxicity appears to be mediated by bursa-derived
lymphocytes.' The concentration of antibody coating
target cells appears to be an important determinant of
whether cytotoxicity or enhancement is produced.10
Complement-dependent antibodies have been known for
many years to be important in the pathogenesis of hemolytic
antemias and renal disease. Fakhri and Hobbs implicate
lymphocyte-dependent antibodies in the pathogenesis
of certain autoimmune diseases such as. Hashimoto's
thyroiditis, thyrotoxic exophthalmos, retina! vasculitis, and
cceliac disease. Lymphocyte-dependent antibodies bridge
the classical distinction between cellular and humoral
Fakhri, O., Hobbs, J. R. Lanat, 1972, ii, >103.
v/underlich, J. R., Rosenberg, E. B., Conolly, J. Al. in Progress in
Immunology (edited by B. Arnos); p. 473. New York, 1971.
Dennert, G., Lennox, E. Mature New Biol. 1972, 235, 114.
Horsey, P., AtacLcnnan, I. Transplant. Prcc. 1972, 4, 277.
Fakhri, O., Hobbs, J. R. Kuttire New Biol. 1972, 235, 177.
Pollack, S., Hcppncr, G., Brown, R. J., Nelson, K. Int. J. Cancer,
1972,9, 316.*
Ringercz, B., Vv'asserman, J., Packalen, T., Perlmann, P. Int.
Arcks Allergy, 1971, 49, 917.
Herding, B., MacLcnnan, I. C. bnmunology, 1972, 23, 35.
van Boxel, J. A., Stobo, J. B., Paul, W. E., Green, I. Science, 1972,
175, 194.
Skurzak, H. M., Klein, E., Yoshida, T. O., Lamon, E. \V. J. exp.
Afed. 1972, 135, 997.
immune responses. Cell-mediated tissue destruction may
not be limited to cytotoxicity by sensitised T lymphocytes,
but instead may include toxicity by a partnership of
humoral, cell-dependent antibody, and non-immune host
lymphoid cells. Early scrum and cell transfer studies do
not mitigate against this possibility, since immune sera
could also contain blocking factors capable of shutting off
cell-dependent antibody cytotoxicity in vivo. We agree
with these .tjjgrkers that further studies of l.d.a. should be
undertaken to better define their role in the pathogenesis
of autoimmune diseases and their potential importance in





U.S.A. Eugene B. Rosenberg.
ACUPUNCTURE AN7SSTHESTA
Sir,—Dr Karols (Dec. 30, p. 1417) questions the
credibility of the reports on acupuncture. He states that
"
as long as the chest wall remains open there is no way
that the patient can reinflate that lung through his own
muscular efforts ". Is it possible that the following explana¬
tion will do ? The patient inspires on the intact side and
then expires against closed upper airways (compare the
Valsalva manoeuvre). This will force the air from the
intact iung over the bifurcation into the collapsed lung.
Fridhenasgasse 10, 21 tr.,
112 40 Stockholm. Lars Gustafsson.
FERRITIN IN SERUM
Sir,—The identification of "-fetoprotein as ferritin by
Dr Alpert and his colleagues (Jan. 6, p. 43) is of con¬
siderable interest, but their suggestion that this protein:
appears in the circulation only under pathological con¬
ditions is not supported by our recent studies using a
sensitive immunoradiometric assay.1
Ferritin is present in al! norma! sera and there is a close
correlation between concentration of the protein and the
iron stores of the body. The amounts found in different

























In patients with refractory anremia there is a close
correlation between the scrum ferritin concentration and
the iron load from transfused red cells (r= 0-93 p< 0-001).
In 22 normal subjects in whom iron stores were estimated
by the phlebotomy technique 3 there is a similar relation¬
ship between serum-ferritin concentration and storage iron
(r=0-83, P< 0-001).
The occurrence of ferritintemia in patients with liver
disease or malignant states has long been recognised 4 and
we have found the phenomenon in a variety of hemato¬
logical malignancies. In 35 cases of acute myeloblascic
leukemia the mean serum concentration was 5S9 pg. per 1.
and in 19 cases of Hodgkin's disease 215 u.g. per l.s Raised
1. Addison, G. M., Beamish, M. R., Hales, C. N., Hodgkins, M.,
Jacobs, A., Llcwellin, P. J. din. Path. 1972, 25, 326.
2. Jacobs, A., Miller, F., Worwood, At., Beamish, Al. R., Wardrop,
C. A. J. Br. med. J. 19/2, iv, 206.
3. Hask'.ns, D., Stevens, A. R., Finch, S., Finch, C. A. J. clin. Invest.
1972, 31, 513.
4. Rcissman, K. R., Dietrich, At. R. ibid. 1955, 35, 583.
5. Jones, P. A. E., Miller, F. At., Worwood, M., Jacobs, A. Br. J.
Cancer (in the press).
STUDIES ON A DIRECT LATEX AGGLUTINATION
TECHNIQUE FOR THE SEMIQUANTITATION OF
FIBRIN/FIBRINOGEN DEGRADATION PRODUCTS.
M.;<Hoq and John D. Cash
S-E Scotland Regional Blood Transfusion Service,
Royal Infirmary, Edinbur^i.
Presented at the conference on Fibrinogen and its derivatives,
Warsaw, October, 24th-26th 1972.
ABSTRACT
A simple^ and reproducible direct latex agglutination technique
is described, designed to quantitate F.D»P. The method appears
to be satisfactory for rapid bedside estimations on serum, but
its practical application for urinary.F.D.P. measurements is
limited.
INTRODUCTION
Over the last 10 years there has been a growing interest in the
quantitation of fibrin/fibrinogen degradation products (F.D.P.) in serum and
urine, on the basis that in some clinical' situations elevated levels may
ropresent direct evidence of fibrin deposition and its subsequent lysis (l).
During this period there has been an associated development in technology to
meet this need. Thus at the present time F.D.P. have been estimated by a
variety of techniques both immunological (2,3,4) and non-immunological (5). HI
have there advantages and disadvantages but the demand for a simple, reliable,
sensitive, specific and rapid one stage technique, using readily available
reagents, has remained and its absence has partly been'responsible for the
retention of this technology within the bounds of highly specialised laboratories
In response to this demand a technique was introduced (known as the Fi test)
in which latex particles, coated with antibody to human fibrinogen, agglutinated
in the presence of fibrinogen or fibrinogen related antigen(s). In our own
hands this reagent has been particularly unreliable and Thomas and his colleagues
(6) have considered that this feature may he due to the absence of reactivity to
fragment E»
The recent introduction of an antibody-coated latex particle preparation
coated with a mixture of specifically prepared anti~D and anti-E has raised
the possibility of restudying this problem. The new latex reagent is known as
the Thrombo-Welleotest and we have compared its performance with the tanned red
cell haemagglutination inhibition immunoassay (T.R.C.H.I. I.) on artificial digests
of fibrinogen and clinical samples of urine and serum.
MATERIALS AliD METHODS
Serum and urine test samples were prepared as described previously (7»8)»
All concentrated urine samples were centrifuged at 3,400 r.p.m. for 10 minutes
at 4°C in a 6L II. S.E. liistral centrifuge prior to assay. The T.R. C.H. 1.1. was
performed using the modifications of Das (9) of the Merskey technique (2).
The Thrombo-Wellcotest reagent was kindly supplied, by Y/ellcome Reagents Limited,
Beckenham, Kent, England, as was a suspension of latex particles coated with nor¬
mal rabbit IgG. Test samples and standards (human fibrinogen; Kabi Pharmaceuti¬
cals) were doubly diluted in a glycine buffer (0.1H in 1c/o NaCI containing 0.1^
sodium azide at pH 8.2). Two drops (0.025 ml) of test material or standard were
placed Into a marked'ring on a clean glass slide. Two drops of the latex
suspension wero then added, mixed using a glass rod and incubated at room
temperature for 2 minutes, k'acroscopic agglutination was visualised against
a dark back-ground.
i Results
Sensitivity to fibrinogen, Fragments D and E
The direct latex test was shown to be sensitive to as little &)4^.g/ml
of fibrinogen. Specific products (kindly supplied by Doctor V. Harder, Temple
University, Philedelphia, U.S.A.) revealed a sensitivity to fragment D of
4^Ag/ml and fragment E of 0.5y*rg/ml.
Comparison of the T.P. C.H. 1.1. and Latex Test during in vitro plasmin
digestion of fibrinogen
Streptokinase (1000 units/ml; Hoechst Fnaxmaceuticals Ltd.) plasminogen
(0.25 casein units/ml; Kabi Pharmaceuticals Ltd., Grade A) end human fibrinogen
(10 mg/ml; Kabi Pharmaceuticals Ltd.) were incubated in Tris buffer at 37°C.
1 ml aliquots were removed at various intervals, the reaction stopped with
Trasylol (0.1-ml of 5000 units/ml} Bayer Pharmaceuticals Ltd.) and the thrombin
time (lO) a fibrinogen estimation (ll), T.E.C.H.I.I. and Latex test performed.
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FIG. 1,
F.D.P. quantitation using the Latex Test and T.B, C.H. I.I.
, thrombin times and fibrinogen estimations on serial aliquots
of an in vitro human fibrinogen plasmin digest.
The apparent higher sensitivity of the Latex test to later digests, compared
to the T.E.C.H.I.I., wa3 thought to be related to the use of antisera in the
T.E.C.H.1.1, directed against -whole fibrinogen, thus being relatively
insensitive to anti-E. This conclusion was supported by the knor/n high
sensitivity to the E fragment of the Latex test and the observation that when a
specific onti~E serum was used in the T.E.C.H.1.1, then continued sensitivity
was retained throughout the period of digestion (Fig. 2).
Comparison of the T.E.C.H.I.I, and Latex Test on Clinical Material
A plot of the results from both techniques on 144 sera and 37 urines is
shown in Fig. 3. There was a very satisfactory correlation between the two
methods (r =0.0942 : p4 O.OOl), despite the use of anti-sera to whole fibrinogen
in the T.ihC»H*I. I»




Results of the T.R,C.H.I.I. on in vitro human fibrinogen
digests using antisera prepared to -whole human fibrinogen?
fragment D and fragment E»
Hon-specific Latex particle agglutination
Less than of 120 sera obtained from healthy blood donors agglutinated
the later particles coated with normal rabbit IgG. However, in patients with
rheumatoid arthritis this rose to 25/°J the highest titre recorded being l/8»
In urine specimens, whether from healthy subjects or patients with glomerulone¬
phritis, this rose to 50$ in fresh specimens but could be reduced to 25/^ after
freezing, thawing and centrifugation. The hi$ie3t titre recorded was l/64*
Complete removal of this non-specific latex agglutinating material was possible
if 1 volume of urine was incubated with 1 volume of normal rabbit IgG coated
latex for 30 minutes at 4°C»
LATEX TECHNIQUE (yug/m!)
FIG, 3.
. A correlation "between the Latex test and
T.R.C.H.I.I, on the F,D*P. values in sera ( open< circles)
and urine ( squares - ) (r**0.894 1 P O.OOl)
. DISCUSSIQII , '
The results of this study suggest that the Thrombo-Wellcotest reagent
appears to he a valuable approach towards a rapid 'one-off' bedside
semiquontitation of serum F.D.P. and could, therefore, be readily introduced
to samller non-specialised laboratories. The presence of non-specific latex
agglutinating substances in sera is unlikely to bo of material significance as
in our experience it has not been recorded above a titre of l/8 which corresponds
to an F.D.P, level of only 32yug/ml fibrinogen equivalents.
At the present time we regard the Thrombo-Wellcotest as essentially
unsuitable for the assay of urinary F.D.P. The high incidence of the non¬
specific latex agglutinating substance(s) would necessitate a pre-absorption
step prior to assay# Moreover, the serial dilution procedure is particularly
laborious, compared to the microtitre technique used for the T.R#C#H#I, I# This
latter feature is of great practical importance as it has been shown that if the
quantitation of urine F.D.P# is proved to be relevant in the management of
patients with certain forms of renal disease then large batches of assays are
required on individual patients (l2)»
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INTRODUCTION
A variety of serological responses to allotransplantation have
been reported in man, including a rise in the titre of serum heterophile
haemagglutinins, directed against sheep, guinea-pig and rat erythrocytes,
1-3
after skin and renal transplantation. The haemagglutinins vere
in the IgG and IgM fractions, did not appear to be the Forssman
or Paul-Bunnel-type and the peak titres were thought to be associated
with clinical and biochemical evidence of graft rejection. The
mechanisms responsible•for this phenomenon are not known, but it has
been proposed that it might represent an immune response to altered
3
tissue antigens arising from the rejection injury. More recent
studies have failed to confirm all aspects of these observations; in
particular, the association between renal allograft rejection and peak
titres of serum heterophile antibody has been regarded as coincidental.
Within the last two years several investigations have shown that
whereas the assay of another non-specific and presumptive marker of
immune damage, fibrin/fibrinogen degradation products (F.D.P.), in the
serum of patients with renal transplant and glomerulonephritis gave
indifferent evidence of disease activity, the urinary F.D.P. content
appeared to be a highly sensitive index of both activity and response to
7-9
therapy. Based on this principle, and the possibility that
heterophile haemagglutinins might be directed at altered glomerular
antigens, a study was established to detect and semiquantitate sheep
haemagglutinins in urine rather than serum from patients with proliferative
glomerulonephritis and those following renal homotransplantation, and
to examine their correlation with the urinary F.D.P. content.
PATIENTS AND METHODS
One hundred presumed healthy colleagues (pO male and 50 female;
aged 18-58 years), were used as controls. Their urine specimens were
obtained at random throughout a working day. Fifteen patients with
proliferative glomerulonephritis and ten following renal homotransplantation
were studied. Aliquots of urine from 24 hour collections were
obtained from all in-patients, whereas out-patients sent early morning
specimens through the postal services. All samples were dialysed
against tap water, concentrated overnight with polyethylene glycol,
. o
centrifuged and stored at -36 C until assayed. Urinary F.D.P. content
was determined by the tanned red -cell haemagglutination inhibition
/ x 10
immunoassay (T.R.C.H.I.I.), using glutaraldehyde fixed human red cells.
The urinary.heterophile haemagglutinin titre was established, using
10 11
glutaraldehyde fixed 'high reacting' sheep red cells. ' Samples
were serially diluted in distilled water. The system of scoring
12
titres arithmetically, introduced by Race and Sanger, was used to
summarise and analyse the data. Both immunoassays were performed by
independent operators who had no prior knowledge of the source of the'
test samples or of each other's results. The total protein content of
13
the urinary concentrates was performed by the biuret method.
RESULTS
Urinary sheep cell haemagglutinins were not detected in the 100
normal subjects studied, nor did the F.D.P. content exceed 0.25 ug/ml.
In a selection o.f 60 urines, obtained, from patients with proliferative
glomerulonephritis and following renal transplantation, there was a
significant positive correlation between the heterophile haemagglutinin
titre and the F.D.P. content (Fig. l). Serial studies performed on
individual patients revealed a general tendency for periods of
high heterophile haemagglutinin excretion to coincide with similar
excesses of F.D.P. excretion. Some urine specimens, however,
contained low F.D.P. arid high heterophile haemagglutinin, and vice
versa. Purified preparations of F.D.P. fragments D and E (kindly
supplied by Doctor P. Gaffney) did not agglutinate sheep erythrocytes.
No correlation was demonstrated between the heterophile haemagglutinin
titre and total protein content in the urines studied (r== 0.179S: p O.l).
Serial urine samples on 6 post-renal transplant patients studied
continuously for 10-42 days demonstrated that the heterophile haem¬
agglutinin titres and F.D.P. excretion provided parallel information
on the detection of acute and sub-acute rejection, and the response to
subsequent treatment. An example is shown in Fig. 2.
The responses to the administr2ition of indomethacin in a group of
7 patients with active proliferative glomerulonephritis was also
studied. In 5 patients there was a fall in F.D.P. and heterophile
haemagglutinin excretion during indomethacin administration, although
the latter was consistently more slow to respond. In all these
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Correlation between F.D.P. and heterophile (sheep)
antibody content in 60 selected urines obtained from
patients with proliferative glomerulonephritis and
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Urine volume, heterophile (sheep) antibody^, F.D.P. and
total protein content, and serum creatinine in a patient
following renal homotransplantation. Clinical evidence
of arejection was apparent by the 22nd. day.
of renal function. An example of this type of dual response is shown
in Fig. 3- One of the 7 patients in this group responded quite
differently: no evidence of a heterophile haemagglutinin response
occurred despite a marked reduction in the F.D.P. excretion (Fig. 4).
It was noted that this patient's renal function continued to
deteriorate during indomethacin administration; and renal transplan¬
tation was undertaken several months later. Of further interest was
the observation that a second patient in whom indomethacin failed to
ellicit a fall in urine F-D.P. also showed no diminution of heterophile
haemagglutinin excretion.
DISCUSSION
Previous studies have demonstrated a significant correlation between
the activity of glomerular disease, as assessed biochemically and
histologically and the excretion of urinary F.D.P. in proliferative
9 14 7,15
glomerulonephritis, ' and during the rejection of renal homografts.
The preliminary study described above suggests that in these two patient
groups similar information may be obtained from serial assays of the
urinary heterophile haemagglutinin content. This general conclusion is
supported by a significant correlation between urinary F.D.P. and heterophile
haemagglutinin concentrations in 60 separate urines, the parallel information
obtained from serial studies and the changes in both pfjrameters during
therapy. Moreover, just as a proportion of patients with active prolif¬
erative glomerulonephritis fail to reduce their F.D.P. excretion during
indomethacin/
indomethacin administration, the same apjjears to hold for the
heterophile haemagglutinin excretion. A potentially important
exception to this parallelism was found in one patient who showed
diminishing F.D.P. excretion in response to indomethacin but
continuing high urinary heterophile haemagglutinin excretion. The
renal function in this patient progressively deteriorated. If'this
observation is confirmed, then a new subgroup of patients has been
demonstrated in which the presence of intraglomerular fibrin may not
be a key aetiolog.ica.1 factor in the progressive damage associated with
proliferative glomerulonephritis.
The mechanisms responsible for urinary heterophile haemagglutinin
excretion in active proliferative glomerulonephritis and renal homograft
rejection are as yet unknown. The data, presented, however, showing
no correlation with the total protein excretion, and rapid responses
to therapy which also appeared independent of total protein excretion,
would suggest that its appearance is part of an active process, rather
than arising from the passive glomerular leakage of serum proteins.
While these preliminary observations require more detailed confirmatory
studies, and should also be extended to other areas in nephrology,
they already appear to have interesting theoretical and practical consequences
Fg&fi the clinician, the study of hetcrophile haemagglutinin titres
alone, or combined with urinary F.D.P. excretion, may provide
yet another approach to the understanding of the pathogenesis and manage¬
ment of patients with proliferative glomerulonephritis and renal allograft
rejection. Moreover, from a laboratory point of view, the assay of
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FIG. 3.
The pattern of urinary heterophile (sheep) antibody
and F.D.P. excretion in a patient with proliferative
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FIG. 4.
The pattern of urinary heterophile (sheep) antibody
and F.I).P. excretion in a patient with proliferative
glomerulonephiritis whose renal function continued to
deteriorate during indomethacin administration.
laborious and time consuming whereas the heterophile haemagglutinin
assay, being a direct agglutination reaction, is technically simpler,
the reagents readily available and preliminary investigations in this
laboratory suggest that automation should be straight forward.
ACKNOWLEDGEMENTS
The authors wish to convey their sincere thanks to Doctor J.S.
Robson for laboratory facilities and continued support; also
Professor Sir Michael Woodfruff, Mr. B. Nolan, Doctor Anne Lambie, '
Doctor A. Doig and Doctor J.F. Munro .for permission to study patients
in their care. This research programme was supported by a grant from
the Scottish Hospital Endowment Research Trust.
REFERENCES
1. Rapaport, F.T. , Kano, K. and Milgrom, F. (1967)
Federation Proceedings, ji6, 640
I
2. Rapaport, F.T., Dausset, J., Hamburger, J., Hume, D.M.,
Kano, K.G. , Williams, M. and Milgrom, F. (19S7)
Annals of Surgery, 166, 596..
3. Rapaport, F.T., Kano, K. and Milgrom, F. (196Q)
Journal of Clinical Investigation, 47, 633-
4. O'Kane, H.O. , Shorter, R.G., Navas, C. and Hallenbeck, G-A. (1969)
Surgery, _66, 682.
5. Tiong, T.S. and Morris, P.J. (1972)
Clin. exp. Immunol., JX), l63-
6. Svehag, S-E, Olander, R. and Sundqvist, K-G. (1973)
Clin. exp. Immunol. , _13, 191-
7- Clarkson, A.R., Morton, J.B. and Cash, J.D. (1970)
Lancet, _ii, 1220.
8. Clarkson, A.R., MacDonald, M.K., Petrie, J.J.B., Cash, J.D.
and Robson, J.S. (l97l)
Brit. Med. J., 3., 447-
9. Clarkson, A.R., MacDonald, M., Cash, J.D. and Robson, J.S. (1972)
Brit. Med. J. , _2, 255-
10. Hoq, M.S. and Das, P.C. (l97l)
Scand. J. Haemat., Suppl. 13, 101.
11. Hoq, M.S., Cash, J.D., Das, P.C. and Cumming, R.A. (l97l)
Brit. J. Haemat. , _2_1, 677-
12. Race, R.R. and Sanger, R. (1954)
2nd Ed. Blackwell Scientific Publ. Ltd., Oxford.
13- Hitler, A., Grief, R.L. and Beckman, W.W. (1948)
J. Biol. Chem., 176, 1421.
14. Davison, A.M., Thomson, D., MacDonald, M.K., Rae, J.K.,
Uttley, W.S. arid Clarkson, A.R. (1973)
J. Clin. Path., (In press)
15. Hume, R. and Pitcher, P.M. ("1973)
Lancet, i, 6-
(A
